[CAS NO. 174722-31-7] Rituximab
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [174722-31-7]
Catalog
HY-P9913
Brand
MCE
CAS
174722-31-7
DESCRIPTION [174722-31-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 144544.44 |
| Molecular Formula | Unspecified |
| SMILES | [Rituximab] |
For research use only. We do not sell to patients.
4 Publications Citing Use of MCE
Summary
Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
In Vitro
Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab [1] . All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00242996 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
March 2004 | Phase 2 |
| NCT01124526 | Asociacion Espanola de Hematologia y Hemoterapia |
Non Hodgkin Lymphoma
|
September 2004 | Phase 4 |
| NCT02446457 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma
|
July 31, 2015 | Phase 2 |
| NCT03366272 | Universität des Saarlandes|Bristol-Myers Squibb|Lymphoma Study Association|University of Leipzig |
Lymphoma, Non-Hodgkin
|
December 5, 2017 | Phase 2|Phase 3 |
| NCT00582166 | University of Wisconsin, Madison|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
January 25, 2005 | Phase 2 |
| NCT00832234 | European Myeloma Network|University of Athens|University of Roma La Sapienza|Niguarda Hospital|University of Turin, Italy|University of Salamanca|Hospital Clinic of Barcelona|Hotel Dieu Hospital|Erasmus Medical Center|University Hospital, Toulouse|IRCCS Policlinico S. Matteo|Laikο General Hospital, Athens|Klinikum der Universitaet Muenchen, Grosshadern|Aalborg University Hospital|Centre Hospitalier de Lens|Universitaire Ziekenhuizen KU Leuven|Theagenio Cancer Hospital|University of Wuerzburg|Skane University Hospital|Sahlgren´s University Hospital |
Waldenstroms Macroglobulinemia
|
September 2006 | Phase 2 |
| NCT00388193 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia|Burkitt´s Lymphoma
|
August 2006 | Phase 2 |
| NCT03072199 | Papworth Hospital NHS Foundation Trust |
Ischemic Heart Disease|Myocardial Infarction|Inflammation
|
June 1, 2017 | Phase 1|Phase 2 |
| NCT03994783 | Imperial College London|Cambridge University Hospitals NHS Foundation Trust|National Institute for Health Research, United Kingdom|Kidney Cancer UK |
Kidney Transplant Rejection|Antibody-mediated Rejection
|
July 17, 2019 | Phase 3 |
| NCT04668365 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma|CD79A Gene Mutation|CD79B Gene Mutation
|
December 25, 2020 | Phase 2 |
| NCT00758693 | University of Kentucky|Cephalon |
Chronic Lymphocytic Leukemia
|
October 2008 | Phase 2 |
| NCT02371096 | Gedeon Richter Plc. |
Rheumatoid Arthritis
|
Phase 1 | |
| NCT02953509 | Gilead Sciences|The Leukemia and Lymphoma Society |
Non Hodgkin Lymphoma
|
November 21, 2016 | Phase 1|Phase 2 |
| NCT03569995 | Won Seog Kim|Celltrion|Samsung Medical Center |
Primary CNS Lymphoma
|
November 30, 2018 | Phase 2 |
| NCT00096460 | Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program |
Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Follicular Lymphoma
|
August 2004 | Phase 2|Phase 3 |
| NCT02044822 | Gilead Sciences |
B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
|
August 6, 2014 | Phase 2 |
| NCT03558750 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb |
Recurrent Central Nervous System Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Central Nervous System Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
June 14, 2018 | Phase 1 |
| NCT00147121 | Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group |
Lymphoma, B-Cell
|
September 2002 | Phase 2|Phase 3 |
| NCT05136976 | Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France |
Anti-MAG Neuropathy
|
June 2022 | Phase 3 |
| NCT01702961 | Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine |
Lymphoma|Hodgkin´s Disease
|
June 2002 | Not Applicable |
| NCT01661881 | Dana-Farber Cancer Institute|Massachusetts General Hospital |
Mantle Cell Lymphoma
|
August 16, 2012 | Phase 2 |
| NCT00052936 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
January 2001 | Phase 3 |
| NCT04115631 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Liver Lymphoma|Mantle Cell Lymphoma
|
October 3, 2019 | Phase 2 |
| NCT05209308 | MEI Pharma, Inc.|Kyowa Kirin, Inc. |
CLL
|
November 2022 | Phase 2 |
| NCT03763643 | University of Minnesota|United States Department of Defense |
Focal Segmental Glomerulosclerosis
|
July 1, 2019 | Early Phase 1 |
| NCT04075292 | AstraZeneca |
Untreated Chronic Lymphocytic Leukemia
|
January 20, 2020 | Phase 3 |
| NCT01419561 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
KSHV Inflammatory Cytokine Syndrome (KICS)|KSHV|HHV-8
|
September 8, 2011 | Phase 2 |
| NCT00824135 | St. Jude Children´s Research Hospital|Genzyme, a Sanofi Company |
Hematologic Malignancies
|
January 2009 | Phase 1 |
| NCT00422942 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
January 2006 | Phase 2 |
| NCT05156710 | Sanofi |
Transplant Rejection
|
June 9, 2022 | Phase 2 |
| NCT00878254 | University of Miami |
Mantle-Cell Lymphoma
|
March 25, 2009 | Phase 2 |
| NCT00004260 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 1 |
| NCT00003716 | Stanford University |
Lymphoma
|
March 1998 | Phase 2 |
| NCT01283386 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
April 27, 2011 | Phase 4 |
| NCT03630042 | University College, London|Merck Sharp & Dohme LLC |
Waldenstrom Macroglobulinemia
|
September 6, 2019 | Phase 2 |
| NCT03791827 | Xiqiang Dang|The Children´s Hospital Affiliated to Suzhou University|Shandong Provincial Hospital|Guizhou Provincial People´s Hospital|LanZhou University|The First Affiliated Hospital of Inner Mongolia Medical College|People´s Hospital of Zhangjiajie|Puyang Oilfield General Hospital|The First Affiliated Hospital of Anhui Medical University|Guizhou Maternal and Child Health Care Hospital|The Second Affiliated Hospital & Yuying Children´s Hospital of Wenzhou Medical University|Shenzhen Children´s Hospital|The Second Affiliated Hospital of Harbin Medical University|Yichang Central People´s Hospital|Xian Children´s Hospital|Wuhan Children´s Hospital, Tongji Medical College, Huazhong University of Science & Technology|The First People´s Hospital of Yunnan|The First Affiliated Hospital of Xiamen University|The First Affiliated Hospital of Xinxiang Medical College|Shanxi Provincial Maternity and Children´s Hospital|Liaocheng People´s Hospital|Fujian Provincial Hospital|First Affiliated Hospital of Guangxi Medical University|Second Hospital of Lanzhou University|Guangzhou First People´s Hospital|The Second Hospital of Shandong University|Children´s Hospital of Hebei Province|Beijing Children´s Hospital|Zhengzhou Children´s Hospital|The Children´s Hospital of Chongqing Medical University|Wuxi Children´s Hospital|The Children´s Hospital of Fudan University|Shanghai Children´s Medical Center|Qilu Children´s Hospital of Shandong University|Second Xiangya Hospital of Central South University |
Lupus Nephritis|Children|Steroid|Immunosuppressive Treatment
|
December 1, 2018 | |
| NCT04745728 | Peking Union Medical College Hospital |
Idiopathic Membranous Nephropathy
|
April 14, 2021 | Phase 3 |
| NCT04609046 | National Cancer Institute (NCI) |
Central Nervous System Lymphoma|Diffuse Large B-Cell Lymphoma
|
January 15, 2021 | Phase 1 |
| NCT02592876 | Seagen Inc. |
Lymphoma, B-cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular, Grade 3b|Follicular Lymphoma, Grade 3b
|
October 2015 | Phase 2 |
| NCT02699892 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
October 2007 | |
| NCT04920968 | Maria Sklodowska-Curie National Research Institute of Oncology|KCRI |
CD20-positive Acute Lymphoblastic Leukemia
|
June 30, 2021 | Phase 2 |
| NCT02048813 | National Cancer Institute (NCI) |
Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
February 20, 2014 | Phase 3 |
| NCT00251394 | Dana-Farber Cancer Institute|Dynavax Technologies Corporation|James P. Wilmot Cancer Center|University of Rochester|Brigham and Women´s Hospital|Massachusetts General Hospital |
Non-Hodgkin´s Lymphoma
|
July 2004 | Phase 2 |
| NCT00438880 | Mayo Clinic|National Cancer Institute (NCI) |
Adult Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
October 2004 | Phase 1|Phase 2 |
| NCT05023980 | Loxo Oncology, Inc.|Eli Lilly and Company |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
September 23, 2021 | Phase 3 |
| NCT00498368 | Mayo Clinic|Ohio State University|Stanford University|University of North Carolina, Chapel Hill|Columbia University|Genentech, Inc.|Biogen |
IgA Nephropathy
|
February 2009 | Phase 4 |
| NCT00086203 | Point Therapeutics|FDA Office of Orphan Products Development |
Chronic Lymphocytic Leukemia
|
Phase 2 | |
| NCT01408342 | Hospital Universitario Dr. Jose E. Gonzalez |
Aplastic Anemia
|
July 2011 | Not Applicable |
| NCT04978584 | M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma
|
March 3, 2022 | Phase 2 |
| NCT00546377 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 1|Phase 2 |
| NCT00670358 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
August 25, 2008 | Phase 1|Phase 2 |
| NCT03536039 | Andres J. M. Ferreri|AGC Biologics S.p.A.|IRCCS San Raffaele |
Lymphoma, Large B-Cell, Diffuse
|
January 27, 2016 | Phase 2 |
| NCT01419665 | Sandoz|Novartis Pharmaceuticals |
Follicular Lymphoma
|
December 1, 2011 | Phase 3 |
| NCT01471067 | M.D. Anderson Cancer Center|American Stem Cell, Inc.|National Cancer Institute (NCI) |
Blood And Marrow Transplantation|Leukemia|Lymphoma|Transplantation Infection|Transplantation, Bone Marrow
|
July 13, 2012 | Phase 1 |
| NCT00980304 | Shanghai Jiao Tong University School of Medicine |
Lymphomas
|
Phase 2 | |
| NCT00274989 | German CLL Study Group|University of Cologne |
Chronic Lymphocytic Leukemia
|
November 2005 | Phase 2 |
| NCT00259974 | Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitie-Salpetriere|University Hospital, Bordeaux|University Hospital, Limoges|Henri Mondor University Hospital|University Hospital, Marseille|Hospices Civils de Lyon|University Hospital, Basel, Switzerland |
Polyneuropathy
|
April 2006 | Phase 3 |
| NCT01830478 | Gruppo Italiano Studio Linfomi |
Indolent Non Hodgkin Lymphoma
|
April 2009 | Phase 2 |
| NCT01381705 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
February 6, 2012 | |
| NCT00038623 | M.D. Anderson Cancer Center|Biogen |
Lymphoma, Mantle-Cell
|
April 2002 | Phase 2 |
| NCT02486952 | Hoffmann-La Roche|Serbian Lymphoma Group |
Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin´s Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
August 2005 | |
| NCT01830465 | Gruppo Italiano Studio Linfomi |
Non Hodgkin´s Follicular Lymphoma
|
August 2006 | Phase 2 |
| NCT04965493 | Loxo Oncology, Inc.|Eli Lilly and Company |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
September 20, 2021 | Phase 3 |
| NCT00422799 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. |
Waldenstrom´s Macroglobulinemia
|
August 30, 2006 | Phase 2 |
| NCT00004179 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland|Australasian Leukaemia and Lymphoma Group|NCIC Clinical Trials Group|Nordic Lymphoma Group |
Lymphoma
|
May 1999 | Phase 3 |
| NCT03615105 | Memorial Sloan Kettering Cancer Center |
Acute Lymphoid Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML)|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
July 25, 2018 | Phase 2 |
| NCT04663347 | Genmab|AbbVie |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma
|
November 16, 2020 | Phase 1|Phase 2 |
| NCT01035463 | University of Nebraska|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma
|
November 12, 2009 | Phase 1|Phase 2 |
| NCT00472056 | M.D. Anderson Cancer Center |
Lymphoma
|
March 2005 | Phase 2 |
| NCT05004064 | University College, London|AstraZeneca |
Mantle Cell Lymphoma
|
January 1, 2023 | Phase 2 |
| NCT04182204 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
February 7, 2020 | Phase 3 |
| NCT01007292 | Astellas Pharma Inc |
Non-Hodgkin´s Lymphoma
|
November 2009 | Phase 2 |
| NCT01473628 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage I Grade 1 Follicular Lymphoma|Ann Arbor Stage I Grade 2 Follicular Lymphoma|Ann Arbor Stage II Grade 1 Follicular Lymphoma|Ann Arbor Stage II Grade 2 Follicular Lymphoma
|
May 20, 2013 | Phase 1|Phase 2 |
| NCT01075477 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
September 2009 | |
| NCT03742258 | Northwestern University|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
March 13, 2019 | Phase 1 |
| NCT05073250 | Chinese PLA General Hospital |
Inert Non Hodgkin´s Lymphoma
|
December 31, 2021 | Phase 2 |
| NCT01456351 | University of Giessen |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
September 2003 | Phase 3 |
| NCT02013817 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
October 11, 2005 | Phase 2 |
| NCT00450801 | University of Miami |
Lymphoma
|
April 2004 | Phase 2 |
| NCT00299182 | M.D. Anderson Cancer Center|Amgen |
Lymphoma
|
March 2006 | Phase 1|Phase 2 |
| NCT00869323 | Masonic Cancer Center, University of Minnesota|Millennium Pharmaceuticals, Inc. |
Lymphoproliferative Disorder
|
March 2009 | Phase 2 |
| NCT05600660 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Primary Central Nervous System Lymphoma
|
August 1, 2022 | Phase 2 |
| NCT00427791 | M.D. Anderson Cancer Center |
Leukemia
|
July 2005 | Phase 2 |
| NCT00937131 | University College, London |
Thrombotic Thrombocytopenic Purpura (TTP)
|
March 2006 | Phase 2 |
| NCT00210340 | International Extranodal Lymphoma Study Group (IELSG) |
Lymphoma, B Cell
|
Phase 1 | |
| NCT05453500 | University of Washington|Incyte Corporation |
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
January 1, 2023 | Phase 2 |
| NCT04578639 | Haukeland University Hospital|University Hospital, Akershus|Oslo University Hospital|Helse Stavanger HF|St. Olavs Hospital|University Hospital of North Norway |
Relapsing Remitting Multiple Sclerosis
|
November 2, 2020 | Phase 3 |
| NCT02972840 | Acerta Pharma BV|AstraZeneca |
Lymphoma, Mantle Cell
|
April 5, 2017 | Phase 3 |
| NCT00183989 | University of Southern California |
Mantle Cell Lymphoma
|
August 2000 | Phase 2 |
| NCT04688151 | National Health Research Institutes, Taiwan|National Taiwan University Hospital|National Cheng-Kung University Hospital|China Medical University Hospital|Chang Gung Memorial Hospital |
Primary Central Nervous System Lymphoma (PCNSL)
|
February 1, 2021 | Phase 1 |
| NCT00715208 | Millennium Pharmaceuticals, Inc. |
Relapsed Follicular Lymphoma
|
September 2008 | Phase 2 |
| NCT01371630 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
August 26, 2011 | Phase 1|Phase 2 |
| NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
| NCT00317096 | Ludwig-Maximilians - University of Munich |
Lymphoma, Follicular|Lymphoma, Low-Grade|Lymphoma, Intermediate-Grade
|
November 1998 | Phase 3 |
| NCT00424151 | Silkiss, Rona Z., M.D., FACS|Lauer, Simeon, M.D.|Reier, Alice M.D.|Coleman, Morton M.D. |
Graves´ Dysthyroid Ophthalmopathy|Thyroid Related Orbitopathy
|
December 2006 | Phase 1|Phase 2 |
| NCT02343536 | Celgene |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular
|
April 29, 2015 | Phase 1 |
| NCT02204982 | SecuraBio |
Follicular Lymphoma
|
September 2014 | Phase 3 |
| NCT00142155 | Dana-Farber Cancer Institute |
Waldenstrom´s Macroglobulinemia
|
January 2002 | Not Applicable |
| NCT05379647 | Zhejiang University|Hangzhou Qihan Biotech Co.,Ltd. |
B-cell Lymphoma|B-cell Acute Lymphoblastic Leukemia
|
November 4, 2021 | Phase 1 |
| NCT03336333 | BeiGene |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
November 2, 2017 | Phase 3 |
| NCT00510887 | Duke University|Millennium Pharmaceuticals, Inc. |
Lymphoma, Follicular
|
January 2007 | Phase 2 |
| NCT01125176 | Weill Medical College of Cornell University|Celgene |
Chronic Lymphocytic Leukemia
|
March 30, 2012 | Phase 2 |
| NCT03112603 | Incyte Corporation |
Graft-versus-host Disease (GVHD)
|
March 7, 2018 | Phase 3 |
| NCT00562965 | Pfizer|UCB Pharma |
Lymphoma, Follicular
|
November 2007 | Phase 3 |
| NCT00692939 | Paul Szabolcs|University of Pittsburgh |
Crohn´s Disease
|
June 26, 2012 | Phase 1|Phase 2 |
| NCT02442648 | E. Steve Woodle|Amgen|University of Cincinnati |
Transplants and Implants
|
December 2014 | Phase 1 |
| NCT03349346 | Gilead Sciences |
Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma
|
June 2019 | Phase 1 |
| NCT00740948 | University Hospital, Brest|Ministry of Health, France |
Sjogren´s Disease
|
March 2008 | Phase 2|Phase 3 |
| NCT04421560 | Dana-Farber Cancer Institute|Merck Sharp & Dohme LLC |
Primary Central Nervous System Lymphoma|Recurrent Cancer
|
August 1, 2020 | Phase 1|Phase 2 |
| NCT02536664 | Hoffmann-La Roche |
Follicular Lymphoma
|
September 2009 | |
| NCT03418038 | Mayo Clinic|National Cancer Institute (NCI) |
Clonal Cytopenia of Undetermined Significance|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Lymphoma
|
March 23, 2018 | Phase 2 |
| NCT03789240 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Follicular Lymphoma|Non-Hodgkin´s Lymphoma|NHL
|
August 22, 2019 | Phase 2 |
| NCT02970318 | Acerta Pharma BV |
Chronic Lymphocytic Leukemia
|
February 2, 2017 | Phase 3 |
| NCT01754870 | University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc. |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
|
November 2013 | Phase 2 |
| NCT02843061 | Fuda Cancer Hospital, Guangzhou|Shenzhen Hank Bioengineering Institute |
B-cell Lymphoma Recurrent
|
July 1, 2016 | Phase 1|Phase 2 |
| NCT00520130 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myelodysplastic Syndrome|Hodgkin´s Lymphoma|Non-Hodgkin´s Disease|Acute Leukemia|Multiple Myeloma
|
October 30, 2007 | Phase 1|Phase 2 |
| NCT03414502 | University of Nebraska |
Rheumatoid Arthritis
|
August 2007 | Phase 3 |
| NCT03267433 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
CD20 Positive|Mantle Cell Lymphoma
|
August 29, 2017 | Phase 3 |
| NCT01199575 | University of California, San Diego|Celgene Corporation |
Chronic Lymphocytic Leukemia|CLL
|
August 2010 | Phase 2 |
| NCT05144009 | ADC Therapeutics S.A. |
Diffuse Large B-cell Lymphoma
|
June 21, 2022 | Phase 2 |
| NCT01686321 | University of Göttingen|Roche Pharma AG|Mundipharma Research GmbH & Co KG |
Aggressive Lymphoma
|
July 4, 2012 | Phase 2 |
| NCT03804359 | Centre Hospitalier Universitaire de Nice |
Idiopathic Membranous Nephropathy
|
January 14, 2020 | Phase 2 |
| NCT02807103 | Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group |
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
|
December 5, 2016 | Phase 3 |
| NCT04871191 | Assistance Publique - Hôpitaux de Paris|URC-CIC Paris Descartes Necker Cochin |
Granulomatosis With Polyangiitis|Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
|
October 2022 | Phase 2 |
| NCT00166439 | Academic and Community Cancer Research United|Mayo Clinic |
Lymphoma
|
March 2005 | Phase 2 |
| NCT00568815 | Fudan University |
Lymphoma
|
April 2007 | Phase 2 |
| NCT01848132 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. |
Diffuse, Large B-Cell, Lymphoma
|
October 3, 2013 | Phase 2 |
| NCT05191225 | Laida Cuevas Palomares|Bioaraba Health Research Institute |
Non-Hodgkin´s Lymphoma
|
September 28, 2021 | Phase 4 |
| NCT04660799 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
February 24, 2021 | Phase 2 |
| NCT04776850 | M.D. Anderson Cancer Center |
Beta Thalassemia Major|Sickle Beta 0 Thalassemia|Sickle Beta Plus Thalassemia|Sickle Beta Thalassemia|Sickle Cell Disease|Sickle Cell-SS Disease
|
December 29, 2020 | Early Phase 1 |
| NCT02110394 | Astellas Pharma Europe B.V.|Astellas Pharma Inc |
Chronic Lymphocytic Leukemia
|
June 2012 | |
| NCT03703167 | Memorial Sloan Kettering Cancer Center|Pharmacyclics LLC. |
Primary Central Nervous System Lymphoma (PCNSL)|Secondary Central Nervous System Lymphoma (SCNSL)
|
January 22, 2019 | Phase 1 |
| NCT03467867 | Georgetown University|Hackensack Meridian Health |
Chronic Lymphocytic Leukemia
|
April 26, 2018 | Phase 2 |
| NCT05583071 | University of Cologne|Incyte Corporation |
Non-Hodgkin Lymphoma
|
January 2023 | Phase 2 |
| NCT02525172 | National Taiwan University Hospital |
Pompe Disease
|
August 2015 | Phase 4 |
| NCT03121677 | Washington University School of Medicine |
Follicular Lymphoma
|
October 16, 2018 | Phase 1 |
| NCT00269113 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
September 1998 | Phase 3 |
| NCT04220008 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
|
June 1, 2023 | Phase 2 |
| NCT04680052 | Incyte Corporation |
Follicular Lymphoma|Marginal Zone Lymphoma
|
April 15, 2021 | Phase 3 |
| NCT03934814 | AbbVie|I-Mab Biopharma Co. Ltd. |
Solid Tumor|Lymphoma
|
April 16, 2019 | Phase 1 |
| NCT03980379 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
CD20 Positive B Cell NHL
|
December 18, 2018 | Phase 1 |
| NCT00060346 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
June 2004 | Phase 2 |
| NCT00087009 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma|Lymphoproliferative Disorder
|
May 2004 | Phase 1 |
| NCT00785330 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|University Hospital Goettingen|German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Non-Hodgkin´s Lymphoma
|
April 2004 | Phase 2 |
| NCT00216762 | Johns Hopkins University|Genentech, Inc. |
Urticaria
|
January 2006 | Phase 1|Phase 2 |
| NCT04712097 | Hoffmann-La Roche |
Relapsed or Refractory Follicular Lymphoma
|
October 27, 2021 | Phase 3 |
| NCT05406401 | Merck Sharp & Dohme LLC |
Lymphoma, Large B-Cell, Diffuse (DLBCL)
|
July 14, 2022 | Phase 2 |
| NCT02219737 | National Cancer Institute (NCI) |
CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
September 12, 2014 | Phase 1 |
| NCT03749018 | David Bond, MD|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center |
Aggressive Non-Hodgkin Lymphoma|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Indolent Non-Hodgkin Lymphoma|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma
|
January 2, 2019 | Phase 2 |
| NCT00462345 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
June 2007 | Phase 4 |
| NCT01641952 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
October 2011 | |
| NCT01855750 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
September 3, 2013 | Phase 3 |
| NCT00609869 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation |
Lymphocytic Leukemia|Mantle Cell Lymphoma
|
October 2007 | Phase 2 |
| NCT04555811 | Masonic Cancer Center, University of Minnesota |
NHL|Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma
|
September 22, 2020 | Phase 1 |
| NCT01010061 | Hoffmann-La Roche|German CLL Study Group|Genentech, Inc. |
Lymphocytic Leukemia, Chronic
|
December 21, 2009 | Phase 3 |
| NCT01272908 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
July 18, 2006 | Phase 3 |
| NCT00254410 | M.D. Anderson Cancer Center|OSI Pharmaceuticals|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
March 14, 2005 | Phase 2 |
| NCT04542629 | Assiut University |
Refractory Epilepsy
|
October 1, 2020 | Phase 4 |
| NCT00381810 | Genentech, Inc. |
Lupus Erythematosus, Systemic
|
June 22, 2006 | Phase 3 |
| NCT00577629 | Duke University|GlaxoSmithKline |
Lymphoma, B-Cell
|
June 18, 2005 | Phase 2 |
| NCT00387959 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2006 | Phase 2 |
| NCT00265928 | University of Virginia|National Cancer Institute (NCI) |
Lymphoma
|
Phase 2 | |
| NCT02260934 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Lupus Nephritis
|
July 9, 2015 | Phase 2 |
| NCT00664599 | Tehran University of Medical Sciences|Hoffmann-La Roche |
Behcet´s Syndrome
|
April 2006 | Phase 2 |
| NCT00180882 | Gustave Roussy, Cancer Campus, Grand Paris |
Burkitt Lymphoma
|
October 2004 | Phase 3 |
| NCT00115700 | Trans Tasman Radiation Oncology Group|Australasian Leukaemia and Lymphoma Group |
Follicular Lymphoma
|
February 2000 | Phase 3 |
| NCT00133991 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2005 | Phase 2 |
| NCT03136146 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Burkitt Leukemia|Recurrent Burkitt Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Acute Lymphoblastic Leukemia|Refractory Burkitt Leukemia|Refractory Burkitt Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Lymphoblastic Lymphoma
|
August 9, 2017 | Phase 2 |
| NCT00532129 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
November 2007 | Phase 2 |
| NCT01200589 | Novartis Pharmaceuticals|GlaxoSmithKline|Novartis |
Non-Hodgkin´s Lymphoma
|
October 11, 2010 | Phase 3 |
| NCT01004991 | Weill Medical College of Cornell University|Celgene |
Diffuse Large B Cell Lymphoma
|
January 2010 | Phase 1|Phase 2 |
| NCT00080847 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
March 2004 | Phase 2 |
| NCT03949855 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|GlaxoSmithKline|PPD|Rho Federal Systems Division, Inc. |
Membranous Nephropathy|Nephrotic Syndrome
|
December 18, 2019 | Phase 2 |
| NCT01117662 | Hannover Medical School|German Federal Ministry of Education and Research |
Acute Rejection
|
May 2012 | Phase 3 |
| NCT01303887 | University of Liverpool|Liverpool University Hospitals NHS Foundation Trust|Cancer Research UK|Roche Pharma AG |
Follicular Lymphoma
|
October 2009 | Phase 3 |
| NCT00144807 | Lymphoma Study Association |
Diffuse Large Cell Lymphoma
|
December 2003 | Phase 2 |
| NCT00097188 | Genentech, Inc. |
Multiple Sclerosis
|
December 2004 | Phase 2 |
| NCT04673617 | Artiva Biotherapeutics, Inc. |
Non Hodgkin Lymphoma
|
March 29, 2021 | Phase 1|Phase 2 |
| NCT00841945 | French Innovative Leukemia Organisation |
B Cell Lymphoma
|
April 2005 | Phase 3 |
| NCT03232307 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CCND1 Positive|CD20-Positive Neoplastic Cells Present|Mantle Cell Lymphoma
|
July 1, 2019 | Phase 2 |
| NCT01047072 | Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Systemic Scleroderma
|
Phase 2 | |
| NCT00427557 | M.D. Anderson Cancer Center |
Multiple Myeloma|Leukemia|Lymphoma
|
October 2006 | Phase 2 |
| NCT00140582 | Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|German Low Grade Lymphoma Study Group|Australasian Leukaemia and Lymphoma Group|Institute of Cancer Research, United Kingdom |
Follicular Lymphoma
|
December 2004 | Phase 3 |
| NCT00372892 | Hamilton Health Sciences Corporation|Hoffmann-La Roche|McMaster University |
Purpura, Thrombocytopenic, Idiopathic
|
September 2006 | Phase 2 |
| NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
| NCT04974216 | The Lymphoma Academic Research Organisation |
DLBCL
|
December 20, 2021 | Phase 2 |
| NCT01230788 | Emory University |
Leukemia|Acute Lymphoblastic Leukemia|ALL
|
September 2010 | Not Applicable |
| NCT00525876 | M.D. Anderson Cancer Center |
Lymphoma
|
January 2005 | Not Applicable |
| NCT02251964 | Human Adams|Amsterdam UMC, location VUmc|St. Antonius Hospital |
Lung Diseases, Interstitial|Pneumonitis, Interstitial
|
September 2014 | Phase 2|Phase 3 |
| NCT04214626 | Henan Cancer Hospital |
Diffuse Large B Cell Lymphoma
|
January 2, 2020 | Phase 2 |
| NCT03206671 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) |
Mature B-cell Non-Hodgkin Lymphoma
|
August 3, 2017 | Phase 3 |
| NCT02871869 | Xinjiang Medical University |
Diffuse, Large B-Cell, Lymphoma
|
September 2016 | Phase 2|Phase 3 |
| NCT04494503 | Ascentage Pharma Group Inc. |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
August 31, 2020 | Phase 1|Phase 2 |
| NCT01014208 | GlaxoSmithKline |
Lymphoma, Large-Cell, Diffuse
|
March 2010 | Phase 3 |
| NCT04361409 | China Medical University Hospital |
Head and Neck Squamous Carcinoma
|
May 2013 | Phase 1 |
| NCT02293109 | Mehrdad Abedi, MD|Amgen|University of California, Davis |
Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia
|
December 17, 2015 | Phase 1 |
| NCT04762160 | Epizyme, Inc.|Swedish Cancer Institute |
Follicular Lymphoma
|
February 3, 2021 | Phase 2 |
| NCT05052528 | Mehrdad Abedi, MD|National Cancer Institute (NCI)|University of California, Davis |
Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
September 17, 2021 | Phase 1 |
| NCT04235036 | Northside Hospital, Inc.|Pharmacyclics LLC. |
Graft Vs Host Disease
|
December 16, 2019 | Phase 2 |
| NCT01560117 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Follicular T-NHL Lymphoma|Rituximab Maintenance
|
January 2004 | Phase 2 |
| NCT00229619 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Anemia, Aplastic|Red-Cell Aplasia, Pure|Anemia, Diamond-Blackfan
|
September 2005 | Phase 2 |
| NCT03689894 | Dartmouth-Hitchcock Medical Center |
Chronic Graft-versus-host-disease
|
April 12, 2019 | Phase 1|Phase 2 |
| NCT00845104 | Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium|Fred Hutchinson Cancer Center |
B-cell Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia
|
January 2009 | Phase 2 |
| NCT00734773 | Northwestern University|Pharmacyclics LLC. |
Brain and Central Nervous System Tumors|Lymphoma|Neurotoxicity
|
November 2008 | Early Phase 1 |
| NCT04624906 | Sunnybrook Health Sciences Centre|AstraZeneca |
Waldenstrom Macroglobulinemia
|
March 2, 2021 | Phase 2 |
| NCT02169219 | Massachusetts General Hospital|Genentech, Inc. |
Granulomatosis With Polyangiitis|Microscopic Polyangiitis
|
June 2014 | Phase 4 |
| NCT03332888 | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud |
Heart Failure With Reduced Ejection Fraction
|
January 1, 2021 | Phase 2 |
| NCT04047797 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma
|
August 28, 2019 | Phase 2 |
| NCT01742988 | Curis, Inc.|The Leukemia and Lymphoma Society |
Lymphoma|Relapsed Lymphoma|Refractory Lymphoma|Relapsed and+or Refractory Lymphoma|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Relapsed and+or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Double-hit Lymphoma (DHL)|Triple-hit Lymphoma (THL)|Double-expressor Lymphoma (DEL)|High-grade B-cell Lymphoma (HGBL)
|
December 2012 | Phase 1 |
| NCT02571842 | Chulalongkorn University |
Recurrent IgA Nephropathy
|
January 2012 | Phase 4 |
| NCT02128061 | The Lymphoma Academic Research Organisation|Centre Henri Becquerel |
Diffuse Large B Cell Lymphoma
|
August 2014 | Phase 3 |
| NCT00647049 | University Hospital Freiburg|University Hospital Tuebingen |
Primary Non Hodgkin Lymphoma of the Central Nervous System
|
January 2007 | Phase 2 |
| NCT03997968 | Cyteir Therapeutics, Inc. |
Malignancy|Non-hodgkin Lymphoma|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Head and Neck Cancer|DLBCL|Mantle Cell Lymphoma|Follicular Lymphoma|Pancreatic Cancer|CLL|Small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Triple Negative Breast Cancer
|
October 9, 2019 | Phase 1|Phase 2 |
| NCT02790515 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myeloid Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)
|
July 14, 2016 | Phase 2 |
| NCT01446900 | European Institute of Oncology |
Chronic Lymphocytic Leukaemia|Small Lymphocytic Lymphoma
|
January 2011 | Phase 2 |
| NCT01278745 | National Institute of Allergy and Infectious Diseases (NIAID)|National Heart, Lung, and Blood Institute (NHLBI)|Clinical Trials in Organ Transplantation|Genentech, Inc.|Rho Federal Systems Division, Inc. |
Cardiac Allograft Vasculopathy|Heart Transplant Recipients
|
September 2011 | Phase 2 |
| NCT01148446 | Fondazione Italiana Linfomi ONLUS |
Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL)
|
January 2003 | Phase 3 |
| NCT02728531 | Washington University School of Medicine |
Mantle Cell Lymphoma
|
April 18, 2016 | Phase 1 |
| NCT01925612 | Seagen Inc. |
Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse
|
August 2013 | Phase 2 |
| NCT00003248 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
March 1998 | Phase 2 |
| NCT01203930 | Gilead Sciences |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
|
October 2010 | Phase 2 |
| NCT03069248 | Sunnybrook Health Sciences Centre |
Follicular Lymphoma
|
June 1, 2000 | Phase 2 |
| NCT00965289 | Nantes University Hospital|French Innovative Leukemia Organisation|Hoffmann-La Roche |
B-Cell Lymphoma
|
April 2002 | Phase 2 |
| NCT00250861 | US Oncology Research|Chiron Corporation|Fred Hutchinson Cancer Center |
Non-Hodgkin´s Lymphoma
|
October 2005 | Phase 2 |
| NCT01650701 | The Lymphoma Academic Research Organisation|Celgene Corporation |
Follicular Lymphoma
|
February 2012 | Phase 3 |
| NCT00057811 | Children´s Oncology Group|National Cancer Institute (NCI) |
Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia
|
June 2004 | Phase 2 |
| NCT04856137 | National Health Research Institutes, Taiwan|Taipei Veterans General Hospital, Taiwan|Chang Gung Memorial Hospital|China Medical University Hospital|Shin Kong Wu Huo-Shih Memorial Hospital |
Refractory Diffuse Large B-cell Lymphoma
|
May 1, 2021 | Phase 1|Phase 2 |
| NCT03579875 | Masonic Cancer Center, University of Minnesota |
Fanconi Anemia|Severe Aplastic Anemia|Myelodysplastic Syndromes
|
November 13, 2018 | Phase 2 |
| NCT00068315 | National Cancer Institute (NCI) |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic+Lymphoid Cancer|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
July 2003 | Phase 1 |
| NCT01697267 | Cambridge University Hospitals NHS Foundation Trust|Arthritis Research UK|Roche Pharma AG|Genentech, Inc.|University of Pennsylvania |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis|Microscopic Polyangiitis|Wegener Granulomatosis
|
April 2013 | Phase 3 |
| NCT04783675 | Children´s Hospital of Fudan University|Children´s Hospital of Nanjing Medical University|The Children´s Hospital of Zhejiang University School of Medicine|Wuhan Union Hospital, China|Anhui Provincial Children´s Hospital|Children´s Hospital Affiliated to Zhengzhou University+Henan Children´s Hospital|The first affiliated hospital of Zhongshan university|Shandong Provincial Hospital|Xuzhou Children´s Hospital |
Steroid-Sensitive Nephrotic Syndrome
|
April 13, 2021 | Phase 2 |
| NCT01029730 | SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Cephalon |
Lymphoma
|
March 2010 | Phase 2 |
| NCT01856192 | National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
August 27, 2013 | Phase 2 |
| NCT04181489 | The First Affiliated Hospital with Nanjing Medical University |
EBV-Positive DLBCL, Nos
|
January 1, 2019 | Phase 2 |
| NCT02914938 | MEI Pharma, Inc. |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma (FL)|Marginal Zone B Cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|High Grade Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma (MCL)
|
October 2016 | Phase 1 |
| NCT00209209 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|Nordic Lymphoma Group |
Lymphoma, Mantle-Cell
|
January 14, 2004 | Phase 3 |
| NCT00290407 | University of Louisville|James Graham Brown Cancer Center |
Leukemia, Lymphocytic, Chronic|Lymphoma, Small Lymphocytic
|
March 2006 | Phase 2 |
| NCT03456466 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Non-hodgkin´s Lymphoma
|
May 1, 2017 | Phase 1|Phase 2 |
| NCT00045864 | Chiron Corporation |
Lymphoma, Non-Hodgkin
|
Phase 2 | |
| NCT00748644 | Assistance Publique - Hôpitaux de Paris |
Wegener Granulomatosis|Microscopic Polyangiitis
|
October 2008 | Phase 3 |
| NCT03531736 | Memorial Sloan Kettering Cancer Center |
Myeloid Diseases
|
May 9, 2018 | Phase 1 |
| NCT00088530 | CTI BioPharma |
Lymphoma, Non-Hodgkin
|
July 2004 | Phase 3 |
| NCT04400994 | The University of Hong Kong |
Pemphigus
|
June 20, 2020 | Phase 2 |
| NCT00972478 | National Cancer Institute (NCI) |
Ann Arbor Stage II Non-Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma
|
November 15, 2010 | Phase 1|Phase 2 |
| NCT00007852 | University of Nebraska|National Cancer Institute (NCI)|Genentech, Inc. |
Lymphoma
|
September 2000 | Phase 2 |
| NCT00259805 | California Pacific Medical Center Research Institute|Genentech, Inc. |
Chronic Focal Encephalitis|Rasmussen´s Encephalitis
|
January 2005 | Phase 1 |
| NCT03704714 | Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI) |
Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 20, 2018 | Phase 1|Phase 2 |
| NCT00994643 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University |
High Risk Non-Hodgkin´s Lymphoma
|
February 5, 2009 | Phase 2 |
| NCT02366663 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
January 2015 | Phase 3 |
| NCT05270057 | Medical College of Wisconsin |
B-cell Lymphoma|Burkitt Lymphoma
|
December 2022 | Phase 1 |
| NCT00005609 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 2 |
| NCT04120350 | Peking Union Medical College Hospital|Beijing Tiantan Hospital|Xuanwu Hospital, Beijing|Peking University Third Hospital|Beijing Hospital|Peking University First Hospital|Chinese PLA General Hospital |
Primary Central Nervous System Lymphoma
|
August 16, 2019 | Phase 1|Phase 2 |
| NCT01135641 | Nantes University Hospital |
Graft Versus Host Disease
|
June 2010 | Phase 2 |
| NCT02162771 | Celltrion |
Lymphoma, Follicular
|
July 14, 2014 | Phase 3 |
| NCT01732913 | Gilead Sciences |
Indolent Non-Hodgkin´s Lymphomas
|
January 16, 2013 | Phase 3 |
| NCT00201682 | John Byrd|Ohio State University Comprehensive Cancer Center |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 2002 | Phase 1|Phase 2 |
| NCT01180036 | Mayo Clinic|Columbia University|University of British Columbia|Ohio State University|Stanford University|University of Washington|University of Michigan|University of Alabama at Birmingham|Case Western Reserve University|The Cleveland Clinic|University of Kansas Medical Center|University of Manchester|University Health Network, Toronto|University of Toronto|CHU de Quebec-Universite Laval|Washington University School of Medicine|Florida International University|University of Mississippi Medical Center|NYU Langone Health|Medical College of Wisconsin|University of Arizona|Sunnybrook Health Sciences Centre|Applied Health Research Centre|Fulk Family Foundation |
Idiopathic Membranous Nephropathy
|
November 2011 | Phase 2|Phase 3 |
| NCT02705638 | Mayo Clinic|Celgene Corporation |
Immunoglobulin G Subclass 4 Related Disease|IgG4-related Disease|Autoimmune Pancreatitis|IgG4-related Sclerosing Cholangitis|Retroperitoneal Fibrosis
|
April 2016 | Phase 1 |
| NCT00502840 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
July 23, 2007 | Phase 3 |
| NCT00255593 | Karolinska University Hospital |
Renal Transplantation
|
November 2005 | Phase 1 |
| NCT00738374 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
November 3, 2008 | Phase 2 |
| NCT00772668 | University of Miami |
Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma
|
September 25, 2009 | Not Applicable |
| NCT00070447 | National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 2 |
| NCT00829205 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
January 2009 | Phase 1|Phase 2 |
| NCT01423539 | Genentech, Inc.|AbbVie (prior sponsor, Abbott) |
Diffuse Large B-Cell Lymphoma
|
October 2011 | Phase 2 |
| NCT02980042 | University of Colorado, Denver |
Multiple Sclerosis
|
January 1, 2017 | Phase 3 |
| NCT00137995 | Lymphoma Study Association |
Lymphoma, Large-Cell, Diffuse
|
June 2003 | Phase 3 |
| NCT01085617 | University College, London |
Leukemia|Mucositis|Oral Complications
|
December 2010 | Phase 3 |
| NCT01956695 | Institut Curie|Centre Hospitalier Universitaire, Amiens|Institut Bergonié|University Hospital, Clermont-Ferrand|University Hospital, Lille|Central Hospital, Nancy, France|Groupe Hospitalier Pitie-Salpetriere|Centre Henri Becquerel|University Hospital, Tours|Centre Leon Berard|University Hospital, Grenoble |
Lymphoma|Relapse
|
September 18, 2013 | Phase 2 |
| NCT02733042 | Celgene |
Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell
|
May 11, 2016 | Phase 1|Phase 2 |
| NCT02451111 | Swiss Group for Clinical Cancer Research|Nordic Lymphoma Group |
Follicular Lymphoma
|
November 6, 2015 | Phase 2 |
| NCT01808599 | International Extranodal Lymphoma Study Group (IELSG) |
MALT Lymphoma
|
December 2013 | Phase 2 |
| NCT00311129 | Genzyme, a Sanofi Company|Sanofi |
Lymphoma, Low-Grade
|
December 2005 | Phase 2 |
| NCT02213913 | University of Chicago|National Cancer Institute (NCI) |
Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
July 29, 2014 | Phase 1|Phase 2 |
| NCT00281931 | German CLL Study Group |
Prolymphocytic Leukemia
|
September 1999 | Phase 2 |
| NCT00451178 | Eli Lilly and Company |
Lymphoma
|
May 2007 | Phase 2 |
| NCT01449344 | Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen, Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance, Pierre Benite|European Mantle Cell Lymphoma Network |
Mantle Cell Lymphoma
|
May 9, 2009 | Phase 3 |
| NCT00109967 | National Cancer Institute (NCI) |
Recurrent Mantle Cell Lymphoma
|
May 2005 | Phase 2 |
| NCT00723658 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2008 | Phase 2 |
| NCT01268033 | University Hospital, Limoges|Hoffmann-La Roche |
Childhood Idiopathic Nephrotic Syndrome
|
December 2010 | Phase 2|Phase 3 |
| NCT05371093 | Kite, A Gilead Company|Gilead Sciences |
Relapsed+Refractory Follicular Lymphoma
|
September 12, 2022 | Phase 3 |
| NCT02205333 | MedImmune LLC |
Advanced Solid Tumors|Aggressive B-cell Lymphomas
|
August 13, 2014 | Phase 1|Phase 2 |
| NCT01813227 | Hackensack Meridian Health|Onyx Therapeutics, Inc. |
Waldenstrom Macroglobulinemia
|
April 2013 | Phase 2 |
| NCT00667329 | M.D. Anderson Cancer Center |
Lymphoma
|
July 9, 1999 | Phase 1 |
| NCT01737177 | Fondazione Italiana Linfomi ONLUS |
Mantle Cell Lymphoma
|
July 31, 2012 | Phase 2 |
| NCT00435955 | Azienda Ospedaliera San Giovanni Battista|University of Turin, Italy|Gruppo Italiano Trapianto di Midollo Osseo|Gruppo Italiano Studio Linfomi|Hoffmann-La Roche |
Follicular Lymphoma
|
March 2000 | Phase 3 |
| NCT00250718 | New Mexico Cancer Care Alliance |
Non-Hodgkin´s Lymphoma|Cancer
|
October 2004 | Phase 2 |
| NCT05388123 | Scripps Health |
Hairy Cell Leukemia
|
January 1, 2022 | Phase 2 |
| NCT03684980 | Memorial Sloan Kettering Cancer Center|University of Alabama at Birmingham |
Central Nervous System Lymphoma
|
November 14, 2018 | Early Phase 1 |
| NCT02436707 | Canadian Cancer Trials Group|Janssen, LP|Roche Pharma AG|Karyopharm Therapeutics Inc |
Lymphoma
|
May 5, 2015 | Phase 2 |
| NCT00251277 | Weill Medical College of Cornell University|Genentech, Inc. |
Thrombotic Thrombocytopenic Purpura
|
November 2005 | Phase 1|Phase 2 |
| NCT01980888 | Gilead Sciences |
Chronic Lymphocytic Leukemia
|
February 5, 2014 | Phase 3 |
| NCT00068250 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Brain and Central Nervous System Tumors|Lymphoma
|
July 2003 | Phase 1|Phase 2 |
| NCT02951728 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
October 2016 | Phase 1|Phase 2 |
| NCT00413959 | Oncology Specialists, S.C.|Millennium Pharmaceuticals, Inc. |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell
|
August 2006 | Phase 2 |
| NCT02073097 | Case Comprehensive Cancer Center |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
January 28, 2015 | Phase 1|Phase 2 |
| NCT00794638 | SymBio Pharmaceuticals |
Non-Hodgkin´s Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma
|
November 2008 | Phase 1 |
| NCT00072592 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Wegener´s Granulomatosis
|
October 2003 | Phase 1 |
| NCT02933320 | Cancer Research UK|BioInvent International AB|Bloodwise |
B-cell Lymphoma|Chronic Lymphocytic Leukaemia|Waldenström Macroglobulinemia
|
October 27, 2016 | Phase 1|Phase 2 |
| NCT00106184 | University of Pittsburgh|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Genentech, Inc.|Biogen |
Myositis|Dermatomyositis|Polymyositis|Juvenile Dermatomyositis
|
March 2006 | Phase 2 |
| NCT00904722 | M.D. Anderson Cancer Center|CureTech Ltd |
Lymphoma
|
January 2010 | Phase 2 |
| NCT04224571 | Chinese University of Hong Kong|Shanghai Children´s Medical Center |
Acute Lymphoblastic Leukemia, in Relapse
|
September 14, 2018 | Phase 2 |
| NCT00036491 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence |
Lupus Erythematosus, Systemic
|
January 2001 | Phase 1|Phase 2 |
| NCT00225212 | Stanford University |
Non-Hodgkin´s Lymphoma|Diffuse Large Cell Lymphoma|Mantle Cell Lymphoma|Transformed Lymphoma|Other Subtypes of B-cell Lymphoma|Lymphoma
|
November 1997 | Phase 2 |
| NCT03804372 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Large-B-cell Diffuse Lymphoma|Chronic Lymphoid Leukemia
|
July 7, 2020 | Phase 2 |
| NCT01011920 | International Extranodal Lymphoma Study Group (IELSG) |
Central Nervous System Lymphoma
|
November 2009 | Phase 2 |
| NCT04416451 | Memorial Sloan Kettering Cancer Center|AbbVie |
Marginal Zone Lymphoma
|
May 4, 2021 | Phase 2 |
| NCT00842595 | French Innovative Leukemia Organisation |
Diffuse Large B-Cell Lymphoma
|
December 2003 | Phase 2 |
| NCT03180723 | Assiut University |
Membranoproliferative Glomerulonephritis
|
July 1, 2017 | Phase 3 |
| NCT00720135 | City of Hope Medical Center|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
January 2008 | Phase 1 |
| NCT00346684 | University of Cologne |
Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
|
July 2006 | Phase 2 |
| NCT00774462 | Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Roche Pharma AG |
Myositis|Myasthenia Gravis
|
January 2008 | Phase 2 |
| NCT01446133 | M.D. Anderson Cancer Center|Celgene Corporation |
Leukemia|Lymphoma
|
December 12, 2011 | Phase 2 |
| NCT02622503 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
April 2008 | |
| NCT00078598 | Corixa Corporation |
Non-Hodgkin´s Lymphoma
|
April 2004 | Phase 3 |
| NCT01045928 | Case Comprehensive Cancer Center |
Adult Non-Hodgkin Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia
|
January 2010 | Phase 1 |
| NCT02693210 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
February 2001 | Phase 2 |
| NCT00193479 | SCRI Development Innovations, LLC|Genentech, Inc.|Amgen |
Non-Hodgkins Lymphoma
|
April 2003 | Phase 2 |
| NCT00299104 | Genentech, Inc.|Hoffmann-La Roche |
Rheumatoid Arthritis
|
January 2006 | Phase 3 |
| NCT00005589 | EBMT Solid Tumors Working Party|Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 3 |
| NCT00006669 | Medstar Health Research Institute |
Lymphoma
|
September 1999 | Phase 2 |
| NCT03018535 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia|University of Bari|Azienda Ospedaliera Brotzu|University of Messina|University of Milan|Universita di Verona|University of Chieti|University of Bologna|Azienda Sanitaria Locale Roma E|IRCCS Azienda Ospedaliero-Universitaria di Bologna|Regione Piemonte|University of Modena and Reggio Emilia|University of Pisa|University of Milano Bicocca|Humanitas Hospital, Italy|Azienda Ospedaliera Universitaria Policlinico|Fondazione Salvatore Maugeri|University of Bern|University of Alberta|Istituto Giannina Gaslini |
Glomerulonephritis, Membranous
|
January 2012 | Phase 3 |
| NCT00293475 | OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Oregon Health and Science University |
Central Nervous System Lymphoma
|
October 14, 2005 | Phase 1|Phase 2 |
| NCT00405340 | Mayo Clinic|Genentech, Inc. |
Membranous Nephropathy
|
October 2006 | Early Phase 1 |
| NCT00209222 | European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association |
Lymphoma, Mantle-Cell
|
July 2004 | Phase 3 |
| NCT00669877 | M.D. Anderson Cancer Center |
Burkitt´s Lymphoma|Burkitt´S-like Lymphoma
|
August 2002 | Phase 2 |
| NCT00764517 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma
|
August 2008 | Phase 2 |
| NCT00769522 | German CLL Study Group|Roche Pharma AG|Mundipharma Pte Ltd. |
Chronic Lymphocytic Leukemia
|
October 2, 2008 | Phase 3 |
| NCT00088881 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
December 2004 | Phase 2 |
| NCT03582098 | Gilead Sciences |
Chronic Lymphocytic Leukaemia
|
September 12, 2018 | |
| NCT01319981 | M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc |
Leukemia
|
March 5, 2013 | Phase 2 |
| NCT00012298 | National Cancer Institute (NCI) |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
April 2001 | Phase 1|Phase 2 |
| NCT00278421 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
| NCT00335140 | Eastern Cooperative Oncology Group |
Lymphoma
|
December 2006 | Phase 2 |
| NCT01842386 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Pulmonary Alveolar Proteinosis (PAP)|Severe Mucocutaneous Candidiasis
|
April 29, 2014 | Phase 1 |
| NCT02983097 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH|Celgene|Amgen |
Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III�)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)
|
November 2010 | Phase 1|Phase 2 |
| NCT00637832 | University of Southampton |
Lymphoma
|
April 1, 2008 | Phase 2 |
| NCT04998669 | Juan P. Alderuccio, MD|ADC Therapeutics S.A.|University of Miami |
Follicular Lymphoma
|
February 11, 2022 | Phase 2 |
| NCT00137969 | Genentech, Inc. |
Lupus Erythematosus, Systemic
|
May 10, 2005 | Phase 2|Phase 3 |
| NCT04268277 | University of Ulm|X-act Cologne Clinical Research GmbH|Zentrum für Klinische Studien Ulm|Merck Sharp & Dohme LLC|Celltrion Healthcare Co., LTD |
Marginal Zone Lymphoma
|
March 1, 2022 | Not Applicable |
| NCT01097057 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Non-Hodgkin Lymphoma
|
November 9, 2010 | Phase 2 |
| NCT00193492 | SCRI Development Innovations, LLC|Genentech, Inc. |
Lymphoma, Follicular
|
September 2005 | Phase 2 |
| NCT00578591 | Baylor College of Medicine |
Graft vs Host Disease|Alogenic Hematopoietic Transplant
|
June 2007 | Phase 2 |
| NCT00006708 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 2000 | Phase 3 |
| NCT01244958 | Frank Behrens|Johann Wolfgang Goethe University Hospital |
Rheumatoid Arthritis
|
August 2010 | Phase 3 |
| NCT00114738 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, Mantle Cell|Mantle Cell Lymphoma
|
June 15, 2005 | Phase 2 |
| NCT01779167 | Weill Medical College of Cornell University|Celgene Corporation |
Waldenstrom Macroglobulinemia
|
June 2012 | Phase 2 |
| NCT05390749 | Peking Union Medical College Hospital|Beijing Tiantan Hospital|Sanbo Brain Hospital Capital Medical University |
Primary Central Nervous System Lymphoma
|
April 11, 2022 | Phase 2 |
| NCT01087151 | Genentech, Inc.|AbbVie (prior sponsor, Abbott) |
Chronic Lymphocytic Leukemia
|
August 2010 | Phase 2 |
| NCT02408042 | Western Regional Medical Center |
Lymphoma|Hodgkin´s Lymphoma|Non-hodgkin´s Lymphoma
|
April 2015 | Phase 1|Phase 2 |
| NCT05578976 | AbbVie|Genmab |
Diffuse Large B-Cell Lymphoma
|
February 5, 2023 | Phase 3 |
| NCT01238692 | Sarit Assouline|Quebec Clinical Research Organization in Cancer|Novartis|Hoffmann-La Roche|Jewish General Hospital |
Diffuse Large B Cell Lymphoma
|
November 2010 | Phase 2 |
| NCT05351346 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
June 1, 2022 | Phase 3 |
| NCT00221325 | University of California, San Francisco |
Central Nervous System Lymphoma|Intraocular Lymphoma
|
April 2007 | Phase 1 |
| NCT01144754 | Stanford University |
Lymphoma|Non-Hodgkin´s Lymphoma
|
February 2009 | |
| NCT01754857 | University of Wisconsin, Madison|Celgene Corporation|Genentech, Inc. |
Lymphoid Leukemia|Small Lymphocytic Lymphoma|Lymphoma, Non-Hodgkin
|
November 12, 2013 | Phase 2 |
| NCT02187133 | University of California, San Francisco|National Comprehensive Cancer Network |
Lymphoma, Non-Hodgkin|Lymphoma
|
May 5, 2015 | Phase 1 |
| NCT00312845 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Non-Hodgkin´s Lymphoma
|
March 2006 | Phase 3 |
| NCT00732498 | University of Arizona|National Cancer Institute (NCI) |
Lymphoma
|
May 15, 2006 | Phase 2 |
| NCT01299857 | University Hospital, Rouen |
Pemphigus
|
June 2011 | Phase 3 |
| NCT04224493 | Epizyme, Inc. |
Relapsed+Refractory Follicular Lymphoma
|
December 19, 2019 | Phase 3 |
| NCT00372905 | Northwestern University|Robert H. Lurie Cancer Center |
Lymphoma
|
July 24, 2007 | Phase 1|Phase 2 |
| NCT01613027 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
February 2012 | |
| NCT03501459 | National University Health System, Singapore |
Nephrotic Syndrome
|
June 2008 | Phase 3 |
| NCT02596971 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
|
December 22, 2015 | Phase 1|Phase 2 |
| NCT05596786 | University Hospital, Tours |
Lung Diseases
|
December 15, 2022 | Phase 3 |
| NCT01312064 | National Taiwan University Hospital |
Renal Insufficiency
|
April 2011 | Phase 4 |
| NCT00373594 | University of Bergen |
Cold Agglutinin Disease
|
June 2005 | Phase 2 |
| NCT02532192 | M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc |
Lymphoma
|
December 2015 | Phase 1 |
| NCT00301795 | National Cancer Institute (NCI) |
Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma
|
March 2006 | Phase 2 |
| NCT00090038 | Biogen |
Non-Hodgkin´s Lymphoma
|
October 2003 | Phase 4 |
| NCT00989352 | University Hospital Freiburg|Universitätsklinikum Köln|Ludwig-Maximilians - University of Munich|University Hospital Heidelberg|University Hospital Ulm |
Primary Non Hodgkin Lymphoma of the Central Nervous System
|
September 2009 | Phase 2 |
| NCT02763319 | MorphoSys AG|ICON Clinical Research |
Diffuse Large B-cell Lymphoma
|
June 2016 | Phase 2|Phase 3 |
| NCT01549886 | Spectrum Pharmaceuticals, Inc |
Non-Hodgkin´s Lymphoma
|
November 2011 | Phase 2 |
| NCT03983031 | Region Örebro County|Örebro University, Sweden |
Obsessive-Compulsive Disorder|Treatment Resistant Disorders
|
August 8, 2019 | Phase 1 |
| NCT00204659 | University Hospital Tuebingen|Hoffmann-La Roche |
Primary Gastric Diffuse-Large B-Cell Lymphoma
|
March 2003 | Phase 2 |
| NCT03579927 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD19 Positive|Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma
|
October 3, 2019 | Phase 1|Phase 2 |
| NCT01569295 | Gilead Sciences |
Chronic Lymphocytic Leukemia
|
June 15, 2012 | Phase 3 |
| NCT01871675 | SCRI Development Innovations, LLC|Infinity Pharmaceuticals, Inc. |
Lymphoma|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|T-cell Lymphoma
|
May 2013 | Phase 1 |
| NCT01992653 | Genentech, Inc. |
Lymphoma, Non Hodgkin
|
November 29, 2013 | Phase 1|Phase 2 |
| NCT02957019 | Philogen S.p.A. |
Diffuse Large B-cell Lymphoma (DLBCL)
|
July 31, 2013 | Phase 1|Phase 2 |
| NCT03778619 | GC Cell Corporation |
Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma
|
November 28, 2018 | Phase 1|Phase 2 |
| NCT00472420 | Hoffmann-La Roche |
Mantle Cell Lymphoma
|
June 27, 2007 | Phase 2 |
| NCT01313611 | The Lymphoma Academic Research Organisation |
Follicular Lymphoma
|
February 2011 | Phase 2 |
| NCT01086631 | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) |
Autoimmune Disease
|
January 22, 2010 | Phase 1 |
| NCT00401817 | Weill Medical College of Cornell University |
Untreated Mantle Cell Lymphoma
|
November 2007 | Phase 2 |
| NCT00908583 | University of Cincinnati|Millennium Pharmaceuticals, Inc. |
HLA Sensitization
|
May 2009 | Phase 4 |
| NCT05455697 | University of Washington |
Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|High Grade B-Cell Lymphoma
|
December 15, 2022 | Phase 1|Phase 2 |
| NCT00553943 | Lymphoma Study Association |
Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma
|
July 2007 | Phase 2 |
| NCT03524235 | Noah Merin|Miltenyi Biomedicine GmbH|Teva Branded Pharmaceutical Products R&D, Inc.|Cedars-Sinai Medical Center |
Multiple Myeloma|CLL|Chronic Lymphocytic Leukemia|Lymphoma|Hodgkin Lymphoma
|
July 18, 2018 | Phase 1 |
| NCT01461928 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
December 20, 2011 | Phase 3 |
| NCT00306670 | Georgetown University|Genentech, Inc. |
Hemophilia A
|
April 2006 | Phase 2|Phase 3 |
| NCT00695786 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma
|
June 10, 2008 | Phase 2 |
| NCT00038844 | M.D. Anderson Cancer Center |
Lymphoma|Leukemia
|
June 2001 | Not Applicable |
| NCT00722137 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda |
Mantle Cell Lymphoma
|
May 1, 2008 | Phase 3 |
| NCT02484053 | Baylor College of Medicine |
Hematologic Disorders|Oncologic Disorders|Rheumatologic Disorders
|
June 2015 | Early Phase 1 |
| NCT00073957 | Beth Israel Deaconess Medical Center |
Lymphoma
|
December 2003 | Phase 2 |
| NCT01044745 | University of Nebraska|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia+Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides+Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult T-cell Leukemia+Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides+Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenström Macroglobulinemia
|
December 2009 | Phase 2 |
| NCT00424749 | Fernando Fervenza|Genentech, Inc.|Biogen|National Center for Research Resources (NCRR)|Mayo Clinic |
Churg-Strauss Syndrome
|
June 2007 | Phase 2 |
| NCT01127841 | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas |
Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.
|
July 2009 | Phase 2 |
| NCT02461290 | Hoffmann-La Roche |
Follicular Lymphoma
|
April 2008 | |
| NCT00749112 | Hospital Universitario Dr. Jose E. Gonzalez |
Idiopathic Thrombocytopenic Purpura|Anemia, Hemolytic, Autoimmune
|
August 2008 | Phase 2|Phase 3 |
| NCT00244361 | National Pediatric Neuroinflammation Organization, Inc.|Genentech, Inc. |
Opsoclonus-myoclonus Syndrome|Opsoclonus|Myoclonus|Ataxia
|
June 2005 | Phase 1|Phase 2 |
| NCT00486421 | Mayo Clinic|National Cancer Institute (NCI) |
Nonneoplastic Condition
|
January 2007 | Early Phase 1 |
| NCT00169208 | Lymphoma Study Association |
Follicular Lymphoma
|
April 2001 | Phase 2 |
| NCT00450385 | University of Miami |
Lymphoma
|
April 24, 2007 | Phase 2 |
| NCT04496037 | Imperial College London|University of Cambridge|Viapath LLP |
Transplant; Complication, Rejection
|
September 1, 2020 | |
| NCT03808610 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia
|
April 3, 2019 | Phase 1|Phase 2 |
| NCT00905034 | M.D. Anderson Cancer Center|Leadiant Biosciences, Inc. |
Leukemia, Lymphocytic, Acute
|
March 2009 | Phase 2 |
| NCT03949062 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
March 13, 2019 | Phase 2 |
| NCT00058227 | National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
April 2003 | Phase 1 |
| NCT03193866 | Karolinska Institutet|Patient-Centered Outcomes Research Institute|Kaiser Foundation Research Institute |
Relapsing-remitting Multiple Sclerosis
|
June 2, 2017 | |
| NCT02749292 | Massachusetts General Hospital |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
|
June 2016 | Phase 4 |
| NCT01153971 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
July 20, 2005 | Phase 2 |
| NCT00854321 | Kuopio University Hospital |
Rheumatoid Arthritis
|
November 2004 | |
| NCT03790293 | University Hospital, Rouen |
Autoimmune Diseases
|
December 2019 | Phase 3 |
| NCT00281983 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
June 2000 | Phase 1|Phase 2 |
| NCT03003520 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
February 28, 2017 | Phase 2 |
| NCT00060684 | CTI BioPharma |
Lymphoma, Low-Grade|Lymphoma, Small Lymphocytic|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular
|
December 2001 | Phase 1 |
| NCT00258206 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
December 2004 | Phase 2 |
| NCT02531308 | Rush University Medical Center |
Diffuse Large B-Cell Lymphoma
|
July 2015 | Phase 2 |
| NCT02281279 | Mayo Clinic|National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
October 2016 | Phase 1|Phase 2 |
| NCT00655837 | Seagen Inc.|Genentech, Inc. |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin
|
April 2008 | Phase 1 |
| NCT03837873 | Institute of Hematology & Blood Diseases Hospital |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma
|
January 21, 2019 | Phase 2 |
| NCT00028665 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
June 2000 | Phase 2 |
| NCT05533164 | Sint Maartenskliniek|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Arthritis Association |
Polymyalgia Rheumatica
|
January 2023 | Phase 3 |
| NCT01117129 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
April 2010 | Phase 4 |
| NCT01186458 | Hoosier Cancer Research Network|Genentech, Inc.|Millennium Pharmaceuticals, Inc. |
Lymphoma, Non-Hodgkin
|
October 2010 | Phase 2 |
| NCT00059904 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
January 2003 | Phase 2 |
| NCT01938001 | Celgene |
Lymphoma, Non-Hodgkin
|
November 21, 2013 | Phase 3 |
| NCT05600686 | Joseph Tuscano|National Cancer Institute (NCI)|ADC Therapeutics|University of California, Davis |
Double-Expressor Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
|
December 1, 2022 | Phase 2 |
| NCT00502996 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
February 2006 | Phase 3 |
| NCT02732236 | Dong-A University Hospital |
Lymphoma, B-Cell, Marginal Zone
|
March 2013 | |
| NCT00963534 | Lund University Hospital|Mundipharma Pte Ltd.|Celgene|Roche Pharma AG |
Mantle Cell Lymphoma
|
September 2009 | Phase 1|Phase 2 |
| NCT01253460 | M.D. Anderson Cancer Center|Cyclacel Pharmaceuticals, Inc.|National Cancer Institute (NCI) |
Leukemia
|
August 22, 2011 | Phase 2 |
| NCT05063513 | European Society for Blood and Marrow Transplantation|EULAR |
REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
|
July 2009 | Phase 2|Phase 3 |
| NCT01998893 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
January 1997 | Phase 2 |
| NCT00121199 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
June 2005 | Phase 2 |
| NCT02099292 | Georg Hess, MD|Roche Pharma AG|Klinikum Frankfurt Höchst|Johannes Gutenberg University Mainz |
Relapsed Non-Hodgkin-Lymphoma
|
May 2001 | Phase 2 |
| NCT03892421 | La Raza Medical Center |
Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma
|
April 5, 2018 | Phase 1|Phase 2 |
| NCT03530462 | First Affiliated Hospital of Zhejiang University |
Cognitive Impairment|Autoimmune Encephalitis
|
April 7, 2017 | |
| NCT00274794 | The Cleveland Clinic|National Cancer Institute (NCI) |
Lymphoma
|
February 2000 | Not Applicable |
| NCT00691652 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Lymphoma
|
May 2008 | Phase 1|Phase 2 |
| NCT02514772 | Sandoz|Hexal AG |
Rheumatoid Arthritis
|
July 2015 | Phase 3 |
| NCT00770224 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2009 | Phase 2 |
| NCT02819726 | Archigen Biotech Limited |
Rheumatoid Arthritis
|
October 11, 2016 | Phase 1 |
| NCT04849715 | Incyte Corporation |
Mantle Cell Lymphoma
|
March 11, 2022 | Phase 3 |
| NCT00267826 | University of Bern|Hoffmann-La Roche|Swiss National Science Foundation |
Dermatitis, Atopic
|
December 2005 | Not Applicable |
| NCT05139017 | Merck Sharp & Dohme LLC |
DLBCL|Diffuse Large B-Cell Lymphoma
|
January 14, 2022 | Phase 2|Phase 3 |
| NCT00476515 | Massachusetts General Hospital|Biogen|Genentech, Inc. |
Kidney Insufficiency
|
March 2007 | Phase 1 |
| NCT03259503 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma
|
September 13, 2019 | Phase 1 |
| NCT02303119 | The Lymphoma Academic Research Organisation|Roche Pharma AG |
Follicular Lymphoma
|
February 2, 2015 | Phase 3 |
| NCT00169143 | Lymphoma Study Association|Amgen |
Untreated CD20-positive Large B-cell Lymphoma
|
May 2004 | Phase 2 |
| NCT04824092 | MorphoSys AG |
Diffuse Large B-cell Lymphoma
|
May 11, 2021 | Phase 3 |
| NCT02040116 | Wake Forest University Health Sciences |
Multiple Sclerosis
|
February 2013 | Phase 4 |
| NCT04136756 | Nektar Therapeutics |
Multiple Myeloma|Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma
|
October 7, 2019 | Phase 1 |
| NCT00529503 | Seagen Inc.|Genentech, Inc. |
Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin
|
September 2007 | Phase 2 |
| NCT00689845 | University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI) |
Lymphoma
|
June 2007 | Not Applicable |
| NCT00505895 | M.D. Anderson Cancer Center |
Multiple Myeloma
|
January 2002 | Phase 2 |
| NCT02787239 | Shanghai Henlius Biotech |
B-cell Non Hodgkin´s Lymphoma
|
October 2015 | Phase 3 |
| NCT04402580 | Istituto Giannina Gaslini|Bambino Gesù Hospital and Research Institute |
Nephrotic Syndrome Steroid-Dependent
|
July 1, 2019 | Phase 2 |
| NCT02569996 | Hoffmann-La Roche |
Lymphoma, Follicular
|
July 2005 | Phase 3 |
| NCT03719131 | Emory University|Genentech, Inc. |
Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV|Stage III Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma|Unresectable Melanoma
|
June 5, 2019 | Phase 2 |
| NCT00981838 | Mario Negri Institute for Pharmacological Research|Agenzia Italiana del Farmaco |
Nephrotic Syndrome
|
April 2009 | Phase 3 |
| NCT01359592 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2011 | Phase 2 |
| NCT02532257 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage II Follicular Lymphoma|Ann Arbor Stage II Marginal Zone Lymphoma|Ann Arbor Stage III Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|CD20 Positive|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma
|
April 11, 2016 | Phase 2 |
| NCT04679012 | Weill Medical College of Cornell University|Genentech, Inc. |
Richter Syndrome|Chronic Lymphocytic Leukemia
|
September 24, 2021 | Phase 2 |
| NCT01156909 | Haukeland University Hospital |
Chronic Fatigue Syndrome|Myalgic Encephalomyelitis
|
October 2010 | Phase 2 |
| NCT00039130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
May 2002 | Phase 2 |
| NCT03919175 | Massachusetts General Hospital|TG Therapeutics |
Lymphoma|Follicular Lymphoma|Follicular Lymphoma, Grade 1|Follicular Lymphoma Grade 2|Follicular Lymphoma Grade IIIa|Marginal Zone Lymphoma|Marginal Zone B Cell Lymphoma
|
September 1, 2019 | Phase 2 |
| NCT00180895 | Gustave Roussy, Cancer Campus, Grand Paris|Hoffmann-La Roche |
Burkitt Lymphoma
|
June 2004 | Phase 2 |
| NCT02538926 | University of Washington|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia+Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma
|
July 1, 2018 | Phase 2 |
| NCT00199004 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
April 2004 | Phase 4 |
| NCT02900976 | Children´s Oncology Group|National Cancer Institute (NCI) |
EBV-Related Post-Transplant Lymphoproliferative Disorder|Monomorphic Post-Transplant Lymphoproliferative Disorder|Polymorphic Post-Transplant Lymphoproliferative Disorder|Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder|Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder|Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder|Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
|
March 6, 2017 | Phase 2 |
| NCT01554514 | Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI) |
Thrombotic Thrombocytopenic Purpura
|
August 2012 | Phase 2 |
| NCT04319601 | Zhejiang Cancer Hospital |
Angioimmunoblastic T-cell Lymphoma|Chemotherapy Effect|Chemotherapeutic Toxicity
|
March 13, 2020 | Not Applicable |
| NCT00210379 | International Extranodal Lymphoma Study Group (IELSG) |
Lymphoma, B Cell
|
November 2000 | Phase 2 |
| NCT00499343 | M.D. Anderson Cancer Center|Bayer |
Lymphoma
|
January 2004 | Phase 2 |
| NCT05495464 | M.D. Anderson Cancer Center|Kite, A Gilead Company|Acerta Pharma, LLC |
Lymphoma|Mantle Cell Lymphoma
|
November 18, 2022 | Early Phase 1 |
| NCT00425802 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
November 28, 2006 | Phase 2 |
| NCT02168907 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
December 2014 | Phase 1 |
| NCT00020943 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
June 2001 | Phase 2 |
| NCT01868269 | Institut Curie |
Opsoclonus Myoclonus Syndrome|Neuroblastoma
|
April 18, 2013 | Phase 3 |
| NCT01072240 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
September 2009 | |
| NCT03002038 | Isfahan University of Medical Sciences |
Neuromyelitis Optica Spectrum Disorder
|
September 2015 | Phase 2|Phase 3 |
| NCT02491398 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Chronic Lymphocytic Leukemia
|
February 2016 | |
| NCT00091897 | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
Stiff Person Syndrome
|
September 2004 | Phase 2 |
| NCT02971982 | The First Affiliated Hospital of Soochow University |
Treatment
|
October 2016 | Phase 1|Phase 2 |
| NCT01439750 | Milton S. Hershey Medical Center |
Mantle Cell Lymphoma
|
May 2012 | Phase 1 |
| NCT03571321 | University of Chicago|Incyte Corporation |
Acute Lymphoblastic Leukemia|ALL, Childhood|ALL
|
May 28, 2019 | Phase 1 |
| NCT00411086 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bayer |
Lymphoma
|
November 2006 | Phase 2 |
| NCT00049413 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Leukemia|Lymphoma
|
June 2002 | Phase 2 |
| NCT00005089 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 2 |
| NCT00005592 | University of Alabama at Birmingham|National Cancer Institute (NCI)|Biogen |
Lymphoma
|
November 1999 | Phase 2 |
| NCT02160015 | National Cancer Institute (NCI) |
Ann Arbor Stage III Small Lymphocytic Lymphoma|Ann Arbor Stage IV Small Lymphocytic Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
May 9, 2014 | Phase 1 |
| NCT01760226 | Baylor College of Medicine|National Cancer Institute (NCI) |
Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma
|
January 2013 | Early Phase 1 |
| NCT04669171 | Enterome |
Follicular Lymphoma|Marginal Zone Lymphoma
|
July 5, 2021 | Phase 1|Phase 2 |
| NCT04285268 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
|
May 6, 2020 | Phase 2 |
| NCT00198978 | Johann Wolfgang Goethe University Hospital |
Adult Acute Lymphocytic Leukemia
|
January 2003 | Phase 4 |
| NCT00299130 | Genentech, Inc.|Hoffmann-La Roche |
Rheumatoid Arthritis
|
October 2005 | Phase 3 |
| NCT00089284 | Northwestern University|Robert H. Lurie Cancer Center |
Non-Hodgkin´s Lymphoma (NHL)
|
October 28, 2003 | Phase 1|Phase 2 |
| NCT01213095 | Dong-A University Hospital |
Lymphoma
|
September 2010 | Phase 2 |
| NCT00509379 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte|Fondazione Italiana Linfomi ONLUS|University of Turin, Italy |
Lymphoma|Non-Hodgkin Lymphoma
|
September 2006 | Phase 2 |
| NCT00844714 | University of California, San Francisco|Genentech, Inc. |
Endothelial Function|Rheumatoid Arthritis|Inflammation
|
November 2009 | Not Applicable |
| NCT00208975 | Emory University|Bayer |
Lymphoma
|
July 2002 | Phase 2 |
| NCT00448019 | M.D. Anderson Cancer Center|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
February 2007 | Phase 2 |
| NCT03952637 | National Human Genome Research Institute (NHGRI)|Sio Gene Therapies|National Institutes of Health Clinical Center (CC) |
Lysosomal Diseases|Gangliosidosis|GM1
|
August 19, 2019 | Phase 1|Phase 2 |
| NCT02378298 | Göteborg University|Sahlgrenska University Hospital, Sweden |
Ophthalmopathy, Thyroid-Associated
|
December 2011 | Phase 4 |
| NCT04245722 | Fate Therapeutics |
Lymphoma, B-Cell|Chronic Lymphocytic Leukemia
|
March 19, 2020 | Phase 1 |
| NCT01664910 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid Cell Neoplasm
|
October 29, 2012 | Phase 1|Phase 2 |
| NCT05409066 | AbbVie|Genmab |
Follicular Lymphoma (FL)
|
September 20, 2022 | Phase 3 |
| NCT00736450 | University of Nebraska|National Cancer Institute (NCI)|Genta Incorporated |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
July 2008 | Not Applicable |
| NCT03777085 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Diffuse Large B-cell Lymphoma
|
January 10, 2019 | Phase 3 |
| NCT05324917 | The Affiliated Hospital of Qingdao University |
Rituximab|Children|Blood Disease
|
April 10, 2022 | |
| NCT03443570 | Shandong University|The Affiliated Hospital of Qingdao University|Yantai Yuhuangding Hospital |
Immune Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic
|
March 1, 2018 | Phase 3 |
| NCT05498259 | The First Affiliated Hospital of Soochow University |
Diffuse Large B-Cell Lymphoma
|
July 27, 2022 | Phase 2 |
| NCT03598725 | Beijing Children´s Hospital |
Hemophilia A With Inhibitor
|
January 1, 2016 | Phase 4 |
| NCT02541565 | University of Washington|National Cancer Institute (NCI) |
Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma
|
November 24, 2015 | Phase 1 |
| NCT01193842 | National Cancer Institute (NCI) |
AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage I Grade 3 Follicular Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma
|
October 6, 2010 | Phase 1|Phase 2 |
| NCT01126541 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
September 2006 | Phase 3 |
| NCT05076097 | Tianjin Medical University Cancer Institute and Hospital |
Mantle Cell Lymphoma
|
September 30, 2021 | Phase 2 |
| NCT02149121 | Celltrion |
Rheumatoid Arthritis
|
August 2014 | Phase 3 |
| NCT01808911 | University Hospital, Rouen |
Acquired Haemophilia
|
May 2012 | Phase 3 |
| NCT00003963 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc. |
Lymphoma
|
May 1999 | Phase 2 |
| NCT00503425 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
June 30, 2005 | Phase 3 |
| NCT03220022 | National Cancer Institute (NCI) |
AIDS-Related Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
November 3, 2017 | Phase 1 |
| NCT00695409 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
March 18, 2008 | Phase 2 |
| NCT01526057 | Pfizer |
Rheumatoid Arthritis
|
March 20, 2012 | Phase 2 |
| NCT02253264 | Johns Hopkins University |
Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis
|
November 2014 | Phase 1 |
| NCT00918723 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
June 2009 | Phase 1|Phase 2 |
| NCT00931918 | Millennium Pharmaceuticals, Inc.|Takeda |
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
|
October 2009 | Phase 2 |
| NCT01400685 | Massachusetts General Hospital|Dana-Farber Cancer Institute |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B Chronic Lymphocytic Leukemia
|
December 2012 | Phase 1 |
| NCT03630211 | Paul Szabolcs|University of Pittsburgh |
Systemic Sclerosis|Diffuse Sclerosis Systemic|Interstitial Lung Disease|Pulmonary Hypertension
|
July 31, 2018 | Phase 2 |
| NCT02471911 | Weill Medical College of Cornell University|Karyopharm Therapeutics Inc|The Leukemia and Lymphoma Society|FDA Office of Orphan Products Development |
Diffuse Large B-Cell Lymphoma
|
December 11, 2015 | Phase 1 |
| NCT00080886 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
May 2002 | Phase 2 |
| NCT00055640 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
| NCT04442022 | Karyopharm Therapeutics Inc |
Relapsed+Refractory Diffuse Large B-cell Lymphoma
|
September 3, 2020 | Phase 2|Phase 3 |
| NCT00720876 | City of Hope Medical Center|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC |
Lymphoma
|
July 23, 2008 | Phase 2 |
| NCT00136396 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital |
Graft vs Host Disease
|
January 2004 | Phase 1|Phase 2 |
| NCT02624986 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
December 23, 2015 | Phase 1|Phase 2 |
| NCT00026351 | Pharmatech Oncology|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
December 2000 | Phase 2 |
| NCT00062114 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
April 2004 | Phase 2 |
| NCT00392834 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
September 2006 | Phase 2 |
| NCT03740529 | Loxo Oncology, Inc.|Eli Lilly and Company |
Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia|Mantle Cell Lymphoma|Marginal Zone Lymphoma|B-cell Lymphoma|Small Lymphocytic Lymphoma
|
November 16, 2018 | Phase 1|Phase 2 |
| NCT02398240 | Mitchell Cairo|New York Medical College |
Hodgkin Lymphoma
|
May 2015 | Phase 2 |
| NCT04236141 | Hoffmann-La Roche |
Diffuse, Large B-Cell, Lymphoma
|
July 10, 2020 | Phase 3 |
| NCT05200312 | The First Affiliated Hospital with Nanjing Medical University |
Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma
|
February 1, 2022 | Phase 2 |
| NCT02954406 | Millennium Pharmaceuticals, Inc.|Takeda |
Lymphoma, Non-Hodgkin
|
March 5, 2017 | Phase 1 |
| NCT01659099 | The Lymphoma Academic Research Organisation|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma CD20 Positive
|
September 2012 | Phase 3 |
| NCT00290511 | M.D. Anderson Cancer Center|Genentech, Inc.|Biogen |
Lymphoma
|
June 29, 2004 | Phase 2 |
| NCT00127569 | French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche |
HIV Infections|Giant Lymph Node Hyperplasia
|
May 2003 | Phase 2 |
| NCT00363636 | Biogen |
Lymphoma, Non-Hodgkin´s
|
September 2006 | Phase 3 |
| NCT00288067 | National Cancer Institute (NCI) |
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Stage II Marginal Zone Lymphoma|Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia
|
October 2005 | Phase 1|Phase 2 |
| NCT00849355 | Asociacion Doctor Peset Para el Estudio de la Hematología|Cephalon|Pivotal S.L. |
No Hodgkin B Lymphoma
|
August 2008 | Phase 2 |
| NCT01729104 | M.D. Anderson Cancer Center|Celgene|Onyx Therapeutics, Inc. |
Lymphoma
|
April 25, 2013 | Phase 1 |
| NCT00098488 | National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia
|
April 2005 | Phase 1 |
| NCT00923013 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hairy Cell Leukemia
|
October 20, 2008 | Phase 2 |
| NCT00193440 | SCRI Development Innovations, LLC|Biogen |
Non-Hodgkins Lymphoma
|
April 2002 | Phase 2 |
| NCT04189588 | TerSera Therapeutics LLC |
Oncology Patients Receiving Chemotherapy
|
March 25, 2020 | Phase 2 |
| NCT02990286 | University Hospital, Tours |
Lung Disease, Interstitial
|
January 20, 2017 | Phase 3 |
| NCT00444912 | Genzyme, a Sanofi Company|Sanofi |
Non-Hodgkin Lymphoma|Hodgkin Disease
|
February 2006 | Phase 2 |
| NCT00282308 | Genentech, Inc. |
Rheumatoid Arthritis
|
January 23, 2006 | Phase 2 |
| NCT01397825 | Millennium Pharmaceuticals, Inc.|Takeda |
Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt´s Lymphoma
|
August 9, 2011 | Phase 1|Phase 2 |
| NCT01224769 | Gruppo Italiano Studio Linfomi |
Relapsed or Refractory Chronic Lymphoproliferative Disorders
|
September 2005 | |
| NCT00790413 | Lund University Hospital |
Neuroblastoma
|
August 2005 | Early Phase 1 |
| NCT03983018 | Region Örebro County|Örebro University, Sweden |
Schizophrenia Spectrum and Other Psychotic Disorders|Treatment-resistant Schizophrenia
|
August 7, 2019 | Phase 1 |
| NCT00017381 | National Cancer Institute (NCI) |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia
|
April 2001 | Early Phase 1 |
| NCT00980395 | University of Arizona|National Cancer Institute (NCI) |
Lymphoma|Mantle Cell Lymphoma|Indolent Lymphoma|SLL
|
July 7, 2009 | Phase 2 |
| NCT03492125 | MingSight Pharmaceuticals, Inc |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Aggressive Lymphoma
|
May 25, 2018 | Phase 1|Phase 2 |
| NCT05057481 | Assiut University |
Autoimmune Hemolytic Anemia|Systemic Lupus Erythematosus
|
September 15, 2021 | Phase 3 |
| NCT01765842 | Fundación Pública Andaluza Progreso y Salud|Ministry of Health, Spain|Andalusian Network for Design and Translation of Advanced Therapies |
Lupus Nephritis
|
November 2012 | Phase 3 |
| NCT00101829 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence |
Sjogren´s Syndrome
|
April 2004 | Phase 1 |
| NCT00851552 | Roswell Park Cancer Institute|Ortho Biotech, Inc. |
Lymphoma
|
January 2009 | Phase 2 |
| NCT00003658 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
September 1998 | Phase 2 |
| NCT01165112 | University of Washington|National Cancer Institute (NCI) |
Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma
|
September 2010 | Phase 1|Phase 2 |
| NCT00261118 | Royal Liverpool University Hospital|Hoffmann-La Roche|University of Liverpool |
Ulcerative Colitis
|
April 2004 | Phase 2|Phase 3 |
| NCT02007044 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma
|
December 6, 2013 | Phase 2 |
| NCT00036855 | National Cancer Institute (NCI) |
AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma
|
June 2002 | Phase 1 |
| NCT04083066 | Mingzhi Zhang|Zhengzhou University |
Primary Central Nervous System Lymphoma
|
September 5, 2019 | Phase 4 |
| NCT00771602 | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company |
Chronic Lymphocytic Leukemia|Leukemia
|
August 2008 | Phase 2 |
| NCT00770562 | Hoffmann-La Roche |
Idiopathic Thrombocytopenic Purpura
|
July 2005 | Phase 3 |
| NCT00552461 | East Carolina University|Genentech, Inc. |
Pulmonary Alveolar Proteinosis|Primary Disease
|
January 2007 | Phase 2 |
| NCT01748084 | Assistance Publique - Hôpitaux de Paris |
Systemic Sclerosis
|
April 9, 2013 | Phase 2|Phase 3 |
| NCT02731560 | Prof. Abid Z. Farooqi|Aga Khan University|Fatima Memorial Hospital|Fauji Foundation Hospital, Rawalpindi|Pakistan Institute of Medical Sciences |
Rheumatoid Arthritis
|
January 2010 | Phase 4 |
| NCT00801632 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Kidney Transplantation|Kidney Failure, Chronic
|
December 2008 | Phase 2 |
| NCT01287741 | Hoffmann-La Roche|Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
July 26, 2011 | Phase 3 |
| NCT02858804 | Institute of Hematology & Blood Diseases Hospital |
Mantle Cell Lymphoma
|
January 2016 | Phase 4 |
| NCT00525603 | M.D. Anderson Cancer Center|Bayer |
Leukemia|Chronic Lymphocytic Leukemia
|
June 2005 | Phase 2 |
| NCT03352765 | Memorial Sloan Kettering Cancer Center |
Lymphoma
|
November 20, 2017 | Phase 1 |
| NCT00250926 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. |
Waldenstrom´s Macroglobulinemia
|
October 2005 | Phase 2 |
| NCT00498316 | M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI) |
Myelodysplastic Syndrome|Leukemia
|
July 3, 2007 | Phase 1 |
| NCT00949988 | University of California, San Diego|Bristol-Myers Squibb |
Chronic Lymphocytic Leukemia
|
May 2009 | Phase 1|Phase 2 |
| NCT01078974 | Steven P. Treon, MD, PhD|Celgene Corporation|Dana-Farber Cancer Institute |
Waldenstrom´s Macroglobulinemia
|
May 2010 | Phase 1 |
| NCT00493467 | M.D. Anderson Cancer Center|Biogen|CTI BioPharma |
Lymphoma
|
June 2006 | Phase 2 |
| NCT05506410 | Zhengzhou University |
Newly Diagnosed Mantle Cell Lymphoma
|
August 12, 2022 | |
| NCT00556699 | Genentech, Inc.|Seagen Inc. |
Non-Hodgkin´s Lymphoma
|
December 2007 | Phase 1 |
| NCT01145495 | National Cancer Institute (NCI) |
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma
|
June 15, 2010 | Phase 2 |
| NCT00074438 | Genentech, Inc.|Roche Pharma AG |
Rheumatoid Arthritis
|
June 2003 | Phase 2 |
| NCT00428142 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
December 2006 | Phase 2 |
| NCT02258529 | Gilead Sciences |
Follicular Lymphoma|Small Lymphocytic Lymphoma
|
September 14, 2015 | Phase 2 |
| NCT04542824 | Genmab|AbbVie |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma
|
August 20, 2020 | Phase 1|Phase 2 |
| NCT04021992 | Sun Yat-sen University |
Lymphoma, Large B-Cell, Diffuse
|
July 15, 2019 | Phase 2 |
| NCT00588822 | Mayo Clinic|Genentech, Inc.|Biogen|National Center for Research Resources (NCRR) |
Precancerous Condition
|
January 2005 | Phase 2 |
| NCT00006721 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group |
Lymphoma
|
March 2001 | Phase 3 |
| NCT03899103 | Nilratan Sircar Medical College|Heidelberg University |
Steroid-Dependent Nephrotic Syndrome
|
May 15, 2019 | Phase 3 |
| NCT00855205 | University of Cincinnati|University of Chicago |
Sarcoidosis
|
July 2009 | Phase 2 |
| NCT02789397 | Medical College of Wisconsin |
Granulomatous and Lymphocytic Interstitial Lung Disease
|
May 2, 2016 | Phase 2 |
| NCT01509300 | Asan Medical Center |
Acute Leukemia|Myelodysplastic Syndrome|Solid Tumors
|
January 2012 | Phase 1|Phase 2 |
| NCT00992030 | Fondazione Michelangelo |
Hodgkin Lymphoma
|
September 2009 | Phase 3 |
| NCT01611259 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
|
May 2012 | Phase 2 |
| NCT00521014 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2007 | Phase 2 |
| NCT05389423 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Large Cell Lymphoma|Non-Hodgkin Lymphoma|Burkitt Lymphoma|Plasmablastic Lymphoma|B-Cell Neoplasm
|
November 28, 2022 | Phase 1 |
| NCT00537290 | Hospital for Special Surgery, New York|Genentech, Inc. |
Antiphospholipid Syndrome
|
September 2007 | Phase 2 |
| NCT00972101 | M.D. Anderson Cancer Center |
Stem Cell Transplantation|Leukemia|Lymphoma|Pediatric Disorders
|
September 2009 | Phase 1 |
| NCT00612612 | National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
January 2008 | Phase 1 |
| NCT00648037 | Memorial Sloan Kettering Cancer Center |
Hodgkin´s Disease|Leukemia|Myelodysplastic Syndrome|Non-Hodgkin´s Lymphoma
|
March 2008 | Not Applicable |
| NCT02617485 | Mabion SA |
Diffuse Large B-Cell Lymphoma
|
December 2015 | Phase 3 |
| NCT04737889 | Henan Cancer Hospital |
Primary Central Nervous System Lymphoma
|
January 13, 2021 | Phase 2 |
| NCT04002297 | BeiGene |
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
|
August 21, 2019 | Phase 3 |
| NCT02898259 | Brian Hill|The Cleveland Clinic|Case Comprehensive Cancer Center |
B Cell Lymphoma|Lymphoma
|
February 20, 2017 | Phase 1|Phase 2 |
| NCT02097745 | Hoffmann-La Roche|Biogen |
Rheumatoid Arthritis
|
June 2004 | Phase 3 |
| NCT02381899 | Czech CLL Study Group |
Chronic Lymphocytic Leukemia
|
September 2014 | |
| NCT00182650 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
June 2004 | Phase 1 |
| NCT03697512 | International Extranodal Lymphoma Study Group (IELSG) |
Marginal Zone Lymphoma|Nodal Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma
|
September 27, 2019 | Phase 2 |
| NCT01332968 | Hoffmann-La Roche|German Low Grade Lymphoma Study Group|Institute of Cancer Research, United Kingdom |
Non-Hodgkin´s Lymphoma
|
July 6, 2011 | Phase 3 |
| NCT04156828 | University of Washington|Bayer |
Grade 3b Follicular Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Non-Hodgkin´s Lymphoma
|
March 31, 2020 | Phase 1 |
| NCT00067002 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cellgenix |
Leukemia, Lymphocytic, Acute|Leukemia, Myelocytic, Acute|Leukemia, Myeloid, Chronic|Lymphoma, Non-Hodgkin
|
April 2003 | Phase 2 |
| NCT04256252 | Tang-Du Hospital |
Neuromyelitis Optica Spectrum Disorder
|
April 2014 | Phase 4 |
| NCT01181999 | Chonnam National University Hospital|Samsung Medical Center|Asan Medical Center|Severance Hospital |
Lymphoma, Large B-cell, Diffuse
|
August 2010 | Phase 2 |
| NCT01811368 | Joseph Tuscano|Spectrum Pharmaceuticals, Inc|University of California, Davis |
Refractory Non Hodgkin Lymphoma|Relapsed Non Hodgkin Lymphoma
|
March 12, 2013 | Phase 2 |
| NCT01506414 | Ming Hou|Peking Union Medical College Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|First Affiliated Hospital, Sun Yat-Sen University|West China Hospital|Shandong Provincial Hospital|Wuhan Union Hospital, China|Zhejiang University|Shandong University |
Purpura|Idiopathic Thrombocytopenic Purpura
|
June 2009 | Phase 3 |
| NCT00664521 | Merck KGaA, Darmstadt, Germany |
Rheumatoid Arthritis
|
March 2008 | Phase 2 |
| NCT00425932 | Gaylis, Norman B., M.D.|Oklahoma Medical Research Foundation|Genentech, Inc. |
Rheumatoid Arthritis
|
February 2007 | Phase 2 |
| NCT05265975 | Antengene Corporation |
Diffuse Large B-cell Lymphoma|Indolent Non-Hodgkin Lymphoma
|
April 7, 2022 | Phase 1|Phase 2 |
| NCT00049036 | National Cancer Institute (NCI) |
AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma
|
March 2003 | Phase 2 |
| NCT00863369 | City of Hope Medical Center|National Cancer Institute (NCI) |
Lymphoma
|
June 29, 2005 | Phase 1|Phase 2 |
| NCT01096992 | M.D. Anderson Cancer Center |
Leukemia
|
April 19, 2010 | Phase 1|Phase 2 |
| NCT03069703 | Assistance Publique - Hôpitaux de Paris|EUCLID Clinical Trial Platform|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne|CIC 1417 Cochin-Pasteur|Groupe Français d´Etude des Vascularites (GFEV) |
Invasive Pneumococcal Infection
|
February 5, 2018 | Phase 2 |
| NCT01759030 | Biocad |
Rheumatoid Arthritis
|
December 2012 | Phase 3 |
| NCT00453102 | University of Miami |
Marginal Zone Lymphoma
|
February 2006 | Phase 2 |
| NCT03593902 | Northwestern University |
Systemic Sclerosis|Scleroderma
|
May 17, 2018 | Phase 2|Phase 3 |
| NCT00076752 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lupus Erythematosus, Systemic
|
January 30, 2004 | Phase 2 |
| NCT00562328 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia
|
January 2008 | Phase 2 |
| NCT00126191 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital |
Burkitt Lymphoma|Non-Hodgkins Lymphoma|Atypical Burkitt Lymphoma
|
July 2005 | Phase 2 |
| NCT04980222 | Hoffmann-La Roche |
Lymphoma
|
March 22, 2022 | Phase 2 |
| NCT01644253 | Aptevo Therapeutics |
Chronic Lymphocytic Leukemia|Peripheral T-cell Lymphoma
|
September 2012 | Phase 1 |
| NCT02329080 | International Extranodal Lymphoma Study Group (IELSG) |
Diffuse Large B-cell Lymphoma
|
December 2014 | Phase 2 |
| NCT00936546 | University Hospital, Ghent |
Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
|
June 2009 | Phase 2 |
| NCT00545714 | Hoffmann-La Roche |
Leukemia, Lymphocytic, Chronic, B-Cell
|
November 21, 2007 | Phase 2 |
| NCT02556866 | Assistance Publique - Hôpitaux de Paris |
Cryoglobulinemia|Systemic Vasculitis
|
July 17, 2015 | Phase 2 |
| NCT00003280 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
January 1998 | Phase 3 |
| NCT04425824 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Diffuse Large B-cell Lymphoma|Rituximab|Toripalimab
|
June 15, 2020 | Phase 2 |
| NCT00031902 | Lymphoma Trials Office|National Cancer Institute (NCI) |
Lymphoma
|
October 2001 | Phase 1 |
| NCT01295151 | Julia Brown|University of Leeds |
Rheumatoid Arthritis
|
August 2011 | Phase 4 |
| NCT00415506 | Oregon Health and Science University|Genentech, Inc. |
Scleritis|Orbital Disease
|
January 2007 | Phase 1|Phase 2 |
| NCT05049473 | PETHEMA Foundation|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Mature B-Cell Leukemia Burkitt Type|Burkitt Lymphoma (BL)|Unclassifiable Lymphoma Between DCBL and BL
|
January 2014 | Phase 2 |
| NCT03623373 | Washington University School of Medicine|Acerta Pharma BV |
Mantle Cell Lymphoma
|
November 29, 2018 | Phase 2 |
| NCT02853370 | International Extranodal Lymphoma Study Group (IELSG) |
Marginal Zone B-cell Lymphoma
|
July 2012 | Phase 2 |
| NCT00060294 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
April 2003 | Phase 1 |
| NCT02594163 | Seagen Inc. |
Diffuse Large B-cell Lymphoma Refractory|Follicular B-cell Non-Hodgkin´s Lymphoma
|
October 2015 | Phase 2 |
| NCT00101010 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ortho Biotech, Inc. |
Lymphoma
|
September 2005 | Phase 2 |
| NCT01670084 | Mayo Clinic |
B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia
|
December 2012 | Phase 2 |
| NCT03384277 | Zhang Lei|Qilu Hospital of Shandong University|Tianjin First Central Hospital|The Second Affiliated Hospital of Kunming Medical University|Henan Cancer Hospital|Institute of Hematology & Blood Diseases Hospital |
Acquired Hemophilia A
|
October 26, 2017 | Phase 3 |
| NCT01584388 | Massachusetts General Hospital|Genentech, Inc. |
Retroperitoneal Fibrosis|Autoimmune Pancreatitis|Sialadenitis|Pseudotumor
|
April 2012 | Phase 1|Phase 2 |
| NCT00881387 | University of Miami |
Lymphoma
|
February 2009 | Phase 2 |
| NCT04525729 | CHENNAN|Dongfang Hospital Affiliated to Tongji University|Shanghai Pudong New Area People´s Hospital|Ruijin Hospital North Shanghai Jiao Tong University School of Medicine|Ningbo Municipal Yinzhou District No.2 Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Xiamen Hongai Hospital|Sir Run Run Shaw Hospital|Ruijin Hospital |
IgA Nephropathy
|
July 1, 2020 | Phase 4 |
| NCT03283202 | Celgene |
Diffuse B-Cell Lymphoma
|
October 4, 2017 | Phase 1 |
| NCT01889069 | Hoffmann-La Roche |
Lymphoma
|
July 31, 2013 | Phase 3 |
| NCT01460602 | Louisiana State University Health Sciences Center Shreveport|Millennium Pharmaceuticals, Inc. |
Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma
|
May 2010 | Phase 1|Phase 2 |
| NCT04419389 | Aprea Therapeutics |
Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma
|
March 2, 2021 | Phase 1|Phase 2 |
| NCT02367040 | Bayer |
Lymphoma,Non-Hodgkin
|
August 3, 2015 | Phase 3 |
| NCT00082836 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 2004 | Not Applicable |
| NCT00086775 | Bayer|National Cancer Institute (NCI) |
Leukemia
|
July 2003 | Phase 2 |
| NCT01042509 | Hospital Universitario Dr. Jose E. Gonzalez |
Graft vs Host Disease
|
October 2009 | Not Applicable |
| NCT02472756 | Hoffmann-La Roche |
Lymphoma, Follicular
|
September 19, 2008 | |
| NCT05364424 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma (DLBCL)
|
November 4, 2022 | Phase 1 |
| NCT04432714 | The First Affiliated Hospital with Nanjing Medical University |
DLBCL|Untreated|MYC Gene Rearrangement
|
June 9, 2020 | Phase 1|Phase 2 |
| NCT03135262 | Hoffmann-La Roche |
Follicular Lymphoma|Lymphoma, Large B-Cell, Diffuse
|
June 15, 2017 | Phase 1|Phase 2 |
| NCT01381692 | National Cancer Institute (NCI) |
Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma
|
July 20, 2011 | Phase 1|Phase 2 |
| NCT02767674 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B Cell Lymphoma
|
May 2016 | Phase 3 |
| NCT01209130 | Genentech, Inc. |
Non-Hodgkin´s Lymphoma, Chronic Lymphocytic Leukemia
|
October 2010 | Phase 1 |
| NCT00120198 | Geriatric Oncology Consortium|Tibotec Pharmaceutical Limited |
Non-Hodgkin´s Lymphoma
|
March 2005 | Phase 2 |
| NCT02339922 | University of Washington|Millennium Pharmaceuticals, Inc. |
Chronic Lymphocytic Leukemia|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia
|
May 19, 2016 | Phase 2 |
| NCT03920722 | Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group |
Microscopic Polyangiitis (MPA)
|
October 24, 2020 | Phase 3 |
| NCT00294632 | M.D. Anderson Cancer Center|Celgene Corporation |
Lymphoma
|
February 2006 | Phase 1|Phase 2 |
| NCT05329090 | Hopital Foch|Ministry of Health, France |
IgA Vasculitis
|
March 11, 2022 | Phase 3 |
| NCT01321541 | CTI BioPharma |
Diffuse Large B-cell Lymphoma|de Novo DLBCL|DLBCL Transformed From Indolent Lymphoma|Follicular Grade 3 Lymphoma
|
April 20, 2011 | Phase 3 |
| NCT02867553 | CHU de Reims |
Indolent Cutaneous B Cell Lymphomas
|
October 2011 | Phase 3 |
| NCT02384954 | Altor BioScience |
Relapsed+Refractory Indolent B Cell Non-Hodgkin Lymphoma
|
April 2015 | Phase 1|Phase 2 |
| NCT02086175 | Dana-Farber Cancer Institute|HiberCell, Inc. |
Relapsed+Refractory Indolent B Cell Non-Hodgkin Lymphomas
|
December 2014 | Phase 2 |
| NCT02110706 | Yale University|National Institute of Neurological Disorders and Stroke (NINDS) |
Myasthenia Gravis
|
May 2014 | Phase 2 |
| NCT01649856 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
August 24, 2012 | Phase 3 |
| NCT02626455 | Bayer |
Lymphoma, Non-Hodgkin
|
January 6, 2016 | Phase 3 |
| NCT01939730 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
August 1999 | Phase 2 |
| NCT00385125 | University of Magdeburg |
Lymphoma, High-Grade
|
August 2004 | Phase 2 |
| NCT00963703 | University of Manitoba|Hoffmann-La Roche |
Rheumatoid Arthritis
|
December 2007 | Not Applicable |
| NCT00324467 | British Columbia Cancer Agency|Hoffmann-La Roche |
Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin´s Lymphoma
|
August 2006 | Phase 2 |
| NCT00186628 | Stanford University|The Leukemia and Lymphoma Society|National Cancer Institute (NCI) |
Leukemia, Mast-Cell|Mantle-cell Lymphoma
|
June 2005 | Phase 2 |
| NCT01206777 | Ohio State University Comprehensive Cancer Center |
Indolent or Intermediate Grade B-cell Malignancy
|
October 2010 | Phase 2 |
| NCT01181258 | Masonic Cancer Center, University of Minnesota |
Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
August 2010 | Phase 2 |
| NCT02251548 | Dana-Farber Cancer Institute|Pharmacyclics LLC.|The Leukemia and Lymphoma Society|Blood Cancer Research Partnership |
Chronic Lymphocytic Leukemia|Leukemia
|
October 2014 | Phase 2 |
| NCT02332941 | Washington University School of Medicine |
Macular Degeneration
|
August 2014 | Phase 1 |
| NCT00244855 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Marginal Zone Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Marginal Zone Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
May 2004 | Phase 2 |
| NCT01156922 | Haukeland University Hospital |
Chronic Fatigue Syndrome|Myalgic Encephalomyelitis
|
June 2010 | Phase 2 |
| NCT01609023 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
April 2012 | |
| NCT03312907 | GlaxoSmithKline |
Systemic Lupus Erythematosus
|
March 1, 2018 | Phase 3 |
| NCT00690560 | Centre Antoine Lacassagne |
Lymphoma
|
May 2007 | Phase 2 |
| NCT04934579 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Primary Central Nervous System Lymphoma
|
January 1, 2020 | Phase 2 |
| NCT04323566 | Uppsala University Hospital|Uppsala University |
Obsessive-Compulsive Disorder|Obsessive-Compulsive Behavior|Schizophrenia|Delusional Disorder|Brief Psychotic Disorder|Schizo Affective Disorder|Other Psychoses|Unspecified Psychosis
|
May 1, 2022 | Phase 2 |
| NCT02296918 | Acerta Pharma BV |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Prolymphocytic Leukemia
|
December 22, 2014 | Phase 1 |
| NCT05032183 | M.D. Anderson Cancer Center |
Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia
|
February 17, 2022 | Phase 1|Phase 2 |
| NCT00379431 | University Hospital, Ghent |
Early and Severe Systemic Sclerosis
|
November 2006 | Phase 2 |
| NCT03844061 | Hospital for Special Surgery, New York|GlaxoSmithKline |
Systemic Sclerosis
|
July 29, 2019 | Phase 2 |
| NCT00759603 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
September 2008 | Phase 2 |
| NCT01514344 | Andres J. M. Ferreri|IRCCS San Raffaele |
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
|
December 2011 | Phase 2 |
| NCT01369849 | National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia
|
September 2011 | Phase 1|Phase 2 |
| NCT00071396 | M.D. Anderson Cancer Center|Bayer |
Chronic Lymphocytic Leukemia
|
October 2002 | Phase 2 |
| NCT00383994 | M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma |
Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation
|
September 2006 | Phase 1 |
| NCT00641095 | University College, London|Cancer Research UK |
Lymphoma
|
December 7, 2006 | Phase 2|Phase 3 |
| NCT02232386 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Chronic Lymphocyte Leukemia|Adult Patients
|
February 2015 | Phase 2 |
| NCT01812005 | Ohio State University Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
May 21, 2013 | Phase 2 |
| NCT05504603 | The First Affiliated Hospital of Soochow University |
Untreated Mantle Cell Lymphoma
|
July 27, 2020 | Phase 2 |
| NCT00080925 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
February 2004 | Phase 1 |
| NCT00045877 | Chiron Corporation |
Lymphoma, Non-Hodgkin
|
Phase 2|Phase 3 | |
| NCT02600897 | Hoffmann-La Roche |
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
March 23, 2016 | Phase 1 |
| NCT05338190 | Assistance Publique - Hôpitaux de Paris|GlaxoSmithKline |
Primary Immune Thrombocytopenia (ITP)
|
June 1, 2022 | Phase 3 |
| NCT00072007 | Swiss Group for Clinical Cancer Research |
Leukemia
|
June 2002 | Phase 2 |
| NCT04138875 | Yale University |
PTLD|Lymphoid Tumor|Hematopoietic+Lymphoid Cancer|Plasmacytic Hyperplasia PTLD|Infectious Mononucleosis|Florid Follicular Hyperplasia PTLD|Polymorphic PTLD|Monomorphic PTLD|Classical Hodgkin Lymphoma Type PTLD
|
January 2022 | Phase 2 |
| NCT02881086 | Goethe University |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
August 2016 | Phase 3 |
| NCT02228512 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma
|
August 15, 2014 | Phase 1|Phase 2 |
| NCT01350232 | Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University |
Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia
|
September 2009 | Not Applicable |
| NCT02229942 | Haukeland University Hospital|The Research Council of Norway|Norwegian Department of Health and Social Affairs|The Kavli Foundation|Oslo University Hospital|Trondheim University Hospital|University Hospital of North Norway|Sykehuset Telemark|MEandYou Foundation|The Norwegian ME association |
Chronic Fatigue Syndrome+ Myalgic Encephalitis (CFS+ME)
|
September 2014 | Phase 3 |
| NCT01279902 | Asan Medical Center |
Diffuse Large B-cell Lymphoma
|
August 2010 | Phase 2 |
| NCT04745832 | MEI Pharma, Inc.|Kyowa Kirin, Inc. |
Follicular Lymphoma (FL)|Non Hodgkin Lymphoma|Marginal Zone Lymphoma
|
August 13, 2021 | Phase 3 |
| NCT00118209 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Large B Cell Lymphoma
|
May 2005 | Phase 3 |
| NCT00581776 | University of Wisconsin, Madison |
Mantle Cell Lymphoma
|
May 2005 | Phase 2 |
| NCT04127747 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Autoimmune Diseases
|
August 18, 2020 | Phase 4 |
| NCT01056510 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
March 2010 | Phase 4 |
| NCT04025593 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 17, 2019 | Phase 2 |
| NCT00054639 | National Cancer Institute (NCI) |
Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
January 2003 | Phase 2 |
| NCT01491841 | Anne Beaven, MD|CTI BioPharma|Duke University |
Non-Hodgkin´s Lymphoma
|
November 1, 2011 | Phase 1 |
| NCT00069966 | Theradex|National Cancer Institute (NCI) |
Lymphoma
|
April 2003 | Phase 2 |
| NCT00651755 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC |
Lymphoma
|
March 2008 | Not Applicable |
| NCT01516567 | Gustave Roussy, Cancer Campus, Grand Paris|Children´s Oncology Group |
Primary Mediastinal Large B Cell Lymphoma
|
April 1, 2012 | Phase 2 |
| NCT04640818 | Claudio Gobbi|Merck AG Switzerland|Ospedale Civico, Lugano |
Multiple Sclerosis
|
December 17, 2020 | |
| NCT00783367 | Abramson Cancer Center of the University of Pennsylvania |
Follicular Lymphoma|Marginal Zone B-Cell Lymphoma|MALT Lymphoma|Lymphoma of Mucosa-Associated Lymphoid Tissue|Lymphoma, Small Lymphocytic|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma
|
July 2008 | Phase 2 |
| NCT03255096 | Hoffmann-La Roche |
Diffuse Large B-cell Lymphoma|High-Grade B-cell Lymphoma
|
August 28, 2017 | Phase 1 |
| NCT00724971 | Pfizer |
Lymphoma, B-Cell
|
July 4, 2008 | Phase 1 |
| NCT00167791 | University of Wisconsin, Madison|Genentech, Inc. |
End Stage Renal Disease
|
July 2005 | Not Applicable |
| NCT04433156 | Henan Cancer Hospital |
Marginal Zone Lymphoma
|
April 22, 2020 | Phase 2 |
| NCT03500731 | Paul Szabolcs|University of Pittsburgh |
Idiopathic Pulmonary Fibrosis|Emphysema or COPD
|
April 19, 2018 | Phase 1|Phase 2 |
| NCT03979456 | Karolinska Institutet |
Multiple Sclerosis, Relapsing-Remitting
|
July 4, 2018 | Phase 3 |
| NCT01987505 | Hoffmann-La Roche |
Lymphoma, Non Hodgkin
|
November 11, 2013 | Phase 3 |
| NCT01701232 | Biocad |
Follicular Non-Hodgkin´s Lymphoma|Nodal Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma
|
September 2011 | Phase 3 |
| NCT00501748 | University of California, San Francisco|Genentech, Inc. |
Neuromyelitis Optica
|
January 2004 | Phase 1 |
| NCT00107614 | University of Arkansas |
Waldenstrom Macroglobulinemia
|
November 2002 | Phase 2 |
| NCT00509678 | Swedish Medical Center|Genentech, Inc. |
Psoriatic Arthritis
|
December 2006 | Phase 1 |
| NCT01466153 | MedImmune LLC |
Chronic Lymphocytic Leukemia (CLL)
|
February 7, 2012 | Phase 2 |
| NCT00274924 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 2006 | Phase 2 |
| NCT00001379 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphomatoid Granulomatosis|Granulomatosis, Lymphomatoid|Non-Hodgkins Lymphoma|Lymphoproliferative Disorder
|
May 5, 1995 | Phase 2 |
| NCT04502706 | Gilead Sciences |
Non-hodgkin Lymphoma
|
November 17, 2020 | Phase 1 |
| NCT02628405 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma
|
May 20, 2016 | Phase 1|Phase 2 |
| NCT00384150 | Biogen |
Lymphoma, Non-Hodgkin´s
|
November 2007 | Phase 3 |
| NCT05078177 | St. Petersburg State Pavlov Medical University |
Multiple Sclerosis
|
December 21, 2020 | Phase 1 |
| NCT00176475 | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey |
Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
|
January 2005 | Phase 1 |
| NCT04121403 | Oslo University Hospital|University of Oslo|Göteborg University|Sykehuset Ostfold|Sykehuset Telemark|Vestre Viken Hospital Trust|Sorlandet Hospital HF|Helse Stavanger HF|Sykehuset Innlandet HF|Sykehuset i Vestfold HF|Helse Forde|University Hospital of North Norway|St. Olavs Hospital |
Relapsing Multiple Sclerosis|Multiple Sclerosis
|
October 16, 2019 | Phase 3 |
| NCT04790903 | Hoffmann-La Roche |
Lymphoma, Large B-Cell, Diffuse
|
July 2, 2021 | Phase 1 |
| NCT05553496 | Ain Shams University |
Pharmacological Action
|
September 25, 2022 | Phase 2|Phase 3 |
| NCT01058239 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|Millennium Pharmaceuticals, Inc. |
Post-transplant Lymphoproliferative Disease|Solid Organ Transplant|Stem Cell Transplant (Bone Marrow Transplant)|Epstein Barr Virus Infections
|
November 2011 | Phase 2 |
| NCT01609010 | Hoffmann-La Roche|Nordic Lymphoma Group |
Lymphoma
|
October 2002 | Phase 3 |
| NCT03455517 | Gruppo Italiano Malattie EMatologiche dell´Adulto |
Chronic Myeloid Leukemia
|
October 31, 2018 | Phase 2 |
| NCT00689169 | Lymphoma Study Association|Bayer |
Lymphoma, Large Cell, Diffuse
|
August 2007 | Phase 2 |
| NCT01185262 | MD Anderson International Spain SA|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
April 2009 | Phase 1 |
| NCT00112931 | University College, London|Cancer Research UK|Roche Pharma AG |
Lymphoma
|
September 2004 | Phase 3 |
| NCT00787969 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
April 2009 | Phase 1 |
| NCT00636155 | David Rizzieri|Eleos, Inc.|Duke University |
Lymphoma, Small Lymphocytic|Leukemia, Lymphocytic, Chronic
|
February 2008 | Phase 2 |
| NCT01307592 | Auxilio Mutuo Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 2011 | Phase 2 |
| NCT00788606 | Royal Marsden NHS Foundation Trust|Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma|B-cell Lymphoma
|
May 2008 | Phase 2 |
| NCT00443651 | Genentech, Inc.|Biogen |
Rheumatoid Arthritis
|
January 2007 | Phase 3 |
| NCT00293072 | Cambridge University Hospitals NHS Foundation Trust|Roche Pharma AG |
Systemic Lupus Erythematosus|ANCA Associated Vasculitis
|
March 2002 | Phase 2 |
| NCT02304354 | University Hospital, Tours |
Rheumatoid Arthritis
|
March 9, 2015 | Phase 3 |
| NCT01684865 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
October 22, 2012 | |
| NCT01832922 | Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
April 2013 | Phase 1 |
| NCT02652468 | University of Wisconsin, Madison |
Lymphoma
|
March 10, 2016 | Not Applicable |
| NCT02741388 | The Lymphoma Academic Research Organisation|Karyopharm Therapeutics Inc |
B-cell Lymphoma
|
October 2016 | Phase 1 |
| NCT00555542 | Chinese University of Hong Kong |
Rheumatoid Arthritis
|
July 2006 | Phase 2 |
| NCT05514015 | First Affiliated Hospital, Sun Yat-Sen University |
Idiopathic Membranous Nephropathy
|
August 25, 2022 | Phase 4 |
| NCT00343447 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
August 2006 | Phase 2 |
| NCT02200848 | Georgetown University|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
April 2014 | Phase 1 |
| NCT04899570 | Peking Union Medical College Hospital |
Intravascular Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
| NCT00845832 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
March 2009 | Phase 2 |
| NCT02043587 | University of California, San Diego|Leadiant Biosciences, Inc. |
Acute Lymphocytic Leukemia|Adult Lymphoblastic Lymphoma
|
January 2014 | Phase 2 |
| NCT03295383 | University Hospital, Rouen |
Severe Forms of Mucous Membrane Pemphigoid
|
July 11, 2019 | Phase 3 |
| NCT00261547 | Massachusetts General Hospital|Genentech, Inc. |
Chronic Rejection|Kidney Insufficiency
|
December 2005 | Phase 1|Phase 2 |
| NCT02945215 | Innovent Biologics (Suzhou) Co. Ltd. |
B-Cell Lymphoma
|
December 13, 2016 | Phase 1 |
| NCT00081861 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 2004 | Phase 2 |
| NCT03304288 | Peking University People´s Hospital|Beijing Hospital|Navy General Hospital, Beijing|Beijing Tongren Hospital |
Immune Thrombocytopenia
|
October 11, 2017 | Phase 2 |
| NCT03863184 | Weill Medical College of Cornell University|AstraZeneca|Celgene Corporation |
Mantle Cell Lymphoma
|
October 11, 2019 | Phase 2 |
| NCT02500251 | E. Steve Woodle|GlaxoSmithKline|University of Cincinnati |
Renal Transplant Rejection
|
June 2015 | Phase 1|Phase 2 |
| NCT00968331 | University of Bologna |
Diffuse Large B-cell Lymphoma
|
March 2009 | Phase 2 |
| NCT03064867 | Molly Gallogly|Case Comprehensive Cancer Center |
Diffuse Large B-cell-lymphoma
|
June 26, 2017 | Phase 1|Phase 2 |
| NCT03147612 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia With BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia
|
February 8, 2018 | Phase 2 |
| NCT01520519 | M.D. Anderson Cancer Center|Pharmacyclics LLC. |
Leukemia
|
February 27, 2012 | Phase 2 |
| NCT02867566 | Innovent Biologics (Suzhou) Co. Ltd. |
Diffuse, Large B-Cell, Lymphoma
|
August 22, 2016 | Phase 3 |
| NCT01164098 | George W. Burke|Genentech, Inc.|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Miami |
FSGS|Proteinuria
|
February 2012 | Phase 3 |
| NCT05168475 | Cambridge University Hospitals NHS Foundation Trust |
Giant Cell Arteritis|Takayasu Arteritis|Cogan Syndrome|Relapsing Polychondritis|Cryoglobulinemic Vasculitis|IgA Vasculitis|Polyarteritis Nodosa|Cutaneous Polyarteritis Nodosa|Primary Angiitis of Central Nervous System
|
July 14, 2021 | Phase 2 |
| NCT05376319 | Mayo Clinic |
Granulomatosis With Polyangiitis|Microscopic Polyangiitis|ANCA Associated Vasculitis
|
November 2022 | Phase 2 |
| NCT01205737 | Teva Branded Pharmaceutical Products R&D, Inc. |
DLBCL
|
September 2010 | Phase 1 |
| NCT02266888 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation in Children|Rho Federal Systems Division, Inc. |
Lung Transplant
|
January 22, 2015 | Phase 2 |
| NCT00772655 | Charite University, Berlin, Germany |
Follicular Lymphoma
|
October 2007 | Phase 2 |
| NCT00499018 | Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte |
Diffuse Large B-Cell Lymphoma|IPI?2
|
January 2006 | Phase 3 |
| NCT02042391 | Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH |
Posttransplant Lymphoproliferative Disorder
|
February 3, 2015 | Phase 2 |
| NCT00230035 | National Institute of Allergy and Infectious Diseases (NIAID) |
Systemic Lupus Erythematosus
|
September 2005 | Phase 2 |
| NCT00012051 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lymphoma
|
September 2000 | Phase 3 |
| NCT02285062 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
January 21, 2015 | Phase 3 |
| NCT00004112 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
September 1999 | Phase 3 |
| NCT02611323 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
March 9, 2016 | Phase 1 |
| NCT04023071 | Fate Therapeutics |
Acute Myelogenous Leukemia|B-cell Lymphoma
|
October 4, 2019 | Phase 1 |
| NCT02257242 | Adam Olszewski|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital|Brown University |
Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone
|
May 10, 2017 | Phase 1 |
| NCT01073163 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
February 2010 | Phase 3 |
| NCT01309997 | Lee, Stephanie|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center |
Graft Versus Host Disease|Systemic Scleroderma
|
March 2011 | Phase 2 |
| NCT00140660 | Lymphoma Study Association|Amgen |
Diffuse Large Cell Lymphoma
|
December 2003 | Phase 3 |
| NCT01282476 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center |
Diffuse Large B Cell Lymphoma
|
June 2011 | Phase 2 |
| NCT02280525 | M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation |
Leukemia
|
March 5, 2015 | Phase 1 |
| NCT00848328 | University of California, Davis|Celgene |
Lymphoma
|
August 25, 2008 | Phase 2 |
| NCT03984448 | National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Double-Expressor Lymphoma|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
|
August 7, 2019 | Phase 2|Phase 3 |
| NCT01538472 | M.D. Anderson Cancer Center|Biogen |
Lymphoma
|
September 2003 | Phase 1|Phase 2 |
| NCT05624554 | Merck Sharp & Dohme LLC |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia
|
December 22, 2022 | Phase 3 |
| NCT03269552 | University of Washington|National Cancer Institute (NCI) |
Marginal Zone Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Marginal Zone Lymphoma|Refractory Waldenstrom Macroglobulinemia|Waldenstrom Macroglobulinemia
|
December 18, 2017 | Phase 2 |
| NCT02951156 | Pfizer|EMD Serono |
Diffuse Large B-Cell Lymphoma
|
December 16, 2016 | Phase 3 |
| NCT00126243 | French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche |
AIDS Related Lymphoma
|
January 1999 | Phase 2 |
| NCT00669318 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2008 | Phase 2 |
| NCT00974233 | University of Wisconsin, Madison|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 2009 | Phase 2 |
| NCT05057468 | Assiut University |
Primary Autoimmune Hemolytic Anemia
|
October 20, 2021 | Phase 3 |
| NCT00379587 | Dana-Farber Cancer Institute|Genentech, Inc.|Biogen |
Hematological Malignancies
|
September 2006 | Phase 1|Phase 2 |
| NCT03467373 | Hoffmann-La Roche |
B-Cell Lymphoma|Non-Hodgkin Lymphoma
|
March 13, 2018 | Phase 1 |
| NCT00788684 | AbbVie|Genentech, Inc. |
CD20-Positive Lymphoid Malignancies|Chronic Lymphoid Leukemia|Hematological Malignancies|Non-Hodgkin´s Lymphoma
|
July 21, 2009 | Phase 1 |
| NCT02394119 | Istituto Giannina Gaslini |
Nephrotic Syndrome
|
June 2015 | Phase 2 |
| NCT03942887 | Leiden University Medical Center |
ANCA Associated Vasculitis
|
May 3, 2019 | Phase 3 |
| NCT00958256 | M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. |
Mantle Cell Lymphoma|Lymphoma
|
August 2009 | Phase 2 |
| NCT04460248 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
July 22, 2020 | Phase 2 |
| NCT01280682 | Nanjing Medical University |
Diabetes Mellitus, Type 1
|
July 2010 | Phase 4 |
| NCT00285389 | French Innovative Leukemia Organisation|Hoffmann-La Roche |
Mantle Cell Lymphoma
|
February 2002 | Phase 2 |
| NCT02752204 | University of Birmingham|Bloodwise|AstraZeneca|Cancer Research UK |
Diffuse Large B-Cell Lymphoma
|
October 2015 | Phase 2 |
| NCT04479267 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma w+MYC & BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma w+MYC, BCL2 & BCL6 Rearrangements
|
August 21, 2020 | Phase 2 |
| NCT00169156 | Lymphoma Study Association|Hoffmann-La Roche |
Untreated T-cell Angioimmunoblastic Lymphoma
|
December 2005 | Phase 2 |
| NCT01955187 | Hospital Universitario 12 de Octubre|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Universitario Fundación Alcorcón|Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre|Biobanco REDinREN|ERA-EDTA|REDinREN|Spanish Society of Nephrology|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|University Hospital, Aachen |
MEMBRANOUS NEPHROPATHY
|
January 2014 | Phase 3 |
| NCT05025800 | M.D. Anderson Cancer Center |
Aggressive B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Composite Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma|Refractory Follicular Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma|Richter Syndrome
|
October 13, 2021 | Phase 1|Phase 2 |
| NCT01862926 | Royal Brompton & Harefield NHS Foundation Trust|Imperial College London|University of East Anglia|University College London Hospitals |
Interstitial Lung Disease|Scleroderma|Idiopathic Inflammatory Myositis|Mixed Connective Tissue Disease
|
November 2014 | Phase 2|Phase 3 |
| NCT02481310 | Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. |
Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma
|
October 28, 2015 | Phase 1|Phase 2 |
| NCT01994382 | Alexion Pharmaceuticals|Portola Pharmaceuticals |
Follicular Lymphoma (FL+Indolent NHL)|Aggressive NHL (a NHL)|Chronic Lymphocytic Leukemia (CLL) + Small Lymphocytic Lymphoma (SLL)|T-cell Lymphoma (PTCL and CTCL)|B-cell Non Hodgkin Lymphoma (NHL)
|
August 30, 2013 | Phase 1|Phase 2 |
| NCT05332587 | First Affiliated Hospital, Sun Yat-Sen University |
Refractory Myasthenia Gravis|Rituximab
|
August 1, 2020 | Phase 3 |
| NCT00816595 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2009 | Phase 2 |
| NCT00398372 | Stanford University|Amgen|National Institutes of Health (NIH) |
Lymphoma, Non-Hodgkin|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Cutaneous Lymphoma|Lymphomas: Non-Hodgkin Diffuse Large B-Cell|Lymphomas: Non-Hodgkin Follicular + Indolent B-Cell|Lymphomas: Non-Hodgkin Mantle Cell|Lymphomas: Non-Hodgkin Marginal Zone|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
|
November 2000 | Not Applicable |
| NCT04799275 | National Cancer Institute (NCI) |
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Grade 3b Follicular Lymphoma|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
March 19, 2021 | Phase 2|Phase 3 |
| NCT03700229 | Peking Union Medical College Hospital |
Acquired Hemophilia A
|
October 10, 2018 | Phase 2 |
| NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
November 1, 2016 | Phase 2 |
| NCT00848692 | Haukeland University Hospital |
Chronic Fatigue Syndrome
|
June 2008 | Phase 2|Phase 3 |
| NCT02367196 | Celgene |
Hematologic Neoplasms
|
March 12, 2015 | Phase 1 |
| NCT02005471 | Hoffmann-La Roche|AbbVie |
Chronic Lymphocytic Leukemia
|
March 17, 2014 | Phase 3 |
| NCT00536341 | SCRI Development Innovations, LLC|Celgene Corporation|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
January 2008 | Phase 1|Phase 2 |
| NCT01419795 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia
|
May 2012 | Phase 2 |
| NCT05457556 | Children´s Oncology Group |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
November 23, 2022 | Phase 3 |
| NCT01086540 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence|Rho Federal Systems Division, Inc. |
Systemic Sclerosis-Associated PAH
|
June 24, 2011 | Phase 2 |
| NCT00003849 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
July 1999 | Phase 2 |
| NCT01125293 | Dana-Farber Cancer Institute|Novartis|Millennium Pharmaceuticals, Inc. |
Waldenstrom´s Macroglobulinemia
|
April 2010 | Phase 1|Phase 2 |
| NCT00279305 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Diabetes Association|Juvenile Diabetes Research Foundation |
Type 1 Diabetes Mellitus
|
August 2005 | Phase 2 |
| NCT02240407 | University of Florida|Lacerta Therapeutics |
Pompe Disease
|
October 17, 2017 | Phase 1 |
| NCT00601718 | University of Washington|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Mycosis Fungoides+Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides+Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Mycosis Fungoides+Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Mycosis Fungoides+Sezary Syndrome|Waldenström Macroglobulinemia
|
December 2007 | Phase 1|Phase 2 |
| NCT00960713 | University Hospital, Toulouse |
Pemphigus|Auto-immune Thrombocytopenic Purpura|Hemolytic Auto-immune Anaemia|Cold Agglutinin Disease|Cryoglobulinemia
|
June 2009 | |
| NCT01682616 | AbbVie|Genentech, Inc. |
Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia
|
July 25, 2012 | Phase 1 |
| NCT03829566 | Northwestern University |
Neuromyelitis Optica|Devic´s Disease|NMO Spectrum Disorder
|
November 2019 | Phase 2|Phase 3 |
| NCT00591630 | M.D. Anderson Cancer Center |
Diffuse Large Cell Lymphoma|Lymphoma
|
November 14, 2007 | Phase 2 |
| NCT00244985 | Roswell Park Cancer Institute|Ortho Biotech, Inc. |
Lymphoma
|
September 2005 | Phase 1|Phase 2 |
| NCT00324779 | University Hospital Erlangen|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 2004 | Phase 2 |
| NCT01390441 | Merck Sharp & Dohme LLC |
Rheumatoid Arthritis
|
July 2011 | Phase 1 |
| NCT00473551 | M.D. Anderson Cancer Center |
Leukemia|Lymphoma|Myeloma
|
May 2007 | Phase 1 |
| NCT00436904 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia
|
December 2004 | Phase 2 |
| NCT00376961 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
August 2006 | Phase 2 |
| NCT00275613 | Mayo Clinic |
Glomerulonephritis, Membranoproliferative
|
November 2005 | Phase 1 |
| NCT00142116 | Steven P. Treon, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Cape Cod Hospital |
Waldenstrom´s Macroglobulinemia|Lymphoplasmacytic Lymphoma
|
May 2003 | Phase 2 |
| NCT03970577 | Assistance Publique - Hôpitaux de Paris |
Minimal Change Nephrotic Syndrome (MCNS)
|
July 29, 2020 | Phase 2 |
| NCT00782821 | University of Cincinnati|Millennium Pharmaceuticals, Inc.|Genzyme, a Sanofi Company |
Kidney Transplantation
|
September 2008 | Phase 4 |
| NCT00389818 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
January 2007 | Phase 2 |
| NCT03361852 | Dana-Farber Cancer Institute |
Follicular Lymphoma
|
March 14, 2022 | Phase 1 |
| NCT00567229 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
November 2007 | Phase 2 |
| NCT00110149 | Beth Israel Deaconess Medical Center |
Lymphoma
|
May 2004 | Phase 2 |
| NCT00169468 | Lymphoma Study Association|Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie |
B Cell Lymphoma
|
January 2005 | Phase 2 |
| NCT01700946 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|Assisi Foundation |
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma
|
April 15, 2013 | Phase 2 |
| NCT04666038 | Loxo Oncology, Inc.|Eli Lilly and Company |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
March 9, 2021 | Phase 3 |
| NCT01370772 | French Innovative Leukemia Organisation|Roche Pharma AG |
B-cell Chronic Lymphocytic Leukemia CLL
|
May 2011 | Phase 2 |
| NCT02564744 | Debiopharm International SA |
Diffuse Large B-Cell Lymphoma|B-cell Non-Hodgkin´s Lymphoma
|
June 15, 2016 | Phase 2 |
| NCT03788291 | University of Rochester |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
|
March 25, 2019 | Phase 2 |
| NCT01521689 | Institut Paoli-Calmettes |
Chronic Lymphocytic Leukemia
|
December 2011 | Phase 2 |
| NCT01682044 | Roswell Park Cancer Institute|National Cancer Institute (NCI) |
Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma
|
April 17, 2007 | Phase 2 |
| NCT00074282 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 16, 2004 | Phase 2 |
| NCT05581030 | H. Lee Moffitt Cancer Center and Research Institute|Servier |
Acute Lymphoblastic Leukemia
|
September 16, 2022 | Phase 1 |
| NCT00238368 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
| NCT01317901 | Aptevo Therapeutics |
B-cell Small Lymphocytic Lymphoma Recurrent
|
May 2011 | Phase 1 |
| NCT01453205 | MedImmune LLC |
Diffuse Large B-Cell Lymphoma
|
February 27, 2012 | Phase 2 |
| NCT01478542 | Universität des Saarlandes|German High-Grade Non-Hodgkin´s Lymphoma Study Group|Spectrum Pharmaceuticals, Inc |
CD20&addition; Aggressive B-Cell Lymphoma
|
November 2011 | Phase 3 |
| NCT00416923 | University of California, San Francisco |
Brain and Central Nervous System Tumors|Lymphoma
|
August 2002 | Phase 1 |
| NCT01134575 | M.D. Anderson Cancer Center|Wyeth is now a wholly owned subsidiary of Pfizer |
Acute Lymphoblastic Leukemia
|
June 4, 2010 | Phase 2 |
| NCT01701986 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic Cell Transplantation Recipient|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma
|
October 25, 2012 | Phase 1|Phase 2 |
| NCT01000610 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
March 17, 2008 | Phase 4 |
| NCT00572013 | University of Nebraska |
Lymphoma
|
May 1998 | Phase 1|Phase 2 |
| NCT02468791 | Mabion SA |
Rheumatoid Arthritis
|
May 2013 | Phase 3 |
| NCT05303792 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma
|
February 2023 | Phase 2 |
| NCT00595335 | Rebecca Bahn|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|Mayo Clinic |
Thyroid-associated Ophthalmopathy
|
April 2008 | Phase 2|Phase 3 |
| NCT03783403 | Celgene |
Neoplasms
|
February 1, 2019 | Phase 1 |
| NCT01980654 | Pharmacyclics LLC. |
Follicular Lymphoma|B-cell Lymphoma|Non-Hodgkin´s Lymphoma
|
December 2013 | Phase 2 |
| NCT04914741 | Peter MacCallum Cancer Centre, Australia|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma
|
June 29, 2021 | Phase 1|Phase 2 |
| NCT05207358 | Institutul Clinic Fundeni |
Lupus Nephritis
|
March 2, 2022 | Phase 4 |
| NCT03161054 | Fondazione Italiana Linfomi ONLUS |
Aggressive Non-Hodgkin Lymphoma
|
September 12, 2017 | Phase 2 |
| NCT04113226 | Centre Hospitalier Universitaire, Amiens|cimiez hospital Nice|Institut Bergonié|groupe hospitalier public sud de l´oise|Henri Mondor University Hospital|Centre Henri Becquerel|Hôpital Charles Foix|Saint-Louis Hospital, Paris, France |
Chemotherapy|Diffuse Large B-Cell Lymphoma (DLBCL), Nos|Elderly
|
July 26, 2021 | Phase 2 |
| NCT00397800 | Technical University of Munich |
Lymphoma
|
June 2005 | Phase 1|Phase 2 |
| NCT00280878 | Bayside Health |
Non-Hodgkin´s Lymphoma (CD20&addition;)
|
January 2006 | Phase 2 |
| NCT04622579 | Guangdong Provincial People´s Hospital|Guangzhou First People´s Hospital|Foshan First People´s Hospital|Huizhou Municipal Central Hospital|Shantou Central Hospital |
Diffuse Large B Cell Lymphoma|Age Over 80 Years
|
October 23, 2020 | Phase 2 |
| NCT00909077 | Copenhagen University Hospital at Herlev |
Idiopathic Thrombocytopenic Purpura
|
August 2004 | Phase 3 |
| NCT00718549 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
July 21, 2009 | Phase 3 |
| NCT00541034 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Astex Pharmaceuticals, Inc. |
Leukemia|Lymphoma
|
May 2005 | Phase 2 |
| NCT00426543 | University of Copenhagen|Rigshospitalet, Denmark |
Primary Sjögren´s Syndrome|Xerostomia|Hyposalivation|Keratoconjunctivitis Sicca|Fatigue
|
January 2007 | Phase 2 |
| NCT02753062 | Asan Medical Center|Cheolwon Suh |
Diffuse Large B Cell Lymphoma
|
August 2015 | Phase 2 |
| NCT01022021 | University of Kansas Medical Center|Cephalon |
Lymphoma
|
January 2010 | Early Phase 1 |
| NCT02758925 | University Hospital, Caen |
Diffuse Large B Cell Lymphoma
|
June 2016 | Phase 2 |
| NCT01015248 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
MALT LYMPHOMA
|
May 2009 | Phase 2 |
| NCT00697996 | Stanford University|Genentech and Biogen IDEC |
Kidney Transplantation
|
June 2005 | Phase 2|Phase 3 |
| NCT00004031 | Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group |
Lymphoma
|
July 1997 | Phase 3 |
| NCT04128176 | University of California, Davis |
Bullous Pemphigoid
|
May 25, 2023 | Phase 3 |
| NCT00476229 | M.D. Anderson Cancer Center|Genzyme, a Sanofi Company |
Lymphoma|Leukemia
|
June 2006 | Not Applicable |
| NCT02197767 | Mayo Clinic|Genentech, Inc. |
Fibrillary Glomerulonephritis
|
November 2014 | Phase 2 |
| NCT01232556 | Pfizer|UCB Pharma |
Lymphoma, Non-Hodgkin
|
April 4, 2011 | Phase 3 |
| NCT00244127 | Zeneus Pharma |
Aggressive Non-Hodgkin´s Lymphoma in the Elderly.
|
October 2002 | Phase 2 |
| NCT04494438 | Istituto Giannina Gaslini |
Idiopathic Nephrotic Syndrome
|
July 2013 | Phase 3 |
| NCT03018626 | Nanfang Hospital of Southern Medical University |
Lymphoma, Large B-Cell, Diffuse
|
July 27, 2017 | Phase 3 |
| NCT00455897 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Dana-Farber Cancer Institute|Bayer |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, Diffuse
|
December 2006 | Phase 2 |
| NCT04323956 | Mayo Clinic|National Cancer Institute (NCI) |
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Follicular Lymphoma|Ann Arbor Stage II Marginal Zone Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Follicular Lymphoma|Ann Arbor Stage III Marginal Zone Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Follicular Lymphoma|Ann Arbor Stage IV Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Indolent Non-Hodgkin Lymphoma
|
June 15, 2020 | Phase 1 |
| NCT04850495 | Yazeed Sawalha|Ohio State University Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
|
November 16, 2021 | Phase 1 |
| NCT01719159 | Anders Svenningsson|Västerbotten County Council, Sweden|Umeå University |
Progressive Multiple Sclerosis
|
November 2009 | Phase 2 |
| NCT02747043 | Amgen |
Lymphoma, Non-Hodgkin
|
May 25, 2016 | Phase 3 |
| NCT01066598 | University Health Network, Toronto|Hoffmann-La Roche |
Graft Versus Host Disease
|
May 2010 | Phase 2 |
| NCT01731561 | Assistance Publique - Hôpitaux de Paris |
Granulomatosis With Polyangiitis|Microscopic Polyangiitis|Renal Limited Forms
|
November 16, 2012 | Phase 3 |
| NCT00628238 | Chronic Lymphocytic Leukemia Research Consortium|Celgene Corporation |
Chronic Lymphocytic Leukemia|CLL|Untreated|Front-line|First-Line|Initial Therapy
|
February 2008 | Phase 2 |
| NCT01307605 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
February 9, 2011 | Phase 2 |
| NCT00057447 | InterMune |
Non-Hodgkin´s Lymphoma
|
March 2003 | Phase 1|Phase 2 |
| NCT02077166 | Pharmacyclics LLC.|Janssen Research & Development, LLC|Celgene Corporation |
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
March 13, 2014 | Phase 1|Phase 2 |
| NCT01054781 | Samsung Medical Center |
Diffuse Large B-cell Lymphoma (DLBCL)
|
January 2009 | Phase 2 |
| NCT03864185 | Nagoya University|Japan Agency for Medical Research and Development|Zenyaku Kogyo Co., Ltd. |
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
March 28, 2019 | Phase 2 |
| NCT02779283 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia
|
January 13, 2016 | Phase 1 |
| NCT00281918 | Hoffmann-La Roche|German CLL Study Group |
Leukemia
|
July 2003 | Phase 3 |
| NCT01886872 | National Cancer Institute (NCI) |
Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
December 9, 2013 | Phase 3 |
| NCT04626791 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
August 3, 2021 | Phase 2 |
| NCT00003356 | University of Rochester|National Cancer Institute (NCI) |
Lymphoma
|
November 1997 | Phase 1|Phase 2 |
| NCT00496340 | H. Lee Moffitt Cancer Center and Research Institute |
Hematologic Malignancies
|
July 2007 | Phase 2 |
| NCT00193466 | SCRI Development Innovations, LLC|Bayer |
Non-Hodgkins Lymphoma
|
January 2002 | Phase 2 |
| NCT00098774 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
October 2004 | Phase 2 |
| NCT02180711 | Acerta Pharma BV|AstraZeneca |
Non Hodgkin Lymphoma
|
December 29, 2014 | Phase 1 |
| NCT02772822 | Sinocelltech Ltd. |
Diffuse Large B Cell Lymphoma
|
June 2016 | Phase 3 |
| NCT00784589 | University Hospital, Rouen |
Pemphigus Disease
|
July 2009 | Phase 3 |
| NCT00820469 | University Hospital, Toulouse |
Renal Transplant|Autoimmune Diseases
|
September 2008 | Phase 4 |
| NCT02950155 | Fredrik Piehl|Karolinska Institutet |
Generalized Myasthenia Gravis
|
October 16, 2016 | Phase 3 |
| NCT03834688 | PrECOG, LLC.|Genentech, Inc. |
Mantle Cell Lymphoma
|
January 13, 2020 | Phase 2 |
| NCT03795571 | The First Affiliated Hospital with Nanjing Medical University |
Diffuse Large B-cell Lymphoma Recurrent|Diffuse Large B Cell Lymphoma Refractory
|
January 1, 2019 | Phase 1 |
| NCT01662102 | Spectrum Pharmaceuticals, Inc |
Follicular Lymphoma
|
December 11, 2012 | Phase 3 |
| NCT00266227 | Genentech, Inc. |
Rheumatoid Arthritis
|
January 2006 | Phase 3 |
| NCT00877006 | Teva Branded Pharmaceutical Products R&D, Inc. |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
April 30, 2009 | Phase 3 |
| NCT04517435 | Deepa Jagadeesh|Case Comprehensive Cancer Center |
Diffuse Large B-Cell Lymphoma
|
April 28, 2021 | Phase 1|Phase 2 |
| NCT02663518 | Pfizer |
Hematologic Malignancies|Solid Tumor
|
January 31, 2016 | Phase 1 |
| NCT02753647 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 2 |
| NCT05267054 | BeiGene |
Relapsed Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma
|
April 25, 2022 | Phase 1|Phase 2 |
| NCT01974440 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma
|
January 31, 2014 | Phase 3 |
| NCT02649504 | Weill Medical College of Cornell University |
Immune Thrombocytopenia
|
December 1, 2016 | Phase 3 |
| NCT02137681 | Shandong University |
Immune Thrombocytopenia
|
May 2014 | Phase 3 |
| NCT05099471 | University of Ulm|Institute for Medical Informatics, Biometry and Epidemiology, University of Munich|Zentrum für Klinische Studien Ulm|AbbVie|Pfizer|University Hospital Schleswig-Holstein, Campus Kiel |
Waldenstrom Macroglobulinemia
|
March 2023 | Phase 2 |
| NCT00076349 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Non-Hodgkin´s Lymphoma
|
April 2004 | Phase 2 |
| NCT00642655 | Cedars-Sinai Medical Center|Genentech, Inc.|Biogen |
Kidney Transplant
|
September 2005 | Phase 1|Phase 2 |
| NCT00481832 | Stanford University |
Lymphoma, Non-Hodgkin
|
January 2007 | Phase 2 |
| NCT03710772 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
May 1, 2019 | Phase 2 |
| NCT01996865 | Celgene |
Lymphoma, Non-Hodgkin
|
April 1, 2014 | Phase 3 |
| NCT00393107 | Gruppo Italiano Studio Linfomi |
Follicular Lymphoma
|
March 2000 | Phase 2 |
| NCT04688788 | Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital|Aalborg University Hospital|Herlev Hospital|Hillerod Hospital, Denmark|Zealand University Hospital|Kolding Sygehus|Regional Hospital Holstebro|Hvidovre University Hospital|Hospital of South West Jutland, Esbjerg, Denmark|GCP unit, Copenhagen University Hospital|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|Hospital of Southern Jutland, Sønderborg, Denmark|Hospital of Central Denmark Region, Viborg, Denmark|Danske Regioner |
Relapsing Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Primary Progressive Multiple Sclerosis
|
April 28, 2021 | Phase 3 |
| NCT00265915 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia
|
July 2005 | Phase 2 |
| NCT00066469 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoproliferative Disorder
|
April 2004 | Phase 2 |
| NCT00308087 | Genzyme, a Sanofi Company|Sanofi |
Lymphoma, Follicular
|
May 2006 | Phase 2 |
| NCT00515554 | University of Cologne |
Hodgkins Lymphoma
|
May 2008 | Phase 3 |
| NCT03527147 | Acerta Pharma BV|AstraZeneca |
NHL|DLBCL|Non-hodgkin´s Lymphoma|Diffuse Large B Cell Lymphoma
|
June 19, 2018 | Phase 1 |
| NCT01103388 | M.D. Anderson Cancer Center|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
August 2003 | Phase 3 |
| NCT01729806 | National Cancer Institute (NCI) |
CD20 Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma
|
November 19, 2012 | Phase 1 |
| NCT00472849 | M.D. Anderson Cancer Center|Sanofi |
Richter´s Transformation|Leukemia
|
May 2007 | Phase 1|Phase 2 |
| NCT01983969 | M.D. Anderson Cancer Center |
Advanced Cancers|Lymphoma
|
November 7, 2013 | Phase 1|Phase 2 |
| NCT05533775 | Hoffmann-La Roche |
Mature B-Cell Non-Hodgkin Lymphoma
|
November 30, 2022 | Phase 1|Phase 2 |
| NCT02314403 | Massachusetts General Hospital |
Kidney Failure, Chronic|Renal Insufficiency
|
February 2015 | Phase 1 |
| NCT01406782 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
December 13, 2011 | |
| NCT00740415 | French Innovative Leukemia Organisation|Janssen, LP|Mundipharma Pte Ltd. |
Lymphoma
|
June 2007 | Phase 2 |
| NCT02834286 | Hospital Universitario Dr. Jose E. Gonzalez |
Immune Thrombocytopenia
|
March 2015 | Phase 2 |
| NCT00536978 | M.D. Anderson Cancer Center |
Lymphoma|Leukemia
|
September 2007 | Phase 2 |
| NCT02259348 | St. Jude Children´s Research Hospital |
Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myelogenous Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)
|
October 2014 | Phase 2 |
| NCT01040871 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Diffuse Large B-Cell Lymphoma
|
January 2010 | Phase 2 |
| NCT00992446 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Diffuse Large B-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Non-Hodgkin Lymphoma
|
September 2, 2010 | Phase 2 |
| NCT02729896 | Hoffmann-La Roche |
Lymphoma
|
November 9, 2016 | Phase 1|Phase 2 |
| NCT01539512 | Gilead Sciences |
Chronic Lymphocytic Leukemia
|
April 2012 | Phase 3 |
| NCT03023046 | University of Washington|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
February 23, 2017 | Phase 2 |
| NCT01719692 | Institute of Hematology & Blood Diseases Hospital|National Natural Science Foundation of China |
Immune Thrombocytopenic Purpura
|
August 2012 | Not Applicable |
| NCT02636322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma Unclassifiable
|
March 29, 2016 | Phase 2 |
| NCT01318915 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) |
Renal Transplant Recipients
|
July 25, 2011 | Early Phase 1 |
| NCT02757196 | Peking University People´s Hospital|Beijing Hospital |
Immune Thrombocytopenia
|
May 2016 | Phase 2 |
| NCT03758989 | University of Rochester |
DLBCL
|
May 8, 2019 | Phase 2 |
| NCT00143871 | University of Michigan Rogel Cancer Center |
Lymphoma, Non-Hodgkin´s
|
April 2001 | Phase 2 |
| NCT00504504 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 2001 | Phase 2 |
| NCT05586737 | Angelica Lindén Hirschberg|Karolinska University Hospital |
Autoimmune Diseases|Premature Ovarian Insufficiency
|
April 29, 2019 | Phase 2 |
| NCT04784052 | Rajni Agarwal|Stanford University |
Fanconi Anemia
|
December 7, 2021 | Phase 1|Phase 2 |
| NCT03003039 | Nanjing Yoko Biomedical Co., Ltd. |
B-Cell Lymphoma
|
June 5, 2017 | Phase 1 |
| NCT00809341 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
January 2009 | Phase 2 |
| NCT00493454 | M.D. Anderson Cancer Center|Biogen |
Lymphoma
|
April 2006 | Phase 2 |
| NCT01421667 | Seagen Inc. |
Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell
|
August 2011 | Phase 2 |
| NCT01542918 | James Rubenstein|Celgene|Genentech, Inc.|University of California, San Francisco |
Recurrent+Refractory CNS|Intraocular Lymphoma
|
December 17, 2012 | Phase 1 |
| NCT00867087 | Pfizer|UCB Pharma |
Lymphoma, B-Cell
|
June 8, 2009 | Phase 2 |
| NCT01116232 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
August 2010 | Phase 2 |
| NCT05201248 | AbbVie|Genmab |
B-Cell Non-Hodgkin Lymphoma
|
March 10, 2022 | Phase 1 |
| NCT00275054 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
October 2005 | Phase 3 |
| NCT04882163 | Celgene |
Lymphoma, B-Cell
|
October 10, 2021 | Phase 1|Phase 2 |
| NCT00363350 | University Medical Center Groningen|Hoffmann-La Roche |
Sjogren´s Syndrome
|
August 2006 | Phase 1|Phase 2 |
| NCT02703272 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma, Non-Hodgkin
|
July 1, 2016 | Phase 3 |
| NCT05551936 | Vaishalee Kenkre|Epizyme, Inc.|University of Wisconsin, Madison|Big Ten Cancer Research Consortium |
Follicular Lymphoma
|
November 2022 | Phase 1|Phase 2 |
| NCT04458610 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma
|
May 26, 2020 | Phase 2 |
| NCT02383589 | Hoffmann-La Roche|Genentech, Inc. |
Pemphigus Vulgaris
|
May 26, 2015 | Phase 3 |
| NCT01926639 | Oslo University Hospital|Norwegian Cancer Society|Helse Sor-Ost |
Follicular Lymphoma
|
October 2009 | Phase 2 |
| NCT00309881 | German CLL Study Group |
Chronic Lymphocytic Leukemia
|
April 2003 | Phase 2 |
| NCT00550342 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Genentech, Inc.|Indiana University |
Focal Segmental Glomerulosclerosis (FSGS)
|
January 2008 | Phase 2 |
| NCT02844322 | Institute of Hematology & Blood Diseases Hospital |
Waldenström Macroglobulinemia
|
May 2016 | Phase 4 |
| NCT03432741 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7
|
March 27, 2018 | Phase 1 |
| NCT00410982 | M.D. Anderson Cancer Center |
Leukemia|Lymphoma|Myeloma
|
December 2006 | Phase 1 |
| NCT00424502 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
January 2007 | Phase 4 |
| NCT00831597 | Pharmatech|Cephalon |
Diffuse Large B-Cell Lymphoma
|
November 2008 | Phase 2 |
| NCT01716442 | Seoul National University Childrens Hospital |
Steroid Resistant Nephrotic Syndrome|Steroid Dependent Nephrotic Syndrome
|
August 2012 | Phase 2|Phase 3 |
| NCT01750697 | Hoffmann-La Roche |
Granulomatosis With Polyangiitis
|
May 23, 2013 | Phase 2 |
| NCT02257567 | Hoffmann-La Roche |
Lymphoma
|
October 15, 2014 | Phase 1|Phase 2 |
| NCT03225924 | The Lymphoma Academic Research Organisation |
DLBCL
|
July 26, 2017 | Phase 1|Phase 2 |
| NCT02428751 | Wenqi Jiang|Sun Yat-sen University |
Lymphoma, Large B-Cell, Diffuse
|
September 2015 | Phase 3 |
| NCT00330252 | Dana-Farber Cancer Institute|Genzyme, a Sanofi Company |
Chronic Lymphocytic Leukemia
|
May 2006 | Phase 1 |
| NCT00150111 | Odense University Hospital |
Graves´ Disease|Thyroid Associated Ophthalmopathy
|
June 2003 | Phase 1|Phase 2 |
| NCT04323748 | New York Medical College |
Immune Thrombocytopenic Purpura
|
February 24, 2021 | Phase 1 |
| NCT01292603 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
April 18, 2011 | Phase 1 |
| NCT00946023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Lymphoma|B-cell Lymphoma|Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia
|
July 2009 | Phase 2 |
| NCT00331006 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)|Genentech, Inc. |
Hemophilia A
|
June 2006 | Phase 2 |
| NCT00496873 | M.D. Anderson Cancer Center|Astex Pharmaceuticals, Inc.|Pharmatech |
Lymphoma
|
June 2005 | Phase 2 |
| NCT01277172 | Probiomed S.A. de C.V. |
Diffuse Large B Cell Lymphoma
|
October 2010 | Phase 2|Phase 3 |
| NCT00654732 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Classic Hodgkin Lymphoma|Lugano Classification Stage III Hodgkin Lymphoma AJCC v8|Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
|
March 19, 2008 | Phase 2 |
| NCT01216683 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
December 13, 2010 | Phase 2 |
| NCT00267865 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
AIDS-Related-Primary Central Nervous System Lymphoma
|
September 14, 2006 | Phase 2 |
| NCT00695097 | University of California, San Francisco|Genentech, Inc. |
Renal Transplant Rejection
|
August 2004 | Not Applicable |
| NCT00064116 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
May 8, 2001 | Phase 3 |
| NCT01434472 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
November 16, 2011 | Phase 2 |
| NCT00141700 | University of Michigan Rogel Cancer Center |
Lymphoma, Non-Hodgkin´s
|
March 2003 | Phase 2 |
| NCT00096044 | Roswell Park Cancer Institute|Celgene |
Leukemia
|
March 2004 | Phase 2 |
| NCT00001586 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Chronic Lymphocytic Leukemia
|
September 1997 | Phase 2 |
| NCT00107380 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2005 | Phase 2 |
| NCT00003820 | Ranjana Advani|Genentech, Inc.|Stanford University |
Lymphoma|Hodgkin Lymphoma (Category)|Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
January 1999 | Phase 2 |
| NCT02320292 | Mayo Clinic|National Cancer Institute (NCI) |
Ann Arbor Stage I Grade 1 Follicular Lymphoma|Ann Arbor Stage I Grade 2 Follicular Lymphoma|Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma
|
February 11, 2015 | Phase 3 |
| NCT02889523 | The Lymphoma Academic Research Organisation|Epizyme, Inc. |
Lymphoma|DLBCL|Follicular Lymphoma
|
October 2016 | Phase 1|Phase 2 |
| NCT00771875 | University of Cincinnati |
Graft Rejection
|
September 2008 | Phase 2 |
| NCT00003659 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Leukemia
|
September 1998 | Phase 2 |
| NCT00140595 | Lymphoma Study Association|Amgen |
Diffuse Large-Cell Lymphoma
|
December 2003 | Phase 3 |
| NCT03929601 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health (NIH)|Juvenile Diabetes Research Foundation |
Type 1 Diabetes Mellitus
|
February 17, 2020 | Phase 2 |
| NCT01382940 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
July 26, 2011 | Phase 4 |
| NCT00636792 | Millennium Pharmaceuticals, Inc. |
Follicular Lymphoma
|
February 2008 | Phase 2 |
| NCT02576275 | SecuraBio |
Indolent Non-Hodgkin´s Lymphoma|Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma
|
December 2015 | Phase 3 |
| NCT00307593 | Assistance Publique - Hôpitaux de Paris |
Wegener´s Granulomatosis|Churg-Strauss Syndrome|Microscopic Polyangiitis
|
May 2004 | Not Applicable |
| NCT00369707 | Northwestern University|Robert H. Lurie Cancer Center |
Non-Hodgkin´s Lymphoma
|
August 9, 2006 | Phase 2 |
| NCT04884035 | Celgene |
Lymphoma, B-Cell
|
September 15, 2021 | Phase 1 |
| NCT03576547 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|t(9;22)
|
June 26, 2018 | Phase 1|Phase 2 |
| NCT00110006 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
December 2004 | Not Applicable |
| NCT03440567 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
April 2, 2018 | Phase 1 |
| NCT01525836 | Shandong University|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|The First Affiliated Hospital of Anhui Medical University|The First Affiliated Hospital of Dalian Medical University|Shandong Provincial Hospital|Shenzhen Second People´s Hospital|First Hospital of China Medical University |
Purpura|Idiopathic Thrombocytopenic Purpura
|
May 2011 | Phase 3 |
| NCT03899337 | University of Birmingham|Bloodwise|Acerta Pharma, LLC |
Richter Syndrome
|
April 2019 | Phase 2 |
| NCT01013961 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Chronic Lymphocytic Leukemia
|
October 2010 | Phase 2 |
| NCT00261612 | Medical University of Vienna |
Lymphoma, Mantle-Cell
|
January 2005 | Phase 2 |
| NCT01973387 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 28, 2013 | Phase 3 |
| NCT02376335 | Newcastle-upon-Tyne Hospitals NHS Trust|National Institute for Health Research, United Kingdom|Department of Health, United Kingdom|Newcastle University |
Fatigue|Primary Biliary Cirrhosis
|
October 2012 | Phase 2 |
| NCT03653338 | Paul Szabolcs|University of Pittsburgh |
Sickle Cell Anemia|Beta-thalassemia Major|Diamond-blackfan Anemia
|
August 2, 2018 | Phase 1|Phase 2 |
| NCT02282514 | Northwestern University |
Stiff-Person Syndrome
|
October 2014 | Phase 1|Phase 2 |
| NCT00058292 | Northwestern University|National Cancer Institute (NCI) |
Lymphoma
|
April 2000 | Phase 1 |
| NCT01573533 | Mayo Clinic|University Health Network, Toronto|National Institutes of Health (NIH)|Genentech, Inc.|Rush University Medical Center|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Primary Focal Segmental Glomerulosclerosis
|
October 2013 | Phase 2 |
| NCT01524068 | University of Pittsburgh |
Idiopathic Pulmonary Fibrosis
|
September 2012 | Phase 2 |
| NCT02198248 | Chiba University |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis|Microscopic Polyangiitis|Wegener Granulomatosis
|
October 2014 | Phase 4 |
| NCT00053027 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
February 2003 | Phase 2 |
| NCT05545384 | Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France |
Acute Demyelinating Syndrome
|
November 2022 | Phase 2|Phase 3 |
| NCT00005631 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
November 1999 | Phase 2 |
| NCT03013218 | ALX Oncology Inc. |
Metastatic Cancer|Solid Tumor|Advanced Cancer|NonHodgkin Lymphoma
|
February 3, 2017 | Phase 1 |
| NCT02400437 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. |
Waldenstrom´s Macroglobulinemia
|
April 2015 | Phase 2 |
| NCT02423915 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cancer Prevention Research Institute of Texas |
Leukemia|Lymphoma
|
July 30, 2015 | Phase 1 |
| NCT03507348 | University Hospital, Grenoble |
End-stage Renal Disease|Kidney Transplantation|Hla-incompatible Kidney Transplant Candidates
|
July 1, 2018 | Not Applicable |
| NCT00412594 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hairy Cell Leukemia|Recurrent Hairy Cell Leukemia
|
June 10, 2004 | Phase 2 |
| NCT02584920 | Shanghai Henlius Biotech |
B-cell Non Hodgkin´s Lymphoma
|
October 2014 | Phase 1|Phase 2 |
| NCT04481815 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
PCNSL
|
October 1, 2020 | Phase 2 |
| NCT01619761 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
May 3, 2013 | Phase 1 |
| NCT04161248 | Canadian Cancer Trials Group|Roche Pharma AG|AbbVie |
Lymphoma, B-Cell
|
December 6, 2019 | Early Phase 1 |
| NCT00893477 | French Innovative Leukemia Organisation|National Cancer Institute (NCI) |
Lymphoma
|
March 2009 | Phase 2 |
| NCT00425217 | Mayo Clinic|Genentech, Inc. |
Membranous Nephropathy
|
August 2004 | Phase 2|Phase 3 |
| NCT03856216 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Lymphocytic Neoplasm|Lymphoma
|
October 28, 2019 | Phase 2 |
| NCT03298698 | Radboud University Medical Center |
Idiopathic Nephrotic Syndrome|Minimal Change Disease|Focal Segmental Glomerulosclerosis
|
August 22, 2018 | Phase 3 |
| NCT00004040 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Leukemia|Multiple Myeloma and Plasma Cell Neoplasm
|
June 1998 | Phase 2 |
| NCT00201721 | Ohio State University Comprehensive Cancer Center|Astex Pharmaceuticals, Inc. |
B-Chronic Lymphocytic Leukemia
|
July 2002 | Phase 2 |
| NCT04074330 | Takeda |
Lymphoma, Non-Hodgkin
|
October 15, 2019 | Phase 1|Phase 2 |
| NCT03864419 | Fred Hutchinson Cancer Center |
Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma
|
October 24, 2019 | Phase 1 |
| NCT00818961 | Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia |
Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases
|
May 2005 | Phase 2 |
| NCT02994927 | ChemoCentryx |
ANCA-Associated Vasculitis
|
March 15, 2017 | Phase 3 |
| NCT00135499 | Lymphoma Study Association|Fondation ARC |
Lymphoma, Large-Cell, Diffuse
|
October 16, 2001 | Phase 3 |
| NCT04154787 | Novartis Pharmaceuticals|Novartis |
Glomerulonephritis, Membranous
|
November 23, 2019 | Phase 2 |
| NCT01613599 | Genentech, Inc. |
Granulomatosis With Polyangiitis|Microscopic Polyangiitis
|
June 20, 2012 | |
| NCT03943901 | University of Wisconsin, Madison|Medical College of Wisconsin |
Diffuse Large B Cell Lymphoma|DLBCL|Cancer
|
February 16, 2021 | Phase 2 |
| NCT05287984 | Institute of Hematology & Blood Diseases Hospital |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Newly Diagnosed
|
March 22, 2022 | Phase 2 |
| NCT00801281 | Polish Lymphoma Research Group |
Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma
|
February 2007 | Phase 3 |
| NCT01679119 | University College, London|Pfizer|Cancer Research UK |
Diffuse Large B Cell Lymphoma
|
October 2013 | Phase 2 |
| NCT01472562 | Weill Medical College of Cornell University|Celgene |
Mantle Cell Lymphoma
|
July 29, 2011 | Phase 2 |
| NCT03010202 | Ostfold Hospital Trust|Oslo University Hospital|St. Olavs Hospital|Helse Stavanger HF|University Hospital of North Norway|Haukeland University Hospital|Odense University Hospital|Centre Hôpital Universitaire Farhat Hached, Tunisia|Henri Mondor University Hospital|University Hospital, Akershus|Hammersmith hospital, UK|Cairo University Hospital, Egypt |
Purpura, Thrombocytopenic, Idiopathic
|
December 2016 | Phase 3 |
| NCT04318678 | St. Jude Children´s Research Hospital |
AML|B-ALL|T-ALL|BPDCN|MDS
|
May 27, 2020 | Phase 1 |
| NCT00911183 | Institut Bergonié|National Cancer Institute, France |
Lymphoma
|
December 2, 2008 | Phase 2 |
| NCT01415752 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Neurotoxicity|Therapy-related Toxicity
|
May 22, 2012 | Phase 2 |
| NCT04361279 | Shanghai Institute Of Biological Products |
Diffuse Large B-Cell Lymphoma
|
July 25, 2019 | Phase 3 |
| NCT00430352 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
September 4, 2006 | Phase 4 |
| NCT00564512 | French Innovative Leukemia Organisation |
Leukemia
|
November 2007 | Phase 3 |
| NCT00117156 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|University of Rochester|Genentech, Inc.|Biogen |
Lymphoma, Non-Hodgkin|MALT Lymphoma
|
December 2003 | Phase 2 |
| NCT05299164 | Institute of Hematology & Blood Diseases Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. |
Non Hodgkin Lymphoma
|
May 15, 2022 | Phase 1 |
| NCT05605899 | Kite, A Gilead Company|Gilead Sciences |
High-risk Large B-cell Lymphoma (LBCL)
|
November 2022 | Phase 3 |
| NCT00517049 | Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
March 2008 | Phase 2 |
| NCT00057343 | Biogen |
Non-Hodgkin´s Lymphoma
|
March 2003 | Phase 3 |
| NCT02682641 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. |
Mantle Cell Lymphoma
|
May 18, 2016 | Phase 2 |
| NCT03189836 | Cogent Biosciences, Inc. |
Lymphoma
|
October 4, 2017 | Phase 1 |
| NCT01493479 | The Christie NHS Foundation Trust|Bayer |
Follicular Lymphoma
|
June 6, 2007 | Phase 2 |
| NCT04665765 | City of Hope Medical Center|National Cancer Institute (NCI) |
Diffuse Large B-Cell Lymphoma Unclassifiable|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma
|
January 18, 2021 | Phase 2 |
| NCT00347971 | ZymoGenetics |
Lymphoma, Non-Hodgkin
|
June 2006 | Phase 1 |
| NCT02453087 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
August 4, 2015 | Phase 1 |
| NCT00029107 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Hepatitis C|Vasculitis
|
December 2001 | Phase 2 |
| NCT05532111 | RenJi Hospital |
Efficacy and Safety
|
September 1, 2022 | Not Applicable |
| NCT01686165 | University of Arizona|National Cancer Institute (NCI) |
Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma
|
August 31, 2012 | Phase 2 |
| NCT01859819 | New York Medical College |
Diffuse Large Cell Lymphoma|Burkitt´s Lymphoma|High Grade B-cell Lymphoma
|
January 2013 | Phase 2 |
| NCT04835870 | The First Affiliated Hospital of Soochow University |
Non-GCB+ABC Diffuse Large B-Cell Lymphoma
|
April 1, 2021 | Phase 2 |
| NCT01332994 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
March 2011 | Phase 3 |
| NCT00104299 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Genentech, Inc. |
Vasculitis|Wegener´s Granulomatosis|Microscopic Polyangiitis
|
January 2005 | Phase 2|Phase 3 |
| NCT01045889 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
HIV-related Lymphoma|HIV Infections
|
January 2007 | Phase 2 |
| NCT02855359 | Seagen Inc. |
Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma + DLBCL
|
August 2016 | Phase 2 |
| NCT01178216 | Stanley Jordan, MD|Genentech, Inc.|Cedars-Sinai Medical Center |
End Stage Renal Disease
|
September 2013 | Phase 1|Phase 2 |
| NCT02433522 | Assistance Publique - Hôpitaux de Paris|Roche Pharma AG |
ANCA-associated Vasculitides
|
March 31, 2015 | Phase 3 |
| NCT02405676 | Children´s Cancer Group, China|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China|Nanjing Children´s Hospital|West China Second University Hospital|Xiangya Hospital of Central South University|Qilu Hospital of Shandong University|Children´s Hospital Of Soochow University|Tianjin Medical University Cancer Institute and Hospital |
Mature B-cell Non-Hodgkin Lymphoma
|
January 2015 | Phase 2|Phase 3 |
| NCT00452374 | M.D. Anderson Cancer Center|Sanofi |
Leukemia
|
November 2004 | Phase 1|Phase 2 |
| NCT02260804 | Celltrion |
Follicular Lymphoma
|
November 9, 2015 | Phase 3 |
| NCT00619671 | University of Vermont|Genentech, Inc. |
Refractory Myasthenia Gravis
|
April 2004 | Phase 1|Phase 2 |
| NCT02199184 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|Atypical Burkitt+Burkitt-Like Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma
|
January 14, 2015 | Phase 2 |
| NCT00895661 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Genentech, Inc. |
B-cell Lymphoma|Indolent B-cell Lymphoma
|
July 2009 | Phase 2 |
| NCT01001780 | University of Rochester |
Active Chronic Graft Versus Host Disease
|
August 2009 | Phase 2 |
| NCT01412879 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2011 | Phase 2 |
| NCT02136511 | Gilead Sciences |
Chronic Lymphocytic Leukemia (CLL)
|
||
| NCT01181154 | Assistance Publique - Hôpitaux de Paris|Hoffmann-La Roche |
Warm Autoimmune Hemolytic Anemia
|
March 3, 2011 | Phase 3 |
| NCT00085696 | Millennium Pharmaceuticals, Inc. |
B-Cell Lymphoma|Follicular Lymphoma|Marginal Lymphoma
|
May 2004 | Phase 2 |
| NCT00243412 | Genentech, Inc. |
Rheumatoid Arthritis
|
August 2005 | Phase 2 |
| NCT00598169 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC |
Lymphoma
|
November 2007 | Phase 1 |
| NCT04933617 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Burkitt Lymphoma|High-grade B-cell Lymphoma|T-cell+Histocyte-rich Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Germinal Center B-cell Type (GCB)
|
March 24, 2022 | Phase 1 |
| NCT01470456 | Sanofi |
Diffuse Large B-Cell Lymphoma
|
November 2011 | Phase 2 |
| NCT02406092 | Hoffmann-La Roche |
Non-Hodgkin Lymphoma
|
October 13, 2015 | Phase 3 |
| NCT04246359 | Huiqiang Huang|Sun Yat-sen University |
Lymphoma, B-Cell
|
January 15, 2020 | Phase 2 |
| NCT05622201 | Region Örebro County |
Schizophrenia Spectrum and Other Psychotic Disorders
|
January 15, 2023 | Phase 2 |
| NCT03474744 | Christian Buske|University of Ulm|SSS International Clinical Research GmbH|X-act Cologne Clinical Research GmbH|Zentrum für Klinische Studien Ulm|Celltrion Healthcare Co., LTD|Bayer Healthcare LTD |
Marginal Zone Lymphoma
|
December 15, 2019 | Phase 2 |
| NCT00064246 | National Cancer Institute (NCI) |
Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Waldenström Macroglobulinemia
|
July 2003 | Phase 1|Phase 2 |
| NCT00003150 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group |
Lymphoma
|
December 1997 | Phase 3 |
| NCT04843904 | Dana-Farber Cancer Institute |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
April 14, 2021 | Phase 1 |
| NCT04915482 | Institute of Hematology & Blood Diseases Hospital |
Immune Thrombocytopenia (ITP)|Autoantibodies|Evan Syndrome|Connective Tissue Diseases
|
June 6, 2021 | Phase 4 |
| NCT01088048 | Gilead Sciences |
Indolent Non-Hodgkin´s Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma
|
March 25, 2010 | Phase 1 |
| NCT00392691 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
October 2006 | Phase 1 |
| NCT00475423 | Hoffmann-La Roche |
Idiopathic Thrombocytopenic Purpura
|
May 2007 | Phase 2 |
| NCT00387023 | M.D. Anderson Cancer Center|Biogen |
Non-Hodgkin´s Lymphoma|Lymphoma
|
February 2004 | Not Applicable |
| NCT04572620 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Interstitial Lymphocytic Lung Disease
|
September 7, 2020 | |
| NCT00940342 | M.D. Anderson Cancer Center|Bayer |
Leukemia
|
October 12, 2004 | Phase 2 |
| NCT01338103 | Rabin Medical Center|Leumit Health Services |
Pemphigus
|
January 2010 | Not Applicable |
| NCT01136395 | University of Giessen|Heidelberg University|German Cancer Research Center|Astellas Pharma US, Inc.|Novartis |
Kidney Transplantation|Rituximab (RTx)|Living Donors|Immunology|Virus
|
January 2010 | Phase 2 |
| NCT00578565 | Eric Matteson|Genentech, Inc.|National Center for Research Resources (NCRR)|Mayo Clinic |
Rheumatoid Arthritis|Interstitial Pneumonia
|
May 2007 | Phase 3 |
| NCT02337985 | City of Hope Medical Center|National Cancer Institute (NCI) |
AIDS-Related Burkitt Lymphoma|AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|HIV Infection|AIDS Related Non-Hodgkin Lymphoma
|
November 20, 2015 | Phase 1 |
| NCT02356159 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Myelodysplastic Syndrome|Hodgkin´s Lymphoma|Non-Hodgkin´s Lymphoma|Acute Leukemia|Multiple Myeloma
|
September 24, 2015 | Phase 1|Phase 2 |
| NCT00033423 | University of Alabama at Birmingham|National Cancer Institute (NCI) |
Lymphoma
|
August 2001 | Phase 1 |
| NCT03458260 | The Lymphoma Academic Research Organisation |
Aggressive Non-Hodgkin Lymphoma
|
March 26, 2018 | Phase 2 |
| NCT02427620 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastoid Variant Mantle Cell Lymphoma|Mantle Cell Lymphoma|Pleomorphic Variant Mantle Cell Lymphoma
|
June 3, 2015 | Phase 2 |
| NCT00070018 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
February 2004 | Phase 2 |
| NCT02966717 | Zhujiang Hospital |
Renal Insufficiency, Chronic|Nephrotic Syndrome
|
August 2016 | Phase 2 |
| NCT01010217 | M.D. Anderson Cancer Center |
Blood Stem Cell Transplant Failure|Leukemia|Hematologic Malignancies
|
November 5, 2009 | Phase 2 |
| NCT00201877 | Ohio State University Comprehensive Cancer Center |
Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma
|
December 2004 | Phase 2 |
| NCT00977977 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
Nephrotic Syndrome|Proteinuria|Autoimmune Disease|Glomerular Disease|Membranous Glomerulonephritis
|
December 22, 2010 | Phase 2 |
| NCT00504751 | Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. |
Non-Hodgkin´s Lymphoma
|
May 2007 | Phase 2 |
| NCT00307125 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation|Cooperative Clinical Trials in Pediatric Transplantation (CCTPT) |
Kidney Transplant|Kidney Transplant Recipient|Graft Function+Survival|de Novo HLA Antibodies Development
|
March 2006 | Phase 2 |
| NCT00072449 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
May 2004 | Phase 2 |
| NCT01290549 | Genentech, Inc. |
Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia
|
March 22, 2011 | Phase 1 |
| NCT00040950 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
March 2002 | Phase 1 |
| NCT03424122 | Incyte Corporation |
B-cell Lymphoma
|
July 2, 2018 | Phase 1 |
| NCT00003663 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
June 1998 | Phase 2 |
| NCT00003757 | Swiss Group for Clinical Cancer Research |
Leukemia
|
February 1998 | Phase 2 |
| NCT04659044 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma
|
April 1, 2021 | Phase 2 |
| NCT00930514 | Hoffmann-La Roche |
Lymphoma, Follicular
|
September 2009 | Phase 1 |
| NCT02735876 | Acerta Pharma BV |
Mantle Cell Lymphoma
|
May 2016 | Phase 3 |
| NCT01490723 | M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc |
Leukemia|Lymphoma
|
January 2013 | Phase 2 |
| NCT00400764 | Genentech, Inc.|Amgen |
Non-Hodgkin´s Lymphoma
|
June 2006 | Phase 1|Phase 2 |
| NCT04518475 | Institute of Hematology & Blood Diseases Hospital|The Second Affiliated Hospital of Kunming Medical University|Henan Cancer Hospital|Tianjin Medical University Second Hospital|The First Affiliated Hospital of Xiamen University|Nantong University |
Primary Immune Thrombocytopenia (ITP)
|
August 10, 2020 | Phase 4 |
| NCT00880815 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD20 Positive|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma
|
February 17, 2009 | Phase 1 |
| NCT00301301 | Royal Marsden NHS Foundation Trust |
Non-Hodgkins Lymphoma
|
||
| NCT01593332 | Mashhad University of Medical Sciences|Roche Pharma AG |
DMARD Resistant Rheumatoid Arthritis
|
July 2010 | Phase 4 |
| NCT01000441 | University Hospital, Strasbourg, France |
Rheumatoid Arthritis
|
December 23, 2009 | Phase 4 |
| NCT02049541 | Kami Maddocks, MD|Novartis|Ohio State University Comprehensive Cancer Center |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
July 21, 2014 | Phase 1 |
| NCT03401853 | University of Washington|Merck Sharp & Dohme LLC |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma
|
March 23, 2018 | Phase 2 |
| NCT00901927 | M.D. Anderson Cancer Center|Cephalon |
Follicular Lymphoma
|
May 2009 | Phase 2 |
| NCT00856245 | University of Kansas Medical Center |
Non-Hodgkins Lymphoma
|
February 2009 | Phase 2 |
| NCT04531865 | Children´s Hospital of Fudan University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai Children´s Medical Center|Shanghai Children´s Hospital |
Frequently Relapsing Nephrotic Syndrome|Steroid-Dependent Nephrotic Syndrome
|
January 1, 2021 | Phase 3 |
| NCT00513747 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Leukemia
|
January 2008 | Phase 3 |
| NCT01451879 | University of Florida |
Pompe Disease
|
October 2008 | |
| NCT01810588 | Weill Medical College of Cornell University |
Hematologic Malignancies
|
October 16, 2012 | Phase 2 |
| NCT01734057 | Shandong University|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Anhui Medical University|The First Affiliated Hospital of Dalian Medical University|Shandong Provincial Hospital|Shenzhen Second People´s Hospital|China Medical University, China|Zhejiang Provincial Hospital of TCM |
Purpura|Idiopathic Thrombocytopenic Purpura
|
July 2012 | Phase 3 |
| NCT00075946 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
November 2003 | Phase 3 |
| NCT04994626 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
DLBCL|MYD88 Gene Mutation|CD79A Gene Mutation|CD79B Gene Mutation|Relapse|Refractory Lymphoma
|
October 1, 2021 | Phase 2 |
| NCT00005601 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
October 2000 | Phase 2 |
| NCT00366418 | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) |
Refractory Chronic Lymphocytic Leukemia
|
August 10, 2006 | Phase 1 |
| NCT01776840 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Mantle Cell Lymphoma
|
May 16, 2013 | Phase 3 |
| NCT00334438 | UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
July 2006 | Phase 1 |
| NCT00556127 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie |
Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS
|
June 2002 | Phase 2 |
| NCT03151044 | FENG Ji-feng|Chinese Anti-Cancer Association|Jiangsu Cancer Institute & Hospital |
Diffuse Large B-cell Lymphoma
|
July 2016 | Phase 3 |
| NCT02692248 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A. |
Diffuse Large B-Cell Lymphoma
|
April 7, 2016 | Phase 2 |
| NCT02438982 | Nilratan Sircar Medical College |
Nephrotic Syndrome
|
May 8, 2015 | Phase 3 |
| NCT01429025 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation |
Refractory+Relapsed Indolent Non-Hodgkin Lymphoma
|
May 2012 | Phase 1 |
| NCT01611090 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
September 19, 2012 | Phase 3 |
| NCT01539174 | Fox Chase Cancer Center|Genentech, Inc. |
Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma
|
Phase 2 | |
| NCT04913103 | Czech Lymphoma Study Group |
Lymphoma, Mantle-Cell
|
September 1, 2021 | Phase 2 |
| NCT02456207 | Sinocelltech Ltd. |
B-cell Non Hodgkin´s Lymphoma
|
May 2015 | Phase 2 |
| NCT04516655 | Fudan University |
Central Nervous System Lymphoma
|
September 1, 2020 | Phase 2 |
| NCT03372837 | SymBio Pharmaceuticals |
Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
|
January 15, 2018 | Phase 3 |
| NCT02481297 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Leukemia|Chronic Lymphocytic Leukemia|Lymphocytic Leukemia
|
June 23, 2015 | Phase 2 |
| NCT00899431 | M.D. Anderson Cancer Center|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
May 6, 2009 | Phase 2 |
| NCT00656084 | US Oncology Research|Eli Lilly and Company |
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
|
December 2004 | Phase 2 |
| NCT04796922 | Incyte Corporation |
Follicular Lymphoma ( FL)|Marginal Zone Lymphoma (MZL)
|
December 30, 2022 | Phase 3 |
| NCT02420938 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
Leukemia
|
July 2015 | Phase 2 |
| NCT01178086 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
February 22, 2010 | |
| NCT03578198 | Seoul National University Hospital|Hallym University Medical Center|Kyunghee University Medical Center|Gyeongsang National University Hospital |
CD20-positive Non-Hodgkin Lymphoma
|
November 8, 2018 | Phase 2 |
| NCT00691015 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms
|
May 2008 | Phase 2 |
| NCT00020800 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
September 2001 | Phase 2 |
| NCT01392716 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
October 1997 | Phase 2 |
| NCT00863187 | Rambam Health Care Campus|Technion, Israel Institute of Technology |
Lymphoma
|
February 2009 | Not Applicable |
| NCT01713738 | Neufeld, Ellis J, MD, PhD|Genentech, Inc.|Biogen|Glaser Pediatric Research Network|Terrana ITP Research Fund |
Idiopathic Thrombocytopenic Purpura (ITP)|Immune Thrombocytopenic Purpura (ITP)
|
May 2003 | Phase 1|Phase 2 |
| NCT04002947 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Non-Hodgkin´s Lymphoma|Diffuse Large B-Cell Lymphoma|DLBCL|NHL
|
August 5, 2019 | Phase 2 |
| NCT00199082 | Nicola Goekbuget|Goethe University |
Burkitt´s Lymphoma|Burkitt´s Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma
|
July 2002 | Phase 4 |
| NCT01744626 | Celgene Corporation |
Leukemia Lymphocytic Chronic B-Cell
|
December 2012 | Phase 1 |
| NCT04899453 | Peking Union Medical College Hospital |
Primary Vitreoretinal Lymphoma
|
August 1, 2020 | Phase 2 |
| NCT02113007 | SCRI Development Innovations, LLC|Genentech, Inc. |
Primary Central Nervous System Lymphoma
|
July 2014 | Phase 2 |
| NCT05618925 | ImmunityBio, Inc. |
NonHodgkin´s Lymphoma Refractory
|
November 15, 2022 | Phase 1 |
| NCT04155840 | University of Washington|Bayer |
Lymphoid Leukemia|Non-Hodgkin´s Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
January 31, 2020 | Phase 2 |
| NCT00553501 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2008 | Phase 2 |
| NCT00482053 | Stanford University |
Lymphoma, B-cell|Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma (DLBCL)|Malignant Lymphoma, Non-Hodgkin
|
October 2006 | Phase 2 |
| NCT04279938 | Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme LLC|Mundipharma-EDO GmbH |
Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
September 2018 | Phase 1 |
| NCT01829568 | National Cancer Institute (NCI)|Celgene Corporation |
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma
|
June 21, 2013 | Phase 1 |
| NCT03651518 | Assistance Publique - Hôpitaux de Paris |
Inflammatory Disease|Autoimmune Diseases
|
October 20, 2020 | Phase 2 |
| NCT00062296 | Fox Chase Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
March 2003 | Phase 2 |
| NCT00086944 | National Cancer Institute (NCI) |
Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma
|
May 2004 | Phase 1|Phase 2 |
| NCT00344149 | Ostfold Hospital Trust|Oslo University Hospital|South-Eastern Regional Health Authority |
Immune Thrombocytopenia (ITP)
|
June 2006 | Phase 3 |
| NCT00031642 | University of Nebraska|Biogen |
Lymphoma
|
January 2002 | Phase 1|Phase 2 |
| NCT05018520 | Ruijin Hospital |
Diffuse Large B Cell Lymphoma
|
September 17, 2021 | Phase 3 |
| NCT04404283 | Seagen Inc. |
Diffuse Large B-cell Lymphoma
|
August 20, 2020 | Phase 3 |
| NCT03422523 | University Hospital Southampton NHS Foundation Trust|Hoffmann-La Roche |
Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
May 9, 2018 | Phase 2 |
| NCT05422066 | Li Zhiming|Antengene Corporation|Sun Yat-sen University |
DLBCL Germinal Center B-Cell Type
|
July 26, 2022 | Phase 2 |
| NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals |
Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma
|
November 13, 2015 | Phase 2 |
| NCT01804712 | Stephen Howell, M.D.|Genentech, Inc.|University of California, San Diego |
Prostate Cancer
|
July 2013 | Early Phase 1 |
| NCT00867529 | Fred Hutchinson Cancer Center|American Cancer Society, Inc.|National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent+Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia
|
February 2009 | Phase 2 |
| NCT01334502 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2012 | Phase 1 |
| NCT00578305 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
November 2007 | Phase 3 |
| NCT03274492 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
November 16, 2017 | Phase 3 |
| NCT01695941 | National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma
|
August 31, 2012 | Phase 1 |
| NCT05564052 | Janssen Research & Development, LLC|Pharmacyclics LLC. |
Lymphoma, Mantle-Cell
|
December 21, 2022 | Phase 2|Phase 3 |
| NCT02055820 | Hoffmann-La Roche|AbbVie |
Lymphoma, Non-Hodgkin
|
November 17, 2013 | Phase 1|Phase 2 |
| NCT00074490 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma|Leukemia|Myeloproliferative Disorders|Multiple Myleoma|Myelodysplastic Syndrome
|
January 1, 2004 | Phase 2 |
| NCT03194815 | University of Cambridge|University of Oxford |
Psychosis|Autoimmune Encephalitis
|
November 1, 2017 | Phase 2 |
| NCT02632396 | Emory University|Millennium Pharmaceuticals, Inc. |
Mantle Cell Lymphoma
|
March 1, 2016 | Phase 1|Phase 2 |
| NCT04061512 | University College, London|Janssen-Cilag Ltd. |
Waldenstrom Macroglobulinemia
|
February 3, 2020 | Phase 2|Phase 3 |
| NCT01326702 | National Cancer Institute (NCI) |
Adult B Acute Lymphoblastic Leukemia|Adult Nasal Type Extranodal NK+T-Cell Lymphoma|Adult Solid Neoplasm|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia+Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Plasma Cell Myeloma|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
July 2011 | Phase 1|Phase 2 |
| NCT02605694 | SecuraBio |
Lymphoma
|
December 2015 | Phase 2 |
| NCT01718691 | SymBio Pharmaceuticals |
Low-grade B Cell Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
|
November 2011 | Phase 2 |
| NCT04607772 | Karyopharm Therapeutics Inc |
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
November 18, 2020 | Phase 1|Phase 2 |
| NCT00001563 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
AIDS Related Lymphoma|AIDS-Associated Lymphoma
|
January 8, 1997 | Phase 2 |
| NCT02746744 | Anders Svenningsson|Karolinska Institutet |
Multiple Sclerosis, Relapsing-Remitting
|
May 2016 | Phase 3 |
| NCT05398224 | Peking University |
Secondary Central Nervous System Lymphoma
|
February 26, 2021 | Phase 2 |
| NCT01267812 | City of Hope Medical Center|National Cancer Institute (NCI) |
Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma
|
October 3, 2011 | Phase 2 |
| NCT04872790 | OHSU Knight Cancer Institute|AbbVie|Oregon Health and Science University |
B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent B Acute Lymphoblastic Leukemia
|
October 2, 2022 | Phase 1 |
| NCT00210353 | International Extranodal Lymphoma Study Group (IELSG) |
Lymphoma, Mucosa-Associated Lymphoid Tissue
|
January 2003 | Phase 3 |
| NCT02734771 | Patrick Reagan|Seagen Inc.|University of Rochester |
Diffuse Large B-Cell Lymphoma
|
June 2016 | Phase 2 |
| NCT02911142 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Effusion Lymphoma|B-Cell Neoplasm
|
July 3, 2017 | Phase 1|Phase 2 |
| NCT05293509 | M.D. Anderson Cancer Center |
Stem Cell Transplantation
|
September 30, 2022 | Phase 2 |
| NCT02265731 | AbbVie|Genentech, Inc. |
Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Acute Myeloid Leukemia (AML)
|
September 22, 2014 | Phase 1|Phase 2 |
| NCT00634179 | Emory University|Millennium Pharmaceuticals, Inc. |
Lymphoma, B-Cell|Follicular Lymphoma
|
February 2008 | Phase 1|Phase 2 |
| NCT03259529 | St. Petersburg State Pavlov Medical University |
Diffuse Large B Cell Lymphoma
|
March 27, 2017 | Phase 1|Phase 2 |
| NCT01482754 | National University Hospital, Singapore |
Non Hodgkin Lymphoma
|
May 2012 | Not Applicable |
| NCT04062448 | Janssen Pharmaceutical K.K. |
Waldenstrom Macroglobulinemia
|
September 25, 2019 | Phase 2 |
| NCT03169790 | ImmunityBio, Inc. |
Non Hodgkin Lymphoma
|
December 2017 | Phase 1|Phase 2 |
| NCT03746223 | Peking Union Medical College Hospital |
Primary Intraocular Lymphoma
|
November 15, 2018 | Phase 2 |
| NCT00003204 | National Cancer Institute (NCI) |
Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Small Lymphocytic Lymphoma
|
March 1998 | Phase 3 |
| NCT01234766 | Dartmouth-Hitchcock Medical Center|Cephalon|Spectrum Pharmaceuticals, Inc |
Lymphoma, Follicular
|
October 2010 | Phase 2 |
| NCT00168740 | Biogen |
Low-Grade or Follicular B-Cell Non-Hodgkin´s Lymphoma
|
April 1995 | Phase 3 |
| NCT05533125 | Sint Maartenskliniek|Dutch Arthritis Association|ZonMw: The Netherlands Organisation for Health Research and Development |
Polymyalgia Rheumatica
|
January 2023 | Phase 3 |
| NCT00416819 | University of California, San Francisco|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Lymphoma
|
September 2003 | Not Applicable |
| NCT02072967 | Astellas Pharma Europe B.V.|Astellas Pharma Inc |
Lymphoma, Non-Hodgkin
|
May 2012 | |
| NCT01238146 | National Cancer Institute (NCI) |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma
|
October 2010 | Phase 1|Phase 2 |
| NCT00142168 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Celgene Corporation|Genentech, Inc. |
Waldenstrom´s Macroglobulinemia
|
September 2004 | Phase 2 |
| NCT00134082 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
November 2005 | Phase 1|Phase 2 |
| NCT01399372 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology |
Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Lymphoma|Neurotoxicity|Radiation Toxicity
|
September 2011 | Phase 2 |
| NCT01107951 | Hospital Universitario Dr. Jose E. Gonzalez |
Immune Thrombocytopenic Purpura
|
April 2010 | Phase 2 |
| NCT01773616 | Imperial College London|Karolinska Institutet|Ohio State University|Dutch Working Party on Systemic Lupus Erythematosus|EULAR Lupus Nephritis Trial Network Study Group |
Systemic Lupus Erythematosus, Lupus Nephritis
|
April 2015 | Phase 3 |
| NCT03505762 | Wake Forest University Health Sciences|National Cancer Institute (NCI) |
B-Cell Non-Hodgkin Lymphoma
|
July 19, 2018 | Phase 2 |
| NCT03930953 | Celgene |
Lymphoma, Non-Hodgkin
|
May 20, 2019 | Phase 1 |
| NCT04022239 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Hematopoietic and Lymphoid System Neoplasm
|
March 13, 2020 | Phase 1|Phase 2 |
| NCT00517699 | Hoffmann-La Roche |
Lymphoma
|
September 2007 | Phase 2 |
| NCT00477412 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma
|
April 3, 2007 | Phase 1|Phase 2 |
| NCT02315118 | National University Hospital, Singapore|National University, Singapore |
B-Cell Chronic Lymphocytic Leukemia|Non-Hodgkin´s Lymphoma
|
December 2014 | Phase 1|Phase 2 |
| NCT04464798 | Celgene |
Lymphoma
|
November 11, 2020 | Phase 1 |
| NCT01212094 | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
Multiple Sclerosis
|
September 2010 | Phase 1|Phase 2 |
| NCT01224093 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
October 2010 | |
| NCT01569451 | University of Colorado, Denver|Rocky Mountain MS Research Group, LLC |
Multiple Sclerosis
|
February 2012 | Phase 2 |
| NCT00324831 | Favrille|National Cancer Institute (NCI) |
Lymphoma
|
Phase 3 | |
| NCT01567475 | The Lymphoma Academic Research Organisation |
Non-Hodgkin´s Lymphomas
|
December 2011 | Phase 1 |
| NCT00350545 | Stanford University |
Graft vs Host Disease
|
August 2006 | Not Applicable |
| NCT00787722 | Northwestern University |
Devic´s Disease
|
October 10, 2009 | Phase 1|Phase 2 |
| NCT01279616 | Nationwide Children´s Hospital |
Sickle Cell Disease
|
September 2010 | Phase 2 |
| NCT01076556 | National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma
|
April 2010 | Phase 1 |
| NCT00147966 | University of California, San Diego|Genentech, Inc. |
Rheumatoid Arthritis
|
June 2008 | Phase 2 |
| NCT00908986 | Northwell Health |
Lupus Nephritis
|
December 2008 | Not Applicable |
| NCT02624492 | Boehringer Ingelheim |
Lymphoma, Large B-Cell, Diffuse
|
January 28, 2016 | Phase 2 |
| NCT00531089 | Hamilton Health Sciences Corporation|Canadian Apheresis Group|Hoffmann-La Roche|McMaster University |
Thrombotic Thrombocytopenic Purpura|Hemolytic Uremic Syndrome
|
December 2007 | Phase 2 |
| NCT03096782 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chemotherapy-Related Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Minimal Residual Disease|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Myelodysplastic Syndrome|Small Lymphocytic Lymphoma|Therapy-Related Myelodysplastic Syndrome
|
October 13, 2017 | Phase 2 |
| NCT02589145 | M.D. Anderson Cancer Center|Celgene Corporation |
Lymphoma
|
June 22, 2016 | Phase 1|Phase 2 |
| NCT01973062 | Case Comprehensive Cancer Center |
Primary Central Nervous System Non-Hodgkin Lymphoma
|
March 2014 | Phase 2 |
| NCT00892827 | Wolfson Medical Center |
Advanced Refractory Chronic Lymphocytic Leukemia
|
April 2009 | Phase 2 |
| NCT02006706 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
August 10, 2006 | Phase 3 |
| NCT00007865 | University of Nebraska|National Cancer Institute (NCI) |
Lymphoma
|
September 2000 | Phase 2 |
| NCT04404088 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma
|
July 16, 2020 | Phase 2 |
| NCT00151281 | Weill Medical College of Cornell University |
Non-Hodgkin´s Lymphoma
|
November 2004 | Phase 2 |
| NCT00001337 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Large B-Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma|Burkitt Lymphoma|Anaplastic Large-Cell Lymphoma|Gray Zone Lymphoma
|
May 8, 1993 | Phase 2 |
| NCT00048737 | M.D. Anderson Cancer Center|Biogen |
Lymphoma|Leukemia
|
October 2002 | Phase 1|Phase 2 |
| NCT00072514 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia
|
August 2003 | Phase 2 |
| NCT00022971 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma
|
August 15, 2001 | Phase 1 |
| NCT01095172 | Guy´s and St Thomas´ NHS Foundation Trust|Astellas Pharma Europe Ltd. |
Function of Renal Transplant
|
November 2010 | Phase 4 |
| NCT00286325 | Duke University|Genentech, Inc. |
Bullous Pemphigoid
|
March 2005 | Phase 1|Phase 2 |
| NCT01592981 | University College, London |
Waldenstrom´s Macroglobulinaemia
|
January 2013 | Phase 2 |
| NCT03036904 | Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center |
Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma
|
February 6, 2017 | Phase 1 |
| NCT03670888 | JHL Biotech, Inc. |
B Cell Lymphoma
|
November 16, 2018 | Phase 1 |
| NCT00074165 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Brain and Central Nervous System Tumors|Drug+Agent Toxicity by Tissue+Organ|Lymphoma|Thrombocytopenia
|
January 2003 | Phase 2 |
| NCT00227695 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
June 8, 2004 | Phase 3 |
| NCT00486759 | Hoffmann-La Roche|Genentech, Inc. |
B-cell Lymphoma
|
July 26, 2007 | Phase 3 |
| NCT01009970 | Fondazione Italiana Linfomi ONLUS |
Diffuse Large B-Cell Lymphoma
|
May 2010 | Phase 2 |
| NCT00440388 | Ascenta Therapeutics |
Follicular Lymphoma
|
October 2006 | Phase 2 |
| NCT01424982 | M.D. Anderson Cancer Center |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia
|
October 5, 2011 | Phase 2 |
| NCT00254163 | US Oncology Research|Astex Pharmaceuticals, Inc. |
B-Cell Chronic Lymphocytic Leukemia
|
December 2003 | Phase 3 |
| NCT00633594 | SCRI Development Innovations, LLC|Millennium Pharmaceuticals, Inc.|Celgene |
Mantle Cell Lymphoma
|
June 2008 | Phase 1|Phase 2 |
| NCT00169195 | Lymphoma Study Association|Hoffmann-La Roche|Sanofi-Synthelabo|Eli Lilly and Company |
Diffuse Large Cell Lymphoma
|
April 2003 | Phase 2 |
| NCT00119392 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia
|
June 2004 | Phase 2 |
| NCT01810926 | Franco Locatelli|University of Milano Bicocca|medac GmbH|Fresenius AG|Bambino Gesù Hospital and Research Institute |
Graft Versus Host Disease
|
September 2011 | Phase 2 |
| NCT01316523 | University of California, Davis|Celgene |
Non Hodgkin´s Lymphoma
|
December 2010 | Phase 2 |
| NCT00004889 | Jonsson Comprehensive Cancer Center|Genentech, Inc. |
Lymphoma
|
December 1999 | Phase 2 |
| NCT01865110 | The Lymphoma Academic Research Organisation |
Mantle Cell Lymphoma
|
November 2013 | Phase 3 |
| NCT00794820 | M.D. Anderson Cancer Center|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
December 2003 | Phase 2 |
| NCT04585893 | UNC Lineberger Comprehensive Cancer Center|Fogarty International Center of the National Institute of Health |
Multicentric Castleman Disease
|
June 22, 2021 | Phase 2 |
| NCT00812669 | Cancer Trials Ireland |
Leukemia
|
August 2008 | Phase 2 |
| NCT01197560 | Celgene |
Diffuse Large B-cell Lymphoma
|
September 2, 2010 | Phase 2|Phase 3 |
| NCT00774202 | Weill Medical College of Cornell University|Biogen|Genentech, Inc. |
Immune Thrombocytopenic Purpura
|
November 2003 | Phase 2|Phase 3 |
| NCT01576588 | Prof. Dr. Med. Laimonas Griskevicius|Vilnius University |
B-Cell Chronic Lymphocytic Leukemia
|
October 2011 | Phase 2 |
| NCT00547534 | University of Rochester|Millennium Pharmaceuticals, Inc.|Cephalon |
Non-Hodgkin´s Lymphoma
|
October 2007 | Phase 2 |
| NCT05494593 | Takeda|Takeda Development Center Americas, Inc. |
Mucopolysaccharidosis (MPS)|Hunter Syndrome
|
December 9, 2022 | Phase 4 |
| NCT00396812 | National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence |
Rheumatoid Arthritis
|
November 2006 | Phase 1|Phase 2 |
| NCT03495960 | International Extranodal Lymphoma Study Group (IELSG) |
Primary Central Nervous System Lymphoma
|
June 15, 2019 | Phase 2 |
| NCT02031419 | Celgene |
Lymphoma, Large B-Cell, Diffuse
|
December 18, 2013 | Phase 1 |
| NCT00151320 | Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc. |
Non-Hodgkin´s Lymphoma
|
January 2004 | Phase 1|Phase 2 |
| NCT01596127 | M.D. Anderson Cancer Center |
Leukemia|Lymphoid Malignancies|Metastatic Malignant Neoplasm to the Leptomeninges
|
January 24, 2013 | Phase 1|Phase 2 |
| NCT00364819 | University of California, Davis|Genentech, Inc. |
Primary Biliary Cirrhosis
|
January 2007 | Phase 1|Phase 2 |
| NCT05065554 | Jorge J. Castillo, MD|AstraZeneca|Dana-Farber Cancer Institute |
IgM MGUS|Waldenstrom Macroglobulinemia|Neuropathy;Peripheral
|
November 16, 2021 | Phase 2 |
| NCT00003595 | National Cancer Institute (NCI) |
Lymphoma
|
January 1999 | Phase 3 |
| NCT02533401 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
February 2006 | Phase 2 |
| NCT00987493 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
September 2009 | Phase 1|Phase 2 |
| NCT00193505 | SCRI Development Innovations, LLC|Biogen |
Non-Hodgkins Lymphoma
|
October 2003 | Phase 2 |
| NCT00509184 | Klaus Herfarth, MD|German Low Grade Lymphoma Study Group|Roche Pharma AG|Heidelberg University |
Lymphoma, Malignant
|
March 2008 | Phase 2 |
| NCT05115409 | Sun Yat-sen University|Chipscreen Biosciences, Ltd. |
Relapsed or Refractory DLBCL
|
June 1, 2022 | Phase 2 |
| NCT00543114 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Celgene Corporation |
Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia
|
October 2007 | Phase 1 |
| NCT00104858 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma|T-Cell Large Granular Lymphocyte Leukemia
|
December 2004 | Phase 2 |
| NCT04045028 | Genentech, Inc. |
Multiple Myeloma|Non-Hodgkin Lymphoma|B-Cell Lymphoma
|
July 22, 2019 | Phase 1 |
| NCT04033276 | Seoul National University Hospital|Severance Hospital|GC Biopharma Corp |
Renal Transplant
|
January 8, 2019 | Phase 4 |
| NCT00576758 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
January 2008 | Phase 2 |
| NCT00100737 | Chiron Corporation |
Non-Hodgkin Lymphoma
|
Phase 2 | |
| NCT04375228 | Columbia University|Genentech, Inc. |
Immune-related Adverse Events|Advanced Solid Tumor
|
September 25, 2020 | Phase 2 |
| NCT00971763 | University College, London |
Lymphoma
|
March 2006 | Phase 2 |
| NCT04274257 | Tokyo University|Japan Agency for Medical Research and Development|Zenyaku Kogyo Co., Ltd. |
Scleroderma, Systemic|Skin Sclerosis|Lung Fibrosis|Autoimmune Diseases|Collagen Diseases
|
December 4, 2017 | Phase 2|Phase 3 |
| NCT03520920 | BeiGene |
Marginal Zone Lymphoma|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma
|
January 4, 2018 | Phase 2 |
| NCT00602459 | National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group |
Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
January 15, 2008 | Phase 2 |
| NCT02677155 | Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme LLC |
Follicular Lymphoma
|
January 2016 | Phase 2 |
| NCT03154385 | Assistance Publique - Hôpitaux de Paris |
Immune Thrombocytopenia
|
March 13, 2017 | Not Applicable |
| NCT04507477 | University Health Network, Toronto |
Epstein-Barr Virus Infections|Post-transplant Lymphoproliferative Disorder
|
July 7, 2020 | Phase 1|Phase 2 |
| NCT01594229 | AbbVie|Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
May 21, 2012 | Phase 1 |
| NCT00446251 | University of Washington|Genentech, Inc. |
Kidney Failure, Chronic|Diabetic Nephropathies|Glomerulonephritis, IGA|Hypertension, Renal
|
December 2006 | Phase 2 |
| NCT02961816 | M.D. Anderson Cancer Center |
Lymphoma
|
June 2017 | Phase 2 |
| NCT00799773 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)|Genentech, Inc. |
Thrombotic Thrombocytopenic Purpura
|
April 2009 | Phase 3 |
| NCT01592292 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
November 2011 | |
| NCT02950051 | German CLL Study Group|Janssen-Cilag Ltd.|Hoffmann-La Roche|AbbVie|Stichting Hemato-Oncologie voor Volwassenen Nederland|Nordic CLL Study Group (NCLLSG)|Swiss Group for Clinical Cancer Research|Cancer Trials Ireland|Israeli CLL Study Group |
Chronic Lymphocytic Leukemia
|
December 13, 2016 | Phase 3 |
| NCT00502853 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
October 25, 2007 | Phase 4 |
| NCT01421173 | M.D. Anderson Cancer Center |
Lymphoma
|
August 2011 | Phase 1 |
| NCT01671904 | Genentech, Inc.|AbbVie (prior sponsor, Abbott) |
Chronic Lymphocytic Leukemia
|
January 13, 2014 | Phase 1 |
| NCT00617929 | Masonic Cancer Center, University of Minnesota |
Cancer
|
January 2008 | Phase 2 |
| NCT00577993 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 16, 1998 | Phase 3 |
| NCT01144364 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
January 19, 2004 | Phase 3 |
| NCT00050245 | National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) |
Polyneuropathies
|
November 27, 2002 | Phase 2 |
| NCT00544219 | Swiss Group for Clinical Cancer Research |
Lymphoma
|
September 2007 | Not Applicable |
| NCT00058422 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
February 10, 2003 | Phase 2 |
| NCT02417129 | Boehringer Ingelheim |
Lymphoma, Non-Hodgkin
|
April 2015 | Phase 3 |
| NCT01780454 | Massachusetts General Hospital |
End Stage Renal Disease
|
March 2013 | Phase 1|Phase 2 |
| NCT00090051 | Hoffmann-La Roche|Biogen|Genentech, Inc. |
Chronic Lymphocytic Leukemia
|
July 31, 2003 | Phase 3 |
| NCT03488225 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia in Remission|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
March 28, 2018 | Phase 2 |
| NCT00003554 | The Cleveland Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
November 1998 | Phase 2 |
| NCT02003222 | National Cancer Institute (NCI)|Canadian Cancer Trials Group |
Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
December 23, 2013 | Phase 3 |
| NCT00576433 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
December 2007 | Phase 4 |
| NCT00765245 | Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
October 2008 | Phase 2 |
| NCT04745949 | M.D. Anderson Cancer Center |
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
May 10, 2021 | Phase 2 |
| NCT00093769 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Lymphoma
|
August 2004 | Phase 2 |
| NCT00726700 | Universität des Saarlandes |
Lymphoma
|
May 2004 | Phase 2 |
| NCT03545035 | Gruppo Italiano Malattie EMatologiche dell´Adulto|ERIC Group |
Chronic Lymphocytic Leukemia
|
February 6, 2019 | |
| NCT00504777 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
July 2007 | Phase 4 |
| NCT04447716 | Thomas Jefferson University|National Cancer Institute (NCI) |
Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Marginal Zone Lymphoma
|
October 16, 2020 | Phase 1 |
| NCT02296775 | Dr. Reddy´s Laboratories Limited |
Rheumatoid Arthritis
|
November 2014 | Phase 1|Phase 2 |
| NCT01969409 | University of Alabama at Birmingham|National Institutes of Health (NIH) |
Ambulatory IPF
|
January 2014 | Phase 2 |
| NCT05498220 | UNC Lineberger Comprehensive Cancer Center|Genentech, Inc. |
Diffuse Large B-cell Lymphoma
|
October 27, 2022 | Phase 2 |
| NCT01271010 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
June 17, 2011 | Phase 4 |
| NCT00361621 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Millennium Pharmaceuticals, Inc. |
Non-Hodgkin´s Lymphoma
|
July 2006 | Phase 2 |
| NCT00556192 | Chinese University of Hong Kong |
Systemic Lupus Erythematosus
|
June 2006 | Phase 2 |
| NCT02093026 | Hoffmann-La Roche|Genentech, Inc. |
Rheumatoid Arthritis
|
August 2002 | Phase 2 |
| NCT04624958 | Sun Yat-sen University |
Mantle Cell Lymphoma|Newly-diagnosed Mantle Cell Lymphoma
|
December 1, 2020 | Phase 2 |
| NCT00575406 | Arbeitsgemeinschaft medikamentoese Tumortherapie |
Diffuse Large B-Cell Lymphoma
|
December 2007 | Phase 2 |
| NCT04529772 | Acerta Pharma BV|AstraZeneca |
Diffuse Large B-Cell Lymphoma
|
October 8, 2020 | Phase 3 |
| NCT02390362 | Nationwide Children´s Hospital|Emory University|Children´s Healthcare of Atlanta|Genentech, Inc.|The NephCure Foundation |
Frequent Relapsing Nephrotic Syndrome|Steroid Dependent Nephrotic Syndrome
|
January 2015 | Phase 3 |
| NCT04752163 | M.D. Anderson Cancer Center |
Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome
|
March 25, 2021 | Phase 1|Phase 2 |
| NCT00551239 | CTI BioPharma |
Leukemia|Lymphoma
|
August 2007 | Phase 3 |
| NCT05040906 | Shandong New Time Pharmaceutical Co., LTD |
Recruiting
|
October 13, 2020 | Phase 3 |
| NCT00248534 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
September 2005 | Phase 2 |
| NCT02776813 | Cogent Biosciences, Inc. |
Lymphoma
|
August 2016 | Phase 1 |
| NCT00577161 | CTI BioPharma |
Non-Hodgkin´s Lymphoma
|
September 2007 | Phase 3 |
| NCT05280626 | Innovent Biologics (Suzhou) Co. Ltd. |
Diffuse Large B-Cell Lymphoma
|
March 25, 2022 | Phase 2 |
| NCT03054259 | University of Leeds |
Systemic Lupus Erythematosus Arthritis
|
September 21, 2017 | Phase 2 |
| NCT02792699 | Amgen |
Arthritis, Rheumatoid
|
May 17, 2016 | Phase 3 |
| NCT04285567 | Hoffmann-La Roche |
Chronic Lymphocytic Leukemia (CLL)
|
May 28, 2020 | Phase 3 |
| NCT03523975 | University of Michigan Rogel Cancer Center |
Mantle Cell Lymphoma
|
December 24, 2018 | Phase 1 |
| NCT00333008 | The Alvin and Lois Lapidus Cancer Institute|Ortho Biotech Products, L.P. |
Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin
|
May 2006 | Phase 2 |
| NCT00877214 | Jurgen Barth|Sponsor GmbH|University of Giessen |
Follicular Lymphomas|Immunocytomas|Marginal Zone Lymphomas|Mantle-Cell Lymphomas|Lymphocytic Lymphoma|Non-Hodgkin´s Lymphoma
|
April 1, 2009 | Phase 3 |
| NCT00404157 | Genentech, Inc. |
Lupus Nephritis
|
Phase 3 | |
| NCT00983619 | MedImmune LLC |
B-cell Malignancies|Cancer
|
April 16, 2010 | Phase 1|Phase 2 |
| NCT03609593 | Nicole Lamanna|Columbia University |
Chronic Lymphocytic Leukemia
|
November 12, 2018 | Phase 2 |
| NCT01088724 | A.O. Ospedale Papa Giovanni XXIII |
Post-transplant Lymphoproliferative Disease (PTLD)|Non Burkitt
|
February 2002 | Phase 4 |
| NCT01458548 | Charite University, Berlin, Germany |
Post-transplantation Lymphoproliferative Disorder
|
December 2002 | Phase 2 |
| NCT01476787 | Celgene|The Lymphoma Academic Research Organisation |
Follicular Lymphoma
|
December 29, 2011 | Phase 3 |
| NCT02960646 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Aplastic Anemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Recurrent Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Therapy-Related Myelodysplastic Syndrome
|
January 18, 2017 | Phase 1 |
| NCT02115997 | Hoffmann-La Roche |
Wegener´s Granulomatosis or Microscopic Polyangiitis
|
July 6, 2015 | Phase 4 |
| NCT00060671 | CTI BioPharma |
Lymphoma, Follicular|Lymphoma, Mixed-Cell, Follicular|Lymphoma, Small Cleaved-Cell, Follicular|Lymphoma, Low-Grade
|
January 2005 | Phase 3 |
| NCT01307267 | Pfizer |
Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Carcinoma, Squamous Cell of Head and Neck|Malignant Melanoma
|
June 21, 2011 | Phase 1 |
| NCT00896519 | French Innovative Leukemia Organisation|National Cancer Institute (NCI) |
Lymphoma
|
March 2009 | Phase 2 |
| NCT02157181 | Jurgen Barth|University of Giessen |
Hairy Cell Leukemia (HCL)
|
June 2004 | Phase 2 |
| NCT00147953 | University of Cologne |
Non-Hodgkin´s Lymphoma
|
June 2004 | Phase 2 |
| NCT00602836 | Mayo Clinic|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2008 | Phase 2 |
| NCT00565331 | Radboud University Medical Center|Hoffmann-La Roche|Astellas Pharma GmbH |
Kidney Transplantation
|
December 2007 | Phase 2|Phase 3 |
| NCT02141451 | Masonic Cancer Center, University of Minnesota |
Diffuse Large B Cell Non-Hodgkin Lymphoma
|
May 2014 | Phase 1|Phase 2 |
| NCT00738829 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene Corporation|Roche Pharma AG |
Leukemia, Lymphocytic, Chronic, B-Cell
|
October 2008 | Phase 1|Phase 2 |
| NCT03315923 | Isfahan University of Medical Sciences |
Secondary Progressive Multiple Sclerosis
|
December 1, 2017 | Phase 2|Phase 3 |
| NCT00053092 | Institute of Cancer Research, United Kingdom|Australasian Leukaemia and Lymphoma Group|National Cancer Institute (NCI) |
Lymphoma
|
October 2002 | Phase 2 |
| NCT00290498 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
August 1, 2005 | Phase 2 |
| NCT05171647 | Hoffmann-La Roche |
Non-Hodgkin Lymphoma
|
April 25, 2022 | Phase 3 |
| NCT02059239 | Weill Medical College of Cornell University |
Hodgkin´s Lymphoma|Non-Hodgkin´s Lymphoma
|
June 4, 2014 | Phase 1|Phase 2 |
| NCT01510184 | Spectrum Pharmaceuticals, Inc |
Diffuse Large B-cell Lymphoma|Follicle Center Lymphoma
|
April 19, 2012 | Phase 3 |
| NCT01415765 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, Diffuse Large-Cell B-cell|Diffuse, Large B-cell Lymphoma|Lymphoma, Diffuse Large-Cell|Large-Cell Lymphoma, Diffuse
|
July 15, 2011 | Phase 1|Phase 2 |
| NCT01724021 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma, Non-Hodgkin´s Lymphoma
|
December 2012 | Phase 3 |
| NCT00337246 | Cancer Research UK|National Cancer Institute (NCI) |
Leukemia
|
July 2005 | Phase 2 |
| NCT04431635 | Big Ten Cancer Research Consortium|Bayer|Bristol-Myers Squibb|University of Michigan |
Indolent Lymphoma
|
June 15, 2020 | Phase 1 |
| NCT00671658 | M.D. Anderson Cancer Center |
Leukemia|Acute Lymphoblastic Leukemia
|
November 2002 | Phase 2 |
| NCT05392257 | Qingdao Central Hospital |
Overall Survival
|
May 1, 2022 | Phase 2 |
| NCT04002401 | Kite, A Gilead Company|Gilead Sciences |
Refractory Large B-cell Lymphoma
|
November 5, 2019 | Phase 2 |
| NCT00807196 | Maisonneuve-Rosemont Hospital|Bayer |
Non-Hodgkins Lymphoma
|
September 2008 | Phase 1|Phase 2 |
| NCT00384553 | University of Magdeburg |
Non-Hodgkin´s Lymphoma
|
June 2004 | Phase 1|Phase 2 |
| NCT04127578 | Prevail Therapeutics|Eli Lilly and Company |
Parkinson Disease
|
January 3, 2020 | Phase 1|Phase 2 |
| NCT01622439 | Lund University Hospital|Valcuria |
Diffuse Large B-cell Lymphoma
|
June 2012 | Phase 1|Phase 2 |
| NCT05283720 | AbbVie|Genmab |
Non-Hodgkin Lymphoma
|
June 14, 2022 | Phase 2 |
| NCT03736616 | Swedish Medical Center|Acerta Pharma BV |
Diffuse Large B Cell Lymphoma
|
August 16, 2019 | Phase 2 |
| NCT00092222 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoproliferative Disorder|HHV-8|Malignancy|HIV
|
October 28, 2004 | Phase 2 |
| NCT01959698 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Amgen |
CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma
|
April 17, 2014 | Phase 1 |
| NCT04480450 | University of Kansas Medical Center |
Chronic Inflammatory Demyelinating Polyneuropathy
|
July 2023 | Phase 2 |
| NCT05384743 | Beijing Friendship Hospital |
Secondary Hemophagocytic Lymphohistiocytosis|Chronic Active Epstein-Barr Virus Infection
|
February 1, 2022 | Phase 3 |
| NCT02654379 | Hoffmann-La Roche |
Off-Label Use
|
December 18, 2015 | |
| NCT01059786 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hairy Cell Leukemia
|
July 1, 2010 | Phase 2 |
| NCT04004819 | First Affiliated Hospital of Fujian Medical University |
HTLV-1-associated Myelopathy
|
August 15, 2019 | Phase 2 |
| NCT03081910 | Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute |
T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia
|
November 1, 2017 | Phase 1 |
| NCT04408625 | Prevail Therapeutics|Eli Lilly and Company |
Frontotemporal Dementia
|
November 9, 2020 | Phase 1|Phase 2 |
| NCT00039195 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc. |
Lymphoma
|
November 2006 | Phase 2 |
| NCT00295932 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University |
Leukemia|Lymphoma
|
December 13, 2005 | Phase 1|Phase 2 |
| NCT01118234 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Roche Pharma AG |
Chronic Lymphocytic Leukemia
|
December 2009 | Phase 3 |
| NCT02018861 | Incyte Corporation |
B-Cell Malignancies
|
September 22, 2016 | Phase 1|Phase 2 |
| NCT02727803 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Acute Myeloid Leukemia With Variant MLL Translocations|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chemotherapy-Related Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Gene Mutation|Myelodysplastic+Myeloproliferative Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome
|
May 19, 2016 | Phase 2 |
| NCT01732926 | Gilead Sciences |
Indolent Non-Hodgkin´s Lymphomas
|
January 2, 2013 | Phase 3 |
| NCT00268983 | GlaxoSmithKline |
Lymphoma, Non-Hodgkin
|
October 2004 | Phase 3 |
| NCT00427856 | Gemin X|Teva Branded Pharmaceutical Products R&D, Inc. |
Lymphoma, Follicular
|
March 2007 | Phase 2 |
| NCT00280241 | University of Pittsburgh|Genentech, Inc.|Biogen |
Chronic Lymphocytic Leukemia
|
June 2004 | Phase 2 |
| NCT00784927 | Mayo Clinic|National Cancer Institute (NCI) |
Lymphoma
|
November 2008 | Phase 2 |
| NCT00004039 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
June 1998 | Phase 2 |
| NCT00028717 | Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI) |
Lymphoma
|
February 2001 | Phase 3 |
| NCT00662948 | PETHEMA Foundation|GELCAB|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Lymphoma
|
December 2008 | Phase 2 |
| NCT00087529 | Genentech, Inc. |
Multiple Sclerosis
|
June 2004 | Phase 2|Phase 3 |
| NCT00032019 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
February 2002 | Phase 2 |
| NCT00117975 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
June 2005 | Phase 2 |
| NCT01880567 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CCND1 Positive|CCND2 Positive|CCND3 Positive|CD20 Positive|Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma
|
July 15, 2013 | Phase 2 |
| NCT00759798 | M.D. Anderson Cancer Center |
Chronic Lymphocytic Leukemia|Leukemia
|
August 13, 2008 | Phase 2 |
| NCT00974792 | Cancer Research UK|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
| NCT00003605 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group |
Lymphoma
|
May 1998 | Phase 2 |
| NCT00490529 | Ronald Levy|National Institutes of Health (NIH)|Stanford University |
Lymphoma, Mantle-Cell
|
August 2009 | Phase 2 |
| NCT01345708 | Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico|University Hospital, Udine, Italy |
Autoimmune Hemolytic Disease (Cold Type) (Warm Type)
|
January 2009 | Phase 2 |
| NCT02079532 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
November 2006 | Phase 3 |
| NCT01625741 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Chronic Lymphocytic Leukemia
|
July 2012 | Phase 2 |
| NCT03258866 | Shandong University |
Purpura, Thrombocytopenic, Idiopathic|Immune Thrombocytopenia
|
January 1, 2010 | Phase 4 |
| NCT03671018 | Hoffmann-La Roche |
B-cell Non-Hodgkin Lymphoma
|
September 25, 2018 | Phase 1|Phase 2 |
| NCT02501473 | Immune Design|Merck Sharp & Dohme LLC |
Follicular Low Grade Non-Hodgkin´s Lymphoma
|
February 3, 2016 | Phase 1|Phase 2 |
| NCT01889797 | PrECOG, LLC.|Genentech, Inc. |
Indolent Non-Hodgkin´s Lymphoma
|
December 2013 | Phase 2 |
| NCT00078949 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Lymphoma
|
August 7, 2003 | Phase 3 |
| NCT00439556 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
CD20 Positive|Hematopoietic and Lymphoid Cell Neoplasm|Lymphocytic Neoplasm|Lymphoma
|
February 13, 2007 | Phase 2 |
| NCT00238238 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
March 2006 | Phase 2 |
| NCT00327678 | Assistance Publique - Hôpitaux de Paris|Group for Research in Adult Acute Lymphoblastic Leukemia |
Leukemia, Lymphocytic
|
May 2006 | Phase 3 |
| NCT02626845 | Hospital for Special Surgery, New York|Genentech, Inc.|Roche Pharma AG |
Granulomatosis With Polyangiitis (Wegener´s Granulomatosis)
|
December 2015 | Phase 4 |
| NCT00006436 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Lymphoma, AIDS-related|Lymphoma, Large B-Cell, Diffuse
|
January 29, 2001 | Phase 2 |
| NCT00701129 | Genzyme, a Sanofi Company|Sanofi |
Pompe Disease|Glycogen Storage Disease Type II
|
October 2009 | Phase 4 |
| NCT00625729 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
January 2008 | Phase 1|Phase 2 |
| NCT00301821 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
January 2006 | Phase 2 |
| NCT02752815 | Ruijin Hospital |
Diffuse Large B-cell Lymphoma
|
April 2016 | Phase 4 |
| NCT00577278 | City of Hope Medical Center|National Cancer Institute (NCI) |
Graft Versus Host Disease|Leukemia|Lymphoma
|
October 3, 2007 | Phase 2 |
| NCT00719472 | Genentech, Inc. |
Non-Hodgkin´s Lymphoma
|
July 2008 | Phase 3 |
| NCT04337827 | Deepa Jagadeesh|Case Comprehensive Cancer Center |
Post-transplant Lymphoproliferative Disorder
|
September 2, 2020 | Phase 2 |
| NCT02689986 | Helse Fonna |
Cold Agglutinin Disease|Autoimmune Hemolytic Anemia
|
January 2013 | Phase 2 |
| NCT00119730 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Biogen |
Mantle Cell Lymphoma
|
February 2005 | Phase 2 |
| NCT00797810 | University of Bologna |
Acute Lymphoblastic Leukemia|Non-Hodgkin´s Lymphoma
|
December 2006 | Phase 4 |
| NCT00891839 | Cephalon|Teva Branded Pharmaceutical Products R&D, Inc. |
Mantle Cell Lymphoma
|
June 2009 | Phase 2 |
| NCT00058461 | National Cancer Institute (NCI) |
B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|L3 Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma
|
November 2003 | Phase 2 |
| NCT02194374 | M.D. Anderson Cancer Center|CLL Global Research Foundation Alliance |
Leukemia
|
January 2015 | Phase 1 |
| NCT05100862 | BeiGene |
Relapsed+Refractory Follicular Lymphoma|Marginal Zone Lymphoma
|
March 10, 2022 | Phase 3 |
| NCT01470196 | Dana-Farber Cancer Institute|Amgen |
Waldenstrom´s Macroglobulinemia
|
October 2011 | Phase 2 |
| NCT01534949 | Celltrion |
Diffuse Large B-Cell Lymphoma
|
February 2012 | Phase 1 |
| NCT03518112 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Philadelphia Chromosome Negative|Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia
|
April 18, 2018 | Phase 2 |
| NCT01479842 | Kami Maddocks, MD|Pharmacyclics LLC.|Ohio State University Comprehensive Cancer Center |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
December 7, 2011 | Phase 1 |
| NCT01665768 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Novartis Pharmaceuticals |
CD20&addition;, B-cell Lymphomas|Mantle Cell Lymphoma|Non-Mantle Cell Low Grade B Cell Lymphomas (SLL+CLL)|Transformed Lymphoma+DLBCL+PMBCL|Hodgkin´s Disease|Gray Zone Lymphoma
|
September 2012 | Phase 2 |
| NCT04231877 | University of Washington|Genentech, Inc. |
Aggressive Non-Hodgkin Lymphoma|ALK-Positive Large B-Cell Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma
|
October 27, 2020 | Phase 1 |
| NCT01765374 | University Hospital, Rouen |
Rheumatoid Arthritis
|
February 2011 | Phase 4 |
| NCT00432653 | Charite University, Berlin, Germany|Hoffmann-La Roche |
Ankylosing Spondylitis
|
March 2007 | Phase 2|Phase 3 |
| NCT01851551 | Acrotech Biopharma Inc. |
Non-Hodgkin´s Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma
|
September 2001 | Phase 1|Phase 2 |
| NCT00476164 | King´s College London|Medical Research Council|Roche Pharma AG |
Kidney Transplantation|Graft Rejection|Immunosuppression
|
January 2007 | Phase 4 |
| NCT01902862 | Janssen-Cilag G.m.b.H |
Lymphoma, Follicular
|
February 2006 | Phase 2 |
| NCT00934648 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
October 2007 | Phase 4 |
| NCT00087425 | National Institute on Aging (NIA)|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
July 2004 | Phase 2 |
| NCT03321643 | National Cancer Institute (NCI) |
Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Richter Syndrome|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
|
March 7, 2018 | Phase 1 |
| NCT01274182 | Sandoz|Novartis Pharmaceuticals |
Rheumatoid Arthritis
|
January 2011 | Phase 1|Phase 2 |
| NCT00422383 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
February 2006 | Phase 3 |
| NCT01964755 | University of Miami |
Epstein Barr Virus Associated Non Hodgkin´s Lymphoma|Epstein Barr Virus Associated Hodgkin´s Lymphoma|Post-Transplant Lymphoproliferative Disease
|
April 21, 2009 | Phase 2 |
| NCT00278161 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
January 2005 | Phase 2 |
| NCT03164473 | Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group |
Eosinophilic Granulomatosis With Polyangiitis
|
March 7, 2018 | Phase 4 |
| NCT00429065 | Instituto Nacional de Cancerologia de Mexico |
Non-Hodgkin Lymphoma
|
January 2007 | |
| NCT00584935 | University of Alabama at Birmingham|Genentech, Inc.|Biogen |
Ocular Cicatricial Pemphigoid
|
January 2006 | Phase 1|Phase 2 |
| NCT00472225 | The Korean Society of Hematopoietic Stem Cell Transplantation|Hoffmann-La Roche |
Steroid-Refractory Chronic GVHD
|
May 2007 | Phase 2 |
| NCT00433537 | National Cancer Institute (NCI) |
Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma
|
May 2007 | Phase 2 |
| NCT00599170 | University of Southern California |
Diffuse, Large B-Cell, Lymphoma
|
January 10, 2008 | Phase 2 |
| NCT00299494 | Pfizer|UCB Pharma |
B-Cell Lymphoma
|
May 4, 2006 | Phase 1|Phase 2 |
| NCT00645606 | University Hospital, Tours|Roche Pharma AG|French Innovative Leukemia Organisation |
Leukemia
|
December 2007 | Phase 3 |
| NCT05508009 | Alice Bertaina|Stanford University |
SIOD With CKD Stage 3 Through 5|Cystinosis With CKD Stage 3 Through 5|FSGS With CKD Stage 3 Through 5|SLE Nephritis With CKD Stage 3 Through 5
|
October 2022 | Phase 1|Phase 2 |
| NCT04989491 | University Hospital, Strasbourg, France |
Epstein-Barr Virus Infections
|
December 1, 2021 | Phase 4 |
| NCT02460276 | Lund University Hospital|Celgene|Janssen, LP|Nordic Lymphoma Group |
Relapsed+Refractory Mantle Cell Lymphoma
|
April 2015 | Phase 2 |
| NCT02060656 | Royal Marsden NHS Foundation Trust|Celgene Corporation |
Diffuse Large B-Cell Lymphoma
|
September 2013 | Phase 2 |
| NCT04058470 | Huiqiang Huang|Sun Yat-sen University |
Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma
|
April 24, 2020 | Phase 1|Phase 2 |
| NCT03620903 | Christian Buske|University of Ulm|ClinAssess|Zentrum für Klinische Studien Ulm|Hoffmann-La Roche|Johnson & Johnson |
Waldenstrom Macroglobulinemia
|
September 11, 2019 | Phase 2 |
| NCT04594798 | University of Rochester|Genentech, Inc. |
DLBCL|Lymphoma, B-Cell
|
September 20, 2021 | Phase 2 |
| NCT02267915 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
Mantle-cell Lymphoma
|
March 2015 | Phase 2 |
| NCT01388959 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
November 1998 | Phase 2 |
| NCT01534884 | Celltrion |
Rheumatoid Arthritis
|
February 2012 | Phase 1 |
| NCT00983944 | Ohio State University Comprehensive Cancer Center |
Lymphoma
|
September 2009 | Phase 2 |
| NCT00921414 | French Innovative Leukemia Organisation|Lymphoma Study Association |
Mantle Cell Lymphoma
|
September 2008 | Phase 3 |
| NCT01775631 | Bristol-Myers Squibb |
B-Cell Malignancies
|
March 2013 | Phase 1 |
| NCT00869999 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Novartis |
Diffuse Large B-cell Lymphoma
|
May 2009 | Phase 2 |
| NCT04840602 | National Cancer Institute (NCI) |
Lymphoplasmacytic Lymphoma|Waldenstrom Macroglobulinemia
|
June 24, 2021 | Phase 2 |
| NCT02670616 | Samsung Medical Center |
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
|
May 1, 2016 | Phase 2 |
| NCT00001805 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Breast Neoplasms|Colonic Neoplasms|Lung Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms
|
March 1999 | Phase 2 |
| NCT04765111 | M.D. Anderson Cancer Center |
Mantle Cell Lymphoma
|
June 30, 2021 | Phase 2 |
| NCT02053610 | Hoffmann-La Roche|German CLL Study Group|Genentech, Inc. |
Lymphocytic Leukemia, Chronic
|
December 31, 2009 | Phase 3 |
| NCT00258336 | Favrille|National Cancer Institute (NCI) |
Lymphoma
|
August 2004 | Phase 2 |
| NCT00907751 | Assistance Publique - Hôpitaux de Paris |
Thrombotic Thrombocytopenic Purpura
|
May 2010 | Phase 2 |
| NCT01829958 | Memorial Sloan Kettering Cancer Center |
Non Hodgkin Lymphoma (NHL)|Diffuse Large B-cell Lymphoma (DLBCL)
|
April 2013 | Not Applicable |
| NCT03136497 | Hackensack Meridian Health|Janssen Scientific Affairs, LLC|Genentech, Inc. |
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
September 5, 2017 | Phase 1 |
| NCT05615974 | LaNova Medicines Limited |
Malignant Tumors
|
January 2023 | Phase 1|Phase 2 |
| NCT04216524 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Blastic Plasmacytoid Dendritic Cell Neoplasm
|
May 29, 2020 | Phase 2 |
| NCT00005959 | Amgen|National Cancer Institute (NCI) |
Lymphoma
|
December 1999 | Phase 2 |
| NCT04974996 | ADC Therapeutics S.A. |
Diffuse Large B-Cell Lymphoma
|
February 1, 2022 | Phase 1 |
| NCT00278564 | Northwestern University |
MYOPATHY
|
September 2005 | Phase 1 |
| NCT04384484 | ADC Therapeutics S.A. |
Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma
|
September 16, 2020 | Phase 3 |
| NCT00041132 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
September 2002 | Phase 2 |
| NCT00278408 | German High-Grade Non-Hodgkin´s Lymphoma Study Group |
Lymphoma
|
November 2005 | Phase 3 |
| NCT00850499 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Follicular Lymphoma
|
September 2009 | Phase 2 |
| NCT00381004 | M.D. Anderson Cancer Center|Bayer |
Chronic Lymphocytic Leukemia
|
September 2006 | Phase 2 |
| NCT03688451 | Tahir Latif|University of Cincinnati |
Non Hodgkin Lymphoma
|
October 29, 2018 | Phase 2 |
| NCT01998880 | Hoffmann-La Roche|German CLL Study Group|Genentech, Inc. |
Lymphocytic Leukemia, Chronic
|
December 22, 2009 | Phase 3 |
| NCT02446236 | Hackensack Meridian Health |
Mantle Cell Lymphoma
|
June 18, 2015 | Phase 1 |
| NCT00939328 | Southwest Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
September 2009 | Phase 2 |
| NCT00131313 | East Valley Hematology and Oncology Medical Group|Mena, Raul, M.D.|Pharmatech Oncology|Astex Pharmaceuticals, Inc. |
Chronic Lymphocytic Leukemia
|
January 2003 | Phase 4 |
| NCT00858117 | Northwestern University|Bayer |
Leukemia
|
September 26, 2005 | Phase 2 |
| NCT00026182 | National Cancer Institute (NCI) |
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma
|
October 2001 | Phase 2 |
| NCT00282347 | Genentech, Inc. |
Lupus Nephritis
|
January 2006 | Phase 3 |
| NCT00711828 | Mayo Clinic|National Cancer Institute (NCI) |
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia
|
August 2008 | Phase 2 |
| NCT01974518 | Uprety Shraddha|Postgraduate Institute of Medical Education and Research |
Pemphigus
|
November 2013 | Phase 3 |
| NCT00003397 | University of Maryland, Baltimore|University of Maryland Greenebaum Cancer Center |
Lymphoma
|
September 1998 | Phase 2 |
| NCT00477815 | Mayo Clinic|National Cancer Institute (NCI) |
Multiple Myeloma and Plasma Cell Neoplasm
|
May 31, 2005 | Phase 1 |
| NCT01021735 | University of Glasgow|Arthritis Research UK|NHS Lothian|NHS Grampian|NHS Tayside|NHS Borders|NHS Fife |
Rheumatoid Arthritis
|
April 2010 | Phase 4 |
| NCT01900496 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc. |
Lymphoma
|
June 2014 | Phase 1 |
| NCT01161628 | Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia |
Chronic Graft-versus-host Disease
|
April 2011 | Phase 2 |
| NCT01318317 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma
|
September 19, 2011 | Phase 1|Phase 2 |
| NCT03636503 | Dana-Farber Cancer Institute|Pfizer |
Follicular Lymphoma
|
October 30, 2018 | Phase 1 |
| NCT00860457 | Georgetown University|Celgene Corporation |
Chronic Lymphocytic Leukemia
|
February 2008 | Phase 2 |
| NCT01805037 | Northwestern University|Seagen Inc. |
Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK+T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Epstein-Barr Virus Infection|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia+Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides+Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia+Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides+Sezary Syndrome|Stage IB Mycosis Fungoides+Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia+Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides+Sezary Syndrome|Stage IIB Mycosis Fungoides+Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia+Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides+Sezary Syndrome|Stage IIIB Mycosis Fungoides+Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia+Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides+Sezary Syndrome|Stage IVB Mycosis Fungoides+Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia
|
March 5, 2013 | Phase 1|Phase 2 |
| NCT05036577 | Huashan Hospital |
Primary Central Nervous System Lymphoma
|
October 10, 2021 | Phase 1 |
| NCT04989621 | Sun Yat-sen University |
Follicular Lymphoma|Relapsed and Refractory Follicular Lymphoma
|
August 1, 2021 | Phase 2 |
| NCT00369681 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
May 2006 | Phase 2 |
| NCT03967925 | Rachel Jones|GlaxoSmithKline|Medical Research Council|Imperial College London|University College, London|Newcastle University|University of Glasgow|University of Cambridge|Cambridge University Hospitals NHS Foundation Trust |
ANCA Associated Vasculitis|Granulomatosis With Polyangiitis
|
February 1, 2019 | Phase 2 |
| NCT04578613 | Beijing InnoCare Pharma Tech Co., Ltd. |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
January 8, 2021 | Phase 3 |
| NCT00590447 | Charite University, Berlin, Germany |
PTLD|Posttransplant Lymphoproliferative Disorder
|
December 2006 | Phase 2 |
| NCT00052923 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B |
Lymphoma
|
March 2003 | Phase 3 |
| NCT00400478 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular NHL Grade 3b
|
January 2006 | Phase 3 |
| NCT01445535 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma
|
January 13, 2009 | Phase 1 |
| NCT04585152 | Istituto Giannina Gaslini|Bambino Gesù Hospital and Research Institute |
Nephrotic Syndrome Steroid-Dependent
|
October 15, 2020 | Phase 2 |
| NCT01200758 | Hoffmann-La Roche |
Non-Hodgkin´s Lymphoma
|
February 15, 2011 | Phase 3 |
| NCT00371904 | Hunter and New England Health|Melbourne Health|Princess Alexandra Hospital, Brisbane, Australia|Royal Prince Alfred Hospital, Sydney, Australia|Auckland City Hospital|Monash Medical Centre|Royal Perth Hospital|Westmead Hospital|Royal Adelaide Hospital |
Kidney Transplantation
|
April 2006 | Phase 2 |
| NCT00216164 | Hoosier Cancer Research Network|Eli Lilly and Company|Walther Cancer Institute |
Lymphoma, B-Cell
|
April 2005 | Phase 2 |
| NCT00005652 | University of Alabama at Birmingham|Office of Rare Diseases (ORD) |
Purpura, Thrombocytopenic, Idiopathic
|
December 2000 | Phase 2 |
| NCT03805932 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hairy Cell Leukemia
|
October 3, 2019 | Phase 1 |
| NCT05575973 | Jianfeng Zhou|CSPC Ouyi Pharmaceutical Co., Ltd.|Huazhong University of Science and Technology |
Diffuse Large B-cell Lymphoma
|
October 10, 2022 | Phase 2 |
| NCT04212013 | Memorial Sloan Kettering Cancer Center|Pharmacyclics LLC. |
Marginal Zone Lymphoma
|
December 23, 2019 | Phase 3 |
| NCT04588194 | David Gomez Almaguer|Hospital Universitario Dr. Jose E. Gonzalez |
Immune Thrombocytopenia|Thrombotic Thrombocytopenic Purpura
|
November 1, 2020 | Phase 2 |
| NCT00833534 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) |
Leukemia|Lymphoma
|
February 2009 | Phase 2 |
| NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia
|
July 15, 2015 | Phase 2 |
| NCT02391545 | SecuraBio |
CD20&addition; Follicular Lymphoma
|
December 2014 | Phase 1|Phase 2 |
| NCT00143065 | Ohio State University Comprehensive Cancer Center |
Lymphoma, Small Lymphocytic|Lymphocytic Leukemia, Chronic
|
August 2005 | Phase 2 |
| NCT00169169 | Lymphoma Study Association |
CD20-Positive Large B-Cell Lymphoma
|
October 1999 | Phase 3 |
| NCT04759586 | National Cancer Institute (NCI) |
Primary Mediastinal (Thymic) Large B-Cell Lymphoma
|
June 7, 2021 | Phase 3 |
| NCT01263704 | Hoffmann-La Roche |
Lymphocytic Leukemia, Chronic
|
July 17, 2011 | Phase 2 |
| NCT02433795 | Seoul National University Hospital|Gyeongsang National University Hospital|Korea Cancer Center Hospital|Seoul National University Boramae Hospital|Hallym University Medical Center|Inje University|Gangnam Severance Hospital|Chonbuk National University Hospital|Chungnam National University|The Catholic University of Korea|Wonju Severance Christian Hospital|Gachon University Gil Medical Center|Seoul National University Bundang Hospital |
Marginal Zone B-cell Lymphoma
|
May 2015 | Phase 2 |
| NCT02187861 | Hoffmann-La Roche|AbbVie |
Follicular Lymphoma
|
December 1, 2014 | Phase 2 |
| NCT02203526 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Primary Central Nervous System Lymphoma
|
August 14, 2014 | Phase 1 |
| NCT01650727 | Merck Sharp & Dohme LLC |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
October 2012 | Phase 1 |
| NCT04758975 | Paolo Ghia|IRCCS San Raffaele |
Chronic Lymphocytic Leukemia (CLL)
|
June 1, 2022 | Phase 2 |
| NCT00298272 | Biogen|Hoffmann-La Roche|Genentech, Inc. |
Rheumatoid Arthritis
|
May 2006 | Phase 2 |
| NCT00098670 | National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia
|
October 2004 | Phase 2 |
| NCT02284984 | Leiden University Medical Center|Dutch Kidney Foundation|ZonMw: The Netherlands Organisation for Health Research and Development |
Lupus Erythematosus, Systemic
|
March 2014 | Phase 2 |
| NCT00656812 | Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche|Lipomed |
Lymphoma of Mucosa-Associated Lymphoid Tissue
|
May 2008 | Phase 2 |
| NCT00010192 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma
|
December 2000 | Phase 1 |
| NCT00006072 | National Center for Research Resources (NCRR)|Genentech, Inc. |
Peripheral Neuropathy
|
Phase 2 | |
| NCT00986947 | Johns Hopkins University |
Kidney Failure
|
September 2009 | Phase 2 |
| NCT04129710 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ruijin Hospital|The First Affiliated Hospital of Nanchang University|Fujian Medical University Union Hospital|RenJi Hospital|Shanghai Tong Ren Hospital|Shandong Provincial Hospital|Cancer Hospital of Guangxi Medical University|Sir Run Run Shaw Hospital|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University|Ningbo Medical Center Lihuili Hospital|Yinzhou Hospital Affiliated to Medical School of Ningbo University|Zhejiang University |
Recurrent+RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
|
January 1, 2020 | Phase 2 |
| NCT01598558 | Sanjiv Sam Gambhir|Stanford University |
Non-Hodgkin´s Lymphoma
|
January 2012 | Not Applicable |
| NCT02545959 | Centre Hospitalier de PAU|University Hospital, Bordeaux |
Multiple Sclerosis, Chronic Progressive|Nervous System Diseases
|
November 30, 2015 | Phase 2 |
| NCT04743739 | Peking Union Medical College Hospital|Beijing Tongren Hospital|Chinese Academy of Medical Sciences, Fuwai Hospital|The Luhe Teaching Hospital of the Capital Medical University|The Seventh Affiliated Hospital of Sun Yat-sen University|First Affiliated Hospital of Xinjiang Medical University|Nanyang Nanshi Hospital of Henan University|Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Idiopathic Membranous Nephropathy
|
April 14, 2021 | Phase 3 |
| NCT04981912 | University of California, San Diego |
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
September 2, 2021 | Phase 1 |
| NCT00460109 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
April 2008 | Phase 2 |
| NCT00310128 | AIDS Malignancy Consortium|National Cancer Institute (NCI) |
AIDS-related Lymphoma|Adult Non-Hodgkin´s Lymphoma|Anaplastic Large Cell Lymphoma
|
February 2006 | Phase 2 |
| NCT00089115 | Favrille|National Cancer Institute (NCI) |
Lymphoma
|
July 2004 | Phase 3 |
| NCT04189952 | University of Miami|AstraZeneca |
Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia|Marginal Zone Lymphoma
|
September 22, 2020 | Phase 2 |
| NCT00070083 | British Columbia Cancer Agency|National Cancer Institute (NCI) |
Lymphoma
|
July 2003 | Phase 1 |
| NCT00202930 | Jean M. Tersak, M.D.|Genentech, Inc.|University of Pittsburgh |
Neuroblastoma|Opsoclonus-myoclonus
|
July 2005 | Phase 2 |
| NCT01082939 | M.D. Anderson Cancer Center|Bayer |
Chronic Lymphocytic Leukemia
|
December 2002 | Phase 2 |
| NCT03019640 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Mantle Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Indolent Adult Non-Hodgkin Lymphoma
|
October 10, 2017 | Phase 2 |
| NCT01234467 | UNC Lineberger Comprehensive Cancer Center|Cephalon |
Diffuse Large B-Cell Lymphoma|Lymphoma, Diffuse Large-Cell|Diffuse Large-Cell Lymphoma|Lymphoma
|
March 2011 | Phase 2 |
| NCT01448096 | Chonbuk National University Hospital|Consortium for Improving Survival of Lymphoma |
Large B Cell Diffuse Lymphoma
|
August 2011 | Phase 2 |
| NCT03274375 | Assistance Publique - Hôpitaux de Paris |
Anti-NMDAR Encephalitis
|
June 23, 2021 | Phase 2 |
| NCT01071798 | Hoffmann-La Roche |
Rheumatoid Arthritis
|
January 2010 | |
| NCT02382575 | Nilratan Sircar Medical College |
Nephrotic Syndrome
|
March 15, 2015 | Phase 4 |
| NCT01702038 | National Institute of Allergy and Infectious Diseases (NIAID) |
Lupus Erythematosus, Systemic
|
September 2009 | Phase 2 |
| NCT02594384 | AI Therapeutics, Inc. |
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
|
October 2015 | Phase 1 |
| NCT01691898 | Genentech, Inc. |
Follicular Lymphoma|Diffuse Large B-Cell Lymphoma
|
September 27, 2012 | Phase 1|Phase 2 |
| NCT02947347 | Pharmacyclics LLC. |
Follicular Lymphoma
|
January 2017 | Phase 3 |
| NCT00500058 | GlaxoSmithKline |
Lymphoma, Non-Hodgkin
|
July 31, 2007 | Phase 1 |
| NCT00129090 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Deutsche Krebshilfe e.V., Bonn (Germany) |
Non-Hodgkin´s Lymphoma (NHL)
|
March 2003 | Phase 3 |
| NCT00161564 | Weill Medical College of Cornell University|Genentech, Inc. |
Idiopathic Thrombocytopenic Purpura (ITP)
|
February 2004 | Phase 2 |
| NCT00290667 | German High-Grade Non-Hodgkin´s Lymphoma Study Group|Universität des Saarlandes |
Lymphoma
|
February 2004 | Phase 2 |
| NCT01933711 | University Hospital Heidelberg |
CD20&addition; Aggressive Lymphoma, Mantle Cell Lymphoma
|
July 2002 | Phase 3 |
| NCT01030900 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma
|
October 22, 2009 | Phase 2 |
| NCT02315326 | Memorial Sloan Kettering Cancer Center|Pharmacyclics LLC.|Janssen Biotech, Inc. |
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)|Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
December 2014 | Phase 1|Phase 2 |
| NCT02165397 | Pharmacyclics LLC.|Janssen Research & Development, LLC |
Waldenström´s Macroglobulinemia
|
July 7, 2014 | Phase 3 |
| NCT05221645 | University of Southampton|Merck Sharp & Dohme LLC |
Diffuse Large B Cell Lymphoma
|
June 27, 2022 | Phase 2 |
| NCT05179733 | Ruijin Hospital|Wuhan Union Hospital, China|Ningbo No. 1 Hospital|National Naval Medical Center|Shanghai Fengxian District Central Hospital|YANCHENG NO.1 PEOPLE´S HOSPITAL|The First Affiliated Hospital of Nanchang University|Affiliated Hospital of Nantong University|Wuxi Branch of Ruijin Hospital|Sir Run Run Shaw Hospital|Northern Jiangsu Province People´s Hospital|The First People´s Hospital of Changde City|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Changzhou No.2 People´s Hospital|The Affiliated Hospital of Xuzhou Medical University|Huai´an First People´s Hospital|Taizhou Hospital|The First people´s Hospital of Kunshan|First Affiliated Hospital of Fujian Medical University|Huadong Hospital|Henan Provincial People´s Hospital|First Hospital of China Medical University |
Diffuse Large B-Cell Lymphoma
|
March 2, 2022 | Phase 3 |
| NCT02623920 | University of Arizona |
Diffuse Large B Cell Lymphoma|Mediastinal Large B-cell Lymphoma|Grey Zone Lymphoma|High Grade B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma
|
December 16, 2015 | Phase 2 |
| NCT00183976 | University of Southern California |
Non-Hodgkin´s Lymphoma|Burkitt Lymphoma|Primary Effusion Lymphomas
|
April 2005 | Phase 2 |
| NCT00079443 | National Cancer Institute (NCI) |
Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Small Lymphocytic Lymphoma
|
January 2004 | Phase 2 |
| NCT01173679 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Bristol-Myers Squibb |
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
|
July 2010 | Phase 2 |
| NCT01269385 | Mayo Clinic|National Cancer Institute (NCI) |
B-cell Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia
|
January 2011 | Phase 1|Phase 2 |
| NCT03078855 | Jonathan Friedberg|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of Rochester |
Follicular Lymphoma|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Mucosal-Associated Lymphoid Tissue Lymphoma
|
September 7, 2017 | Phase 3 |
| NCT02316613 | Hoffmann-La Roche |
Follicular Lymphoma
|
February 2007 | |
| NCT02158091 | Dana-Farber Cancer Institute|Secura Bio, Inc. |
Chronic Lymphocytic Leukemia
|
June 27, 2014 | Phase 1|Phase 2 |
| NCT00468442 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Type 1 Diabetes Mellitus
|
November 2006 | Phase 2 |
| NCT00927797 | Heidelberg University|Diakonie Krankenhaus Schwäbisch Hall, Germany|Ludwig-Maximilians - University of Munich|Klinikum am Plattenwald, Bad Friedrichshall, Germany|Diakonie-Klinikum Stuttgart|Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany|Universitätsmedizin Mannheim |
Immunocytoma+Morbus Waldenström|B-Cell Non-Hodgkin´s Lymphoma|B-Cell Chronic Lymphocytic Leukemia
|
February 2005 | Phase 2 |
| NCT01144403 | Hoffmann-La Roche |
Diffuse Large B-Cell Lymphoma
|
June 2010 | Phase 2 |
| NCT01027000 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Genentech, Inc.|Biologics, Inc. |
Leukemia|Lymphoma
|
February 2010 | Phase 2 |
| NCT02142335 | California Cancer Assocaties for Research & Excellence |
Malignant Melanoma of Skin Stage III|Metastatic Melanoma
|
March 2014 | Phase 2 |
| NCT02135874 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Mixed Phenotype Acute Leukemia, B+Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, T+Myeloid, Not Otherwise Specified|Recurrent Mixed Phenotype Acute Leukemia
|
October 27, 2014 | Phase 2 |
| NCT01118845 | SymBio Pharmaceuticals |
Non-Hodgkin´s Lymphoma|Lymphoma, Large Cell|Diffuse, Mantle Cell Lymphoma, Lymphoma|Follicular Lymphoma|Large B-Cell, Diffuse
|
April 2010 | Phase 2 |
| NCT01032122 | Medical University of Vienna |
Metastatic Melanoma
|
October 2007 | Phase 1 |
| NCT00492050 | M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. |
Waldenstrom´s Macroglobulinemia
|
August 2006 | Phase 2 |
| NCT00136552 | Lymphoma Study Association |
Lymphoma
|
May 2000 | Phase 3 |
| NCT02631538 | GlaxoSmithKline |
Sjogren´s Syndrome
|
February 17, 2016 | Phase 2 |
| NCT00436280 | Eli Lilly and Company |
Lymphoma, Large Cell, Diffuse
|
February 2007 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.
- [2] Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.
- [3] Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.
Synonyms
Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 γ1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
Immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 γ1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer
IDEC 102
Rituximab
IDEC-C 2B8
Rituxan
MabThera
Retuxin
5: PN: WO2008003319 PAGE: 45 claimed protein
Reditux
Kikuzubam
GP 2013
1: PN: WO2016077505 PAGE: 164 claimed sequence
RG 105
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.